

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 September 2004 (10.09.2004)

PCT

(10) International Publication Number
WO 2004/076458 A1

(51) International Patent Classification⁷: **C07D 487/04**,
A61K 31/519, A61P 19/08, 35/00, 37/02, 43/00, 3/10,
13/12, 17/00, 27/00, 19/02, 7/00, 1/16, 21/04, 1/00, 17/06,
7/00, 1/16, 21/04, 1/00, 17/06

(21) International Application Number:
PCT/JP2004/002522

(22) International Filing Date: 1 March 2004 (01.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0304665.3 28 February 2003 (28.02.2003) GB
60/500,695 8 September 2003 (08.09.2003) US
0329446.9 19 December 2003 (19.12.2003) GB

(71) Applicant (*for all designated States except US*): **TEI-
JIN PHARMA LIMITED** [JP/JP]; 1-1, Uchisaiwaicho
2-chome Chiyoda-ku Tokyo, 1000011 (JP).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **KATAOKA,**
Kenichiro [JP/JP]; c/o Teijin Pharma Limited, Tokyo Re-
search Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo,
1910065 (JP). **SUZUKI, Naotaka** [JP/JP]; c/o Teijin

Pharma Limited 1-1, Uchisaiwaicho 2-chome Chiyoda-ku
Tokyo, 1000011 (JP). **KOSUGI, Tomomi** [JP/JP]; c/o
Teijin Pharma Limited, Tokyo Research Center 3-2, Asahi-
gaoka 4-chome Hino-shi Tokyo, 1910065 (JP). **IMAI,**
Minoru [JP/JP]; c/o Teijin Pharma Limited, Tokyo Re-
search Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo,
1910065 (JP). **MAKINO, Hiroaki** [JP/JP]; c/o Teijin
Pharma Limited, Tokyo Research Center 3-2, Asahigaoka
4-chome Hino-shi Tokyo, 1910065 (JP). **TAKAKUWA,**
Mika [JP/JP]; c/o Teijin Pharma Limited, Tokyo Research
Center 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065
(JP). **UNOKI, Gen** [JP/JP]; c/o Teijin Pharma Limited,
Tokyo Research Center 3-2, Asahigaoka 4-chome Hino-shi
Tokyo, 1910065 (JP). **FUJINO, Aiko** [JP/JP]; c/o Teijin
Pharma Limited, Tokyo Research Center 3-2, Asahigaoka
4-chome Hino-shi Tokyo, 1910065 (JP). **OUE, Yasuhiro**
[JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Cen-
ter 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065
(JP). **YAMAKOSHI, Yuko** [JP/JP]; c/o Teijin Pharma
Limited, Tokyo Research Center 3-2, Asahigaoka 4-chome
Hino-shi Tokyo, 1910065 (JP). **SUGIURA, Satoshi**
[JP/JP]; c/o Teijin Pharma Limited, Tokyo Research Cen-
ter 3-2, Asahigaoka 4-chome Hino-shi Tokyo, 1910065
(JP). **MITCHELL, Dale Robert** [GB/GB]; c/o Bio Fo-
cus Chesterford Park Saffron Walden Essex, CB101XL

[Continued on next page]

(54) Title: **PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES**

Pathogens, cytokines, growth factors, environmental stresses, GPCRs



(57) Abstract: The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth. H,N,R³

WO 2004/076458 A1



(GB). SIMPSON, Donald James [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB). HARRIS, Clifford John [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB). LE, Joelle [GB/GB]; c/o Bio Focus Chesterford Park Saffron Walden Essex, CB101XL (GB).

(74) Agent: MIHARA, Hideko; c/o Teijin Intellectual Property Center Limited 1-1, Uchisaiwaicho 2-chome Chiyoda-ku Tokyo, 1000011 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

ABSTRACT

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity. Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.



DESCRIPTION

Pyrazolo[1,5-a]pyrimidine derivatives

Field of the Invention

The present invention relates to novel compounds, their use in the inhibition of protein kinases, their use in medicine and particularly in the prevention and/or treatment of a wide variety of diseases including inflammatory disorders, cancer, angiogenesis, diabetes and neurological disorders. The invention also provides processes for the manufacture of said compounds, compositions containing them and processes for manufacturing such compositions.

Background Art

Protein kinases are a family of enzymes that catalyse the phosphorylation of hydroxyl groups in proteins. Approximately 2% of the genes encoded by the human genome are predicted to encode protein kinases. The phosphorylation of specific tyrosine, serine, or threonine residues on a target protein can dramatically alter its function in several ways including activating or inhibiting enzymatic activity, creating or blocking binding sites for other proteins, altering subcellular localisation or controlling protein stability. Consequently, protein kinases are pivotal in the regulation of a wide variety of cellular processes, including metabolism, proliferation, differentiation and survival (Hunter, T. Cell, 1995, 80, 224-236). Of the many different cellular functions known to require the actions of protein kinases, some represent targets for therapeutic intervention for certain disease (Cohen, P. Nature Rev. Drug Disc., 2002,

1, 309-315).

It is known that several diseases arise from, or involve, aberrant protein kinase activity. In humans, protein tyrosine kinases are known to have a significant role in the development of many diseases including diabetes, cancer and have also been linked to a wide variety of congenital syndromes (Robertson, S. C. Trends Genet. 2000, 16, 265-271). Serine/threonine kinases also represent a class of enzymes, inhibitors of which are likely to have relevance to the treatment of cancer, diabetes and a variety of inflammatory disorders (Adams, J. L. et al. Prog. Med. Chem. 2001, 38, 1-60).

One of the principal mechanisms by which cellular regulation is affected is through the transduction of extracellular signals across the membrane that in turn modulate biochemical pathways within the cell. Protein phosphorylation represents one course by which intracellular signals are propagated from molecule to molecule resulting finally in cellular responses. These signal transduction cascades are regulated and often overlapping as evidenced by the existence of many protein kinases as well as phosphatases. It is currently believed that a number of disease and/or disorders are a result of either aberrant activation or inhibition in the molecular components of kinase cascades.

Three potential mechanisms for inhibition of protein kinases have been identified thus far. These include a pseudo-substrate mechanism, an adenine mimetic mechanism and the locking of the enzyme into an inactive conformation by using surfaces other than the active site (Taylor, S. S. Curr. Opin. Chem. Biol. 1997, 1, 219-226). The majority of inhibitors identified/designed to date act at the ATP-binding site. Such ATP-competitive inhibitors have demonstrated selectivity by virtue of their ability to target the more poorly conserved areas of the ATP-binding site (Wang, Z. et al.

Structure 1998, 6, 1117-1128).

There exists a need for the provision of further compounds that are inhibitors of protein kinases.

MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) is a serine/threonine kinase that operates immediately downstream of the p38 kinase in the stress-induced MAPK pathway (Figure 1).

The p38 kinase pathway is involved in transducing the effects of a variety of stress-related extracellular stimuli such as heat shock, UV light, bacterial lipopolysaccharide, and pro-inflammatory cytokines. Activation of this pathway results in the phosphorylation of transcription and initiation factors, and affects cell division, apoptosis, invasiveness of cultured cells and the inflammatory response (Martin-Blanco, Bioessays 22, 637-645 (2000)).

p38 kinase itself activates a number of protein kinases other than the MAPKAP kinases such as Mnk1/2, PRAK and MSK1 (Figure 1). The specific and/or overlapping functions of the majority of these targets have yet to be resolved. This pathway has been of particular interest for the discovery of new anti-inflammatory agents. Previous strategies to intervene this pathway have involved the development of selective inhibitors of p38 kinase. Such inhibitors are effective both for inhibiting pro-inflammatory cytokine production in cell-based models and animal models of chronic inflammations (Lee et al., Immunopharmacology 47, 185-201 (2000)). p38 kinase knockout mouse is embryonic lethal. And cells derived from such embryos have demonstrated a number of abnormalities in fundamental cell responses. These observations indicate that caution should be paid to the long-term therapy with p38 kinase inhibitors.

An alternative strategy for the development of anti-inflammatory agents could be the inhibition of this pathway at the level of MAPKAP-K2. Human MAPKAP-K2 has two proline-rich domains at its N-terminus followed by the kinase domain and the C-terminal regulatory domain. This kinase has low homology with other serine/threonine kinases except MAPKAP-K3 and -K4. The C-terminal regulatory domain contains a bipartite nuclear localisation signal and a nuclear export signal. The crystal structure of inactive MAPKAP-K2 has been resolved (Meng, W. et al. *J. Biol. Chem.* 277, 37401-37405 (2002)). Activation of MAPKAP-K2 by p38 kinase occurs via selective phosphorylation of threonine residues 222 and 334 (Stokoe et al., *EMBO J.* 11, 3985-3994 (1992)). MAPKAP-K2 has an amphiphilic A-helix motif located within its C-terminal region that is likely to block the binding of substrates. The dual phosphorylation by p38 kinase has been proposed to reposition this motif resulting in enhanced catalytic activity (You-Li et al., *J. Biol. Chem.* 270, 202-206 (1995)). MAPKAP-K2 is present in the nucleus of unstimulated cells, and translocates to the cytoplasm upon cell stimulation. This kinase is known to phosphorylate a number of nuclear transcription factors as well as cytosolic proteins such as heat shock proteins and 5-lipoxygenase (Stokoe et al., *FEBS Lett.* 313, 307-313 (1992), Werz, et al., *Proc. Natl. Acad. Sci. USA* 97, 5261-5266 (2000), Heidenreich, et al., *J. Biol. Chem.* 274, 14434-14443 (1999), Tan, et al., *EMBO J.* 15, 4629-4642 (1996), Neufeld, *J. Biol. Chem.* 275, 20239-20242 (2000)). All such substrates contain a unique amino acid motif (XX-Hyd-XRXXSXX, where Hyd is a bulky hydrophobic residue) that is required for efficient phosphorylation by MAPKAP-K2 (Stokoe et al., *Biochem. J.* 296, 843-849 (1993)).

Currently MAPKAP-K2 is the only p38 kinase substrate for which a specific

function has been identified. A specific role for MAPKAP-K2 in mediating the inflammatory response has been strongly indicated by the phenotype of the MAPKAP-K2-deficient mouse (MAPKAP-K2^{-/-}) (Kotlyarov, et al., Nature Cell Biol. 1, 94-97 (1999)). This mouse is viable and normal except for a significantly reduced inflammatory response. Recently it has also been shown that MAPKAP-K2 deficiency results in a marked neuroprotection from ischaemic brain injury (Wang et al., J. Biol Chem. 277, 43968-43972 (2002)). MAPKAP-K2 is believed to regulate the translation and/or stability of important pro-inflammatory cytokine mRNAs. It is thought to function via phosphorylation of proteins that bind to the AU-rich elements found within untranslated regions of these cytokines. The identity of these proteins is currently under investigation.


MAPKAP-K2 therefore represents an intervention point in the stress-induced kinase cascade for perturbation of the inflammatory response.

Disclosure of the Invention

As a result of much diligent research directed toward achieving the object stated above, the present inventors have completed the present invention upon discovering that the novel Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I below and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity.

In other words, the present invention provides as follows:

(1) A compound of formula I:



wherein R¹ is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl;

R² is hydrogen, halogen, -CN, -NO₂, -CHO, -G-R⁷ [G is a bond, -C(=O)- or -O-C(=O)-; and R⁷ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclalkynyl, -OR⁸ (R⁸ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclalkyl), -NR⁹R¹⁰ (R⁹ is as defined for R⁸; R¹⁰ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl or -OCH₃), -R¹¹ (R¹¹ is an optionally substituted saturated heterocyclyl with 5 to 7

members containing one to four heteroatoms selected from N, O and S), C6-C14 optionally substituted aryl or optionally substituted heteroaryl; provided that when R⁷ is C6-C14 optionally substituted aryl or optionally substituted heteroaryl, then G is not a bond], -NR⁹C(=O)R¹² (R⁹ is as defined for R⁸; R¹² is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl); -NR⁹C(=X)OR¹³ (R⁹ and R¹³, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁹C(=X)NR¹³R¹⁴ (R⁹, R¹³ and R¹⁴, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁹SO₂R¹³ (R⁹ and R¹³, which may be the same or different, are as defined for R⁸), -SR⁹ (R⁹ is as defined for R⁸) or -S(O)_mR⁹ (R⁹ is as defined for R⁸; m is 1 or 2); R³ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 unsubstituted aryl, C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R¹⁵ {G is a bond, -C(=O)- or -O-C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl, optionally substituted

heterocyclalkynyl, $-OR^{16}$ (R^{16} is as defined for R^8) or $-NR^{17}R^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8), $-NR^{17}C(=O)R^{19}$ (R^{17} is as defined for R^8 ; R^{19} is as defined for R^{12}), $-NR^{17}C(=X)OR^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{17}C(=X)NR^{18}R^{20}$ (R^{17} , R^{18} and R^{20} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{17}SO_2R^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8), $-S(O)_mR^{17}$ (R^{17} is as defined for R^8 ; m is 0, 1 or 2) and $-SO_2NR^{21}R^{22}$ (R^{21} and R^{22} , which may be the same or different, are as defined for R^8 ; R^{21} and R^{22} together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], unsubstituted heterocycl, substituted heterocycl [As substituents of heterocycl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R²³ {G is a bond, -C(=O)- or -O-C(=O)-; R²³ is as defined for R¹⁵}, $-NR^{24}C(=O)R^{25}$ (R^{24} is as defined for R^8 ; R^{25} is as defined for R^{12}), $-NR^{24}C(=X)OR^{26}$ (R^{24} and R^{26} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{24}C(=X)NR^{26}R^{27}$ (R^{24} , R^{26} and R^{27} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{24}SO_2R^{26}$ (wherein R^{24} and R^{26} , which may be the same or different, are as defined for R^8), $-S(O)_mR^{24}$ (R^{24} is as defined for R^8 ; m is 0, 1 or 2) and $-SO_2NR^{28}R^{29}$ (R^{28} and R^{29} , which may be the same or different, are as defined for R^8 ; R^{28} and R^{29} together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally

containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl;

R^4 is hydrogen, halogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocycl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclalkynyl, $-OR^{30}$ (R^{30} is as defined for R^8), $-SR^{30}$ (R^{30} is as defined for R^8), $-NR^{30}R^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8), $-NR^{30}C(=O)R^{32}$ (R^{30} is as defined for R^8 ; and R^{32} is as defined for R^{12}), $-NR^{30}C(=X)OR^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined R^8 ; X is O, S, N-CN or NH), $-NR^{30}C(=X)NR^{31}R^{33}$ (R^{30} , R^{31} and R^{33} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH) or $-NR^{30}SO_2R^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8);

R^5 is C1-C8 substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 substituted cycloalkyl [As substituents of C3-C8 cycloalkyl may be mentioned one or more selected from the group consisting of halogen, -CN, $-NO_2$, -CHO, $-G-R^{34}$ {G is a bond, $-C(=O)-$ or $-O-C(=O)-$; R^{34} is as defined for R^{15} }, $-NR^{35}C(=O)R^{36}$ (R^{35} is as defined for R^8 ; R^{36} is as defined for R^{12}), $-NR^{35}C(=X)OR^{37}$

(R^{35} and R^{37} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{35}C(=X)NR^{37}R^{38}$ (R^{35} , R^{37} and R^{38} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH) and $-NR^{35}SO_2R^{37}$ (R^{35} and R^{37} , which may be the same or different, are as defined for R^8), unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R³⁹ {G is a bond, -C(=O)- or -O-C(=O)-; R³⁹ is as defined for R¹⁵}, -NR⁴⁰C(=O)R⁴¹ (R⁴⁰ is as defined for R^8 ; R⁴¹ is as defined for R¹²), -NR⁴⁰C(=X)OR⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), -NR⁴⁰C(=X)NR⁴²R⁴³ (R⁴⁰, R⁴² and R⁴³, which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH) and -NR⁴⁰SO₂R⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R^8)], optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl or -NR⁴⁴R⁴⁵ (R⁴⁴ and R⁴⁵, which may be the same or different, are C1-C8 optionally substituted alkyl; R⁴⁴ and R⁴⁵ together may be taken together with the nitrogen to which they are attached to form a mono heterocycle with 5 - 7 members and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said mono heterocycle may optionally be substituted with one or more substituents);

R^6 is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H;


that R^4 is not pentafluorophenyl;

that R^5 is not a group represented as the following (a):

(a) C1-C6 alkyl or C3-C6 cycloalkyl, in which an alkyl group or a cycloalkyl group optionally may be substituted by phenyl or by one or more fluoro substituents;

and pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs.

(2) A compound of formula I-b:



wherein R^{1b} is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl;

R^{2b} is hydrogen, halogen, -CN, -NO₂, -CHO or -G-R⁵² {G is a bond, -C(=O)- or -O-C(=O)-}; and R^{52} is C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl,

optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl, optionally substituted heteroarylalkynyl, $-OR^{53}$ (R^{53} is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl), $-NR^{54}R^{55}$, $-NR^{54}C(=O)R^{55}$, $-SR^{54}$, optionally substituted aryl or optionally substituted heteroaryl; provided that when R^{52} is optionally substituted aryl or optionally substituted heteroaryl then G is not a bond; wherein R^{54} and R^{55} , which may be the same or different, are as defined for R^{53} ; or wherein R^{54} and R^{55} together form an optionally substituted ring that optionally contains one or more heteroatoms selected from N, O and S};

R^{3b} is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl;

R^{4b} is hydrogen, halogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted

arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl, optionally substituted heteroarylalkynyl, $-OR^{56}$, $-SR^{56}$, $-NR^{56}R^{57}$ or $-NR^{56}C(=O)R^{57}$; wherein R^{56} and R^{57} , which may be the same or different, are as defined for R^{53} ; or wherein R^{56} and R^{57} together form an optionally substituted ring which optionally contains one or more heteroatoms;

R^{5b} is C1-C6 substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 substituted cycloalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclalkyl;

R^{6b} is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl or C3-C8 optionally substituted cycloalkyl;

with the provisos:

that R^{1b} , R^{2b} and R^{4b} are not all H;

that R^{4b} is not pentafluorophenyl;

that R^{5b} is not a group represented as the following (a):

(a) C1-C6 alkyl or C3-C6 cycloalkyl, in which an alkyl group optionally may be substituted by phenyl or by one or more fluoro substituents;

and pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs.

(3) The compound as (1) wherein R^1 is hydrogen or C1-C8 optionally substituted alkyl.

(4) The compound as (1) wherein R^1 is hydrogen.

(5) The compound as any one of (1), (3) or (4) wherein R^2 is $-\text{NO}_2$, $-\text{OC}(=\text{O})\text{R}^7$, $-\text{CO}_2\text{R}^8$ or $-\text{CONR}^9\text{R}^{10}$; wherein R^7 , R^8 , R^9 and R^{10} are as defined in claim 1.

(6) The compound as any one of (1), (3) or (4) wherein R^2 is $-\text{NR}^9\text{C}(=\text{O})\text{R}^{12}$, $-\text{NR}^9\text{C}(=\text{X})\text{OR}^{13}$, $-\text{NR}^9\text{C}(=\text{X})\text{NR}^{13}\text{R}^{14}$, $-\text{NR}^9\text{SO}_2\text{R}^{13}$, $-\text{SR}^9$ or $-\text{S}(\text{O})_m\text{R}^9$; wherein R^9 , R^{12} , R^{13} , R^{14} and X are as defined in claim 1; m is 1 or 2.

(7) The compound as any one of (1), (3) or (4) wherein R^2 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl or optionally substituted arylalkyl.

(8) The compound as any one of (1), (3) or (4) wherein R^2 is hydrogen, halogen, $-\text{CN}$ or $-\text{SCH}_3$.

(9) The compound as any one of (1), (3) or (4) wherein R^2 is halogen.

(10) The compound as any one of (1), (3) or (4) wherein R^2 is F.

(11) The compound as any one of (1), (3) or (4) wherein R^2 is hydrogen.

(12) The compound as any one of (1), (3) to (11) wherein R^3 is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 unsubstituted aryl, C6-C14

substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.

(13) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl.

(14) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl {As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} , -NR¹⁷C(=O)R¹⁹ and -S(O)_mR¹⁷; wherein R^{15} , R^{17} , R^{19} or G are as defined in claim 1; m is 0, 1 or 2.}.

(15) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} {G is a bond or -C(=O)-; R^{15} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, -OR¹⁶ or -NR¹⁷R¹⁸}, -NR¹⁷C(=O)R¹⁹ and S(O)_mR¹⁷; wherein R^{16} , R^{17} , R^{18} or R^{19} are as defined in claim 1; m is 0, 1 or 2.].

(16) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} {G is a bond; R^{15} is C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted

heterocyclalkyl, $-\text{OR}^{16}$ or $-\text{NR}^{17}\text{R}^{18}$, $-\text{NR}^{17}\text{C}(=\text{O})\text{R}^{19}$ and $\text{S}(\text{O})_m\text{R}^{17}$; wherein R^{16} , R^{17} , R^{18} or R^{19} are as defined in claim 1; m is 0, 1 or 2.].

(17) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{G}-\text{R}^{15}$ { G is a bond or $-\text{C}(=\text{O})-$; R^{15} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, $-\text{OR}^{16}$ or $-\text{NR}^{17}\text{R}^{18}$, $-\text{NR}^{17}\text{C}(=\text{O})\text{R}^{19}$ and $\text{S}(\text{O})_m\text{R}^{17}$; wherein R^{16} , R^{17} , R^{18} or R^{19} are as defined in claim 1; m is 0, 1 or 2.].

(18) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$, $-\text{G}-\text{R}^{15}$ { G is a bond or $-\text{C}(=\text{O})-$; R^{15} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, $-\text{OR}^{16}$ or $-\text{NR}^{17}\text{R}^{18}$, $-\text{NR}^{17}\text{C}(=\text{O})\text{R}^{19}$ and $\text{S}(\text{O})_m\text{R}^{17}$; wherein R^{16} , R^{17} , R^{18} or R^{19} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl; m is 0, 1 or 2.].

(19) The compound as any one of (1), (3) to (11) wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$ and $-\text{G}-\text{R}^{15}$ { G is $-\text{C}(=\text{O})-$; R^{15} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclalkyl, $-\text{OR}^{16}$ or $-\text{NR}^{17}\text{R}^{18}$; wherein R^{16} , R^{17} or R^{18} are as defined in claim 1.].

- (20) The compound as any one of (1), (3) to (11) wherein R^3 is unsubstituted heterocyclyl.
- (21) The compound as any one of (1), (3) to (11) wherein R^3 is substituted heterocyclyl.
- (22) The compound as any one of (1), (3) to (11) wherein R^3 is substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{23} , -NR²⁴C(=O) R^{25} and -S(O)_m R^{24} ; wherein R^{23} , R^{24} , R^{25} or G are as defined in claim 1; m is 0, 1 or 2.].
- (23) The compound as any one of (1), (3) to (11) wherein R^3 is unsubstituted bicyclic heteroaryl.
- (24) The compound as any one of (1), (3) to (11) wherein R^3 is substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{23} , -NR²⁴C(=O) R^{25} and -S(O)_m R^{24} ; wherein R^{23} , R^{24} , R^{25} or G are as defined in claim 1; m is 0, 1 or 2.].
- (25) The compound as any one of (1), (3) to (24) wherein R^4 is halogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, -OR³⁰; wherein R^{30} is as defined in claim 1.

(26) The compound as any one of (1), (3) to (24) wherein R^4 is C1-C8 optionally substituted alkyl.

(27) The compound as any one of (1), (3) to (24) wherein R^4 is methyl.

(28) The compound as any one of (1), (3) to (24) wherein R^4 is hydrogen.

(29) The compound as any one of (1), (3) to (28) wherein R^5 is C3-C8 substituted cycloalkyl, unsubstituted heterocyclyl or substituted heterocyclyl.

(30) The compound as any one of (1), (3) to (28) wherein R^5 is C3-C8 substituted cycloalkyl [As substituents of cycloalkyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and $-NR^{17}R^{18}$; wherein R^{17} or R^{18} is as defined in claim 1].

(31) The compound as any one of (1), (3) to (28) wherein R^5 is substituted cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and $-NR^{17}R^{18}$; wherein R^{17} or R^{18} is as defined in claim 1].

(32) The compound as any one of (1), (3) to (28) wherein R^5 is 4-amino-cyclohexyl.

(33) The compound as any one of (1), (3) to (28) wherein R^5 is unsubstituted heterocyclyl or substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and -NR¹⁷R¹⁸; wherein R¹⁷ or R¹⁸ is as defined in claim 1]

(34) The compound as any one of (1), (3) to (28) wherein R^5 is unsubstituted piperidin-3-yl, unsubstituted piperidin-4-yl or unsubstituted pyrrolidin-3-yl.


(35) The compound as any one of (1), (3) to (28) wherein R^5 is substituted piperidin-3-yl, substituted piperidin-4-yl or substituted pyrrolidin-3-yl.

(36) The compound as any one of (1), (3) to (28) wherein R^5 is substituted piperidin-3-yl, substituted piperidin-4-yl or substituted pyrrolidin-3-yl [As their substituents may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl and C3-C8 optionally substituted cycloalkyl]

(37) The compound as any one of (1), (3) to (36) wherein R^6 is hydrogen.

(38) The compound as any one of (1), (3) to (36) wherein R^6 is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl.

(39) A compound of the formula II-26:




wherein $R^1 - R^6$ are as defined in claim 1; R^{58} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H.

(40) A compound of the formula III-01:




wherein $R^1 - R^4$ are as defined in claim 1; R^{58} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H.

(41) A compound of the formula IV:



wherein $R^1 - R^4$ are as defined in claim 1;

with the provisos:

that R^1 , R^2 and R^4 are not all H;

that R^4 is not optionally substituted aryl or optionally substituted heteroaryl.

(42) The compound as any one of (39), (40) or (41) wherein R^1 is hydrogen;

(43) The compound as any one of (39), (40) or (41) wherein R^2 is hydrogen, halogen, -CN, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, -OR⁸ (R⁸ is hydrogen or C1-C8 optionally substituted alkyl), -NR⁹R¹⁰ (R⁹ and R¹⁰, which may be the same or different, hydrogen or C1-C8 optionally substituted alkyl), -C(=O)NR⁹R¹⁰ (R⁹ and R¹⁰, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)R¹² (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹² is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)OR¹³ (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹³ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)NR¹³R¹⁴ (R⁹ and R¹³, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl; R¹⁴ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹SO₂R¹³ (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹³ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -SR⁹ (R⁹ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) or -SO₂R⁹ (R⁹ is C1-C8 optionally substituted alkyl, C3-C8

optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl).

(44) The compound as any one of (39), (40) or (41) wherein R^3 is substituted phenyl [As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkynyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl) and -C(=O)NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)], unsubstituted bicyclic heteroaryl, substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NHC(=O)R¹⁹ (R¹⁹ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and -SR¹⁷ (R¹⁷ is C1-C8 optionally substituted alkyl)].

(45) The compound as any one of (39), (40) or (41) wherein R⁴ is hydrogen, methyl or ethyl.

(46) The compound as (39) wherein R⁵ is preferably selected from cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂].

(47) The compound as (39) wherein R⁶ is hydrogen.


(48) The compound as any one of (39), (40) or (41) wherein R⁵⁸ is *tert*-butyl or benzyl.

(49) The compound as (39) wherein R¹ is hydrogen; R² is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R³ is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R⁴ is hydrogen or -CH₃; R⁵ is 4-amino-cyclohexyl or piperidin-3-yl; R⁶ is hydrogen; R⁵⁸ is *tert*-butyl; with the provisos that R¹, R² and R⁴ are not all H.


(50) The compound as (40) wherein R^1 is hydrogen; R^2 is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R^3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R^4 is hydrogen or -CH₃; R^5 is *tert*-butyl; with the provisos that R^1 , R^2 and R^4 are not all H

(51) The compound as (41) wherein R^1 is hydrogen; R^2 is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R^3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R^4 is hydrogen or -CH₃; with the provisos that R^1 , R^2 and R^4 are not all H.

(52) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein removal of Boc protecting group from compound II.




(53) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound III




is reacted with a compound of the formula R⁵R⁶NH.

(54) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound IV




is reacted with a compound of the formula R⁵R⁶NH.

(55) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound IV




is reacted with di-*tert*-butyl dicarbonate.

(56) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound V




is reacted with a compound of the formula R^3NH_2 or $R^3NH(COCH_3)$.

(57) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound VI




is reacted with phosphorus oxychloride or phenyl phosphonic dichloride.

(58) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound VII




is reacted with a compound of the formula $R^4CH(CO_2Me)_2$ or $R^4CH(CO_2Et)_2$.

(59) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound V-01




is reacted with a halogenating, thiocyanating or acylating agent.

(60) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound IV-01




is reacted with a Grignard reagent.

(61) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-01




is reacted with a halogenating agent.

(62) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-01




is reacted with a compound of the formula $(\text{CF}_3\text{CO})_2\text{O}$.

(63) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-03




is reacted with hydroxide for a hydrolysis of ester group; R^{67} is methyl or ethyl.

(64) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-04




is reacted with a compound of the formula $R^9R^{10}NH$ in the presence of a peptide coupling agent.

(65) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-06




is rearranged via isocyanate intermediate under Hofmann rearrangement conditions, followed by removal of carbonate.

(66) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-08




is reacted with a compound of the formula $R^{12}COCl$, $R^{12}COOH$, $R^{10}SO_2Cl$, $R^{10}NCO$ or $R^{10}NCS$.

(67) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-13




is condensed with an alcohol derivative under Mitsunobu conditions; Ar^1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.

(68) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-15




is reacted with a boronic acid derivative in the presence of metal catalysis under Suzuki-Miyaura coupling conditions; Ar^1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.

(69) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-15



is reacted with a 1-alkyne in the presence of metal catalyst under Sonogashira coupling conditions; Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.


(70) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-18



is reacted with a compound of the formula R¹⁶R¹⁷NH in the presence of a peptide coupling agent; Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.


(71) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-20

33




is reacted with an alkyl lithium reagent.

(72) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-22




is reacted with alkyl halide, followed by removal of trifluoroacetyl group.

(73) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-08




is reacted with an aldehyde in the presence of reducing agent.

(74) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound II-24




is reacted with alkyl halide in the presence of sodium hydride

(75) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound I-26



is reacted with hydrogen in the presence of Palladium on activated carbon or with chloroformate followed by methanol; R⁶⁰ is benzyl or *p*-MeO-benzyl; n is 1, 2 or 3.

(76) A process for the manufacture of a compound as defined in any one of (1), (3) to (38) wherein compound V-04



is reacted with reducing agent or diol derivative for formation of acetal.

(77) A composition comprising a compound as defined in any one of (1), (3) to (38) in combination with a pharmaceutically acceptable carrier, diluent or excipient.

(78) The composition as (77) further comprising one or more active agents.

(79) A process for the manufacture of a composition as defined in (77) or (78) comprising combining a compound as defined in any one of (1), (3) to (38) with the pharmaceutically acceptable carrier or diluent, optionally with an additional active agent.

(80) A compound as defined in any one of (1), (3) to (38), or a composition as defined in any one of (77) or (78), for use in medicine.

(81) A compound as defined in any one of (1), (3) to (38), or a composition as defined in any one of (77) or (78), for inhibiting protein kinase.

(82) A compound as defined in any one of (1), (3) to (38), or a composition as defined in any one of (77) or (78), for selectively inhibiting MAPKAP-K2.

(83) A compound as defined in any one of (1), (3) to (38), or a composition as defined in any one of (77) or (78), for selectively inhibiting CDK.

(84) A compound as defined in any one of (1), (3) to (38), or a composition as defined in any one of (77) or (78), for use in the prevention or treatment of a protein kinase-mediated disorder.

(85) The compound or composition as (84), wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.

(86) The compound or composition as (84), wherein the disorder is inflammatory disease and/or autoimmune disease.

(87) The compound or composition as (84), wherein the disorder is autoimmune disease.

(88) The compound or composition as (87), wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma,

Sjogren's syndrome, juvenile rheumatoid arthritis, psoriatic arthritis, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

(89) The compound or composition as (87), wherein the autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.

(90) A method of treating or preventing a protein kinase-mediated disorder in an individual, which method comprises administering to said individual a compound as claimed in any one of (1), (3) to (38) or a composition as defined in (77) or (78).

(91) The method as (90) wherein the individual is in need of the treatment or prevention of the disorder.

(92) The method as (90) or (91) wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.

- (93) The method as (90) or (91) wherein the disorder is autoimmune disease.
- (94) The method as (93) wherein the autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.
- (95) The method as (90) to (94) wherein one or more active agent is administered to the individual simultaneously, subsequently or sequentially to administering the compound.
- (96) Use of a compound as defined in any one of (1), (3) to (38) in the manufacture of a medicament for the prevention or treatment of a protein kinase-mediated disorder.
- (97) Use as (96) wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.
- (98) Use as (96) wherein the disorder is autoimmune disease.
- (99) Use as (98) wherein the autoimmune disease is rheumatoid arthritis, psoriasis,

ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.

(100) Use as (96) or (97) wherein one or more active agent is administered to the individual simultaneously, subsequently or sequentially to administering the compound.

(101) An assay for determining the activity of the compounds as defined in any one of (1), (3) to (38), comprising providing a system for assaying the activity and assaying the activity of a compound as defined in any one of (1), (3) to (38).

(102) The assay as (101) wherein the assay is for the protein kinase inhibiting activity of the compound.

(103) A method of inhibiting the activity or function of a protein kinase, which method comprises exposing a protein kinase to a compound as defined in any one of (1), (3) to (38) or a composition as defined in (77) or (78).


(104) The method as (103) which is performed in a research model, *in vitro*, *in silico* or *in vivo* such as in an animal model.

brief description of the drawings

Figure 1 shows the p38 MAPK cascade. Figures 2 - 8 show general reaction schemes for the preparation of compounds of Formula I.

Best Mode for Carrying Out the Invention

In a first aspect the invention provides a compound of formula I:



wherein R^1 is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclylalkynyl;

R^2 is hydrogen, halogen, -CN, -NO₂, -CHO, -G-R⁷ [G is a bond, -C(=O)- or -O-C(=O)-];

and R^7 is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl, -OR⁸ (R^8 is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR⁹R¹⁰ (R^9 is as defined for R^8 ; R^{10} is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl or

-OCH₃), -R¹¹ (R¹¹ is an optionally substituted saturated heterocyclyl with 5 to 7 members containing one to four heteroatoms selected from N, O and S), C6-C14 optionally substituted aryl or optionally substituted heteroaryl; provided that when R⁷ is C6-C14 optionally substituted aryl or optionally substituted heteroaryl, then G is not a bond], -NR⁹C(=O)R¹² (R⁹ is as defined for R⁸; R¹² is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclylalkynyl), -NR⁹C(=X)OR¹³ (R⁹ and R¹³, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁹C(=X)NR¹³R¹⁴ (R⁹, R¹³ and R¹⁴, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁹SO₂R¹³ (R⁹ and R¹³, which may be the same or different, are as defined for R⁸), -SR⁹ (R⁹ is as defined for R⁸) or -S(O)_mR⁹ (R⁹ is as defined for R⁸; m is 1 or 2);

R³ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 unsubstituted aryl, C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R¹⁵ {G is a bond, -C(=O)- or -O-C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted

heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl, $-OR^{16}$ (R^{16} is as defined for R^8) or $-NR^{17}R^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8), $-NR^{17}C(=O)R^{19}$ (R^{17} is as defined for R^8 ; R^{19} is as defined for R^{12}), $-NR^{17}C(=X)OR^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{17}C(=X)NR^{18}R^{20}$ (R^{17} , R^{18} and R^{20} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{17}SO_2R^{18}$ (R^{17} and R^{18} , which may be the same or different, are as defined for R^8), $-S(O)_mR^{17}$ (R^{17} is as defined for R^8 ; m is 0, 1 or 2) and $-SO_2NR^{21}R^{22}$ (R^{21} and R^{22} , which may be the same or different, are as defined for R^8 ; R^{21} and R^{22} together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R²³ {G is a bond, -C(=O)- or -O-C(=O)-; R²³ is as defined for R¹⁵}, $-NR^{24}C(=O)R^{25}$ (R^{24} is as defined for R^8 ; R^{25} is as defined for R^{12}), $-NR^{24}C(=X)OR^{26}$ (R^{24} and R^{26} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{24}C(=X)NR^{26}R^{27}$ (R^{24} , R^{26} and R^{27} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{24}SO_2R^{26}$ (wherein R^{24} and R^{26} , which may be the same or different, are as defined for R^8), $-S(O)_mR^{24}$ (R^{24} is as defined for R^8 ; m is 0, 1 or 2) and $-SO_2NR^{28}R^{29}$ (R^{28} and R^{29} , which may be the same or different, are as defined for R^8 ; R^{28} and R^{29} together may be taken together with the nitrogen to which they are attached to form a

monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl;

R^4 is hydrogen, halogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocycl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclalkynyl, $-OR^{30}$ (R^{30} is as defined for R^8), $-SR^{30}$ (R^{30} is as defined for R^8), $-NR^{30}R^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8), $-NR^{30}C(=O)R^{32}$ (R^{30} is as defined for R^8 ; and R^{32} is as defined for R^{12}), $-NR^{30}C(=X)OR^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined R^8 ; X is O, S, N-CN or NH), $-NR^{30}C(=X)NR^{31}R^{33}$ (R^{30} , R^{31} and R^{33} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH) or $-NR^{30}SO_2R^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8);

R^5 is C1-C8 substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 substituted cycloalkyl [As substituents of C3-C8 cycloalkyl may be mentioned one or more selected from the group consisting of halogen, -CN, $-NO_2$, -CHO, $-G-R^{34}$ {G is a bond, $-C(=O)-$ or $-O-C(=O)-$; R^{34} is as defined for R^{15} },

$-\text{NR}^{35}\text{C}(=\text{O})\text{R}^{36}$ (R^{35} is as defined for R^8 ; R^{36} is as defined for R^{12}), $-\text{NR}^{35}\text{C}(=\text{X})\text{OR}^{37}$ (R^{35} and R^{37} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-\text{NR}^{35}\text{C}(=\text{X})\text{NR}^{37}\text{R}^{38}$ (R^{35} , R^{37} and R^{38} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH) and $-\text{NR}^{35}\text{SO}_2\text{R}^{37}$ (R^{35} and R^{37} , which may be the same or different, are as defined for R^8), unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R³⁹ {G is a bond, -C(=O)- or -O-C(=O)-; R³⁹ is as defined for R¹⁵}, -NR⁴⁰C(=O)R⁴¹ (R⁴⁰ is as defined for R⁸; R⁴¹ is as defined for R¹²), -NR⁴⁰C(=X)OR⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁴⁰C(=X)NR⁴²R⁴³ (R⁴⁰, R⁴² and R⁴³, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH) and -NR⁴⁰SO₂R⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R⁸)], optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl or -NR⁴⁴R⁴⁵ (R⁴⁴ and R⁴⁵, which may be the same or different, are C1-C8 optionally substituted alkyl; R⁴⁴ and R⁴⁵ together may be taken together with the nitrogen to which they are attached to form a mono heterocycle with 5 - 7 members and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said mono heterocycle may optionally be substituted with one or more substituents);

R^6 is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

with the provisos:

that R¹, R² and R⁴ are not all H;

that R⁴ is not pentafluorophenyl;

that R⁵ is not a group represented as the following (a):

(a) C1-C6 alkyl or C3-C6 cycloalkyl, in which an alkyl group or a cycloalkyl group optionally may be substituted by phenyl or by one or more fluoro substituents; and pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs thereof.

For the purposes of this invention, alkyl relates to both straight chain or branched alkyl radicals of 1 to 8 carbon atoms including, but not limited to, methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, isopentyl, neopentyl, *tert*-pentyl, 2-methylpentyl, 4-methylpentyl, 1-ethylbutyl, *n*-hexyl, *n*-heptyl, 2-methylhexyl, 5-methylhexyl, 1,1-dimethylpentyl, 6-methylheptyl and *n*-octyl.

The term "cycloalkyl" means a cycloalkyl radical of 3 to 8 carbon atoms including but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

The term "alkenyl" means a straight chain, branched or ring structured alkenyl radical of 2 to 8 carbon atoms and containing one or more carbon-carbon double bonds and includes, but is not limited to, vinyl, allyl, isopropenyl, 1-propenyl, 2-butenyl, 1-butenyl, 2-methyl-1-propenyl, 2-methyl-3-pentenyl, 1-pentenyl, 2-pentenyl, 4-methyl-1-pentenyl, 1-hexenyl, 2-hexenyl, 2-cyclopentenyl, 2-cyclohexenyl, 2-heptenyl, 2-octenyl, 3-cyclopentenyl, 1,3-butadienyl and 1,5-hexadienyl. When they have cis and trans geometrical isomers, both isomers are included.

The term "alkynyl" means a straight chain or branched alkynyl radical of 2 to 8

carbon atoms and containing one or more carbon-carbon triple bonds and includes, but is not limited to, ethynyl, 2-propynyl, 1-propynyl, 1-butylnyl, 2-butylnyl, 3-hexynyl, 3-methyl-1-butylnyl, 3,3-dimethyl-1-butylnyl, 3-pentylnyl, 2-pentylnyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 1-methyl-3-pentylnyl, 1-methyl-3-hexynyl, 2-heptylnyl and 2-octynyl.

“Aryl” means an aromatic 6-10 membered hydrocarbon containing one ring or being fused to one or more saturated or unsaturated rings including, but not limited to, phenyl, naphthyl, anthracenyl, 5-indanyl and 5,6,7,8-tetrahydro-2-naphthyl.

“Heteroaryl” means an aromatic 5-10 membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S and containing one ring or being fused to one or more saturated or unsaturated rings. Examples of heteroaryl include, but are not limited to, monovalent group including furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, thiadiazole, oxadiazole, tetrazole, pyridine, pyrazine, pyrimidine, pyridazine, benzofuran, dibenzofuran, benzothiophene, indole, benzimidazole, benzothiazole, benzoxazole, quinoline, isoquinoline, quinoxaline, quinoxaline, purine, pteridine, phenoxazine and phenazine.

“Saturated heterocyclyl” means a 3-10 membered saturated ring containing 1 to 4 heteroatoms selected from N, O or S and containing one ring or being fused to one or more saturated rings; the saturated heterocyclyl is fully saturated. Examples of saturated heterocyclyl include, but are not limited to, monovalent group including piperidine, piperazine, morpholine, pyrrolidine, imidazolidine, pyrazolidine and quinuclidine.

“Heterocyclyl” means a 3-10 membered ring system containing 1 to 4 heteroatoms selected from N, O or S. The heterocyclyl system can contain one ring or may be fused to one or more saturated or unsaturated rings; the heterocyclyl can be fully

saturated, partially saturated or unsaturated and includes, but is not limited to, heteroaryl and saturated heterocyclyl; the heterocyclyl can contain one or two $-(C=O)-$ or $-(C=S)-$ groups. Examples of heterocyclyl include, but are not limited to, monovalent group including furan, thiophene, pyrrole, pyrroline, pyrrolidine, oxazole, oxazolidine, isoxazolidine, thiazole, thiazolidine, isothiazole, isothiazolidine, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, triazole, thiadiazole, oxadiazole, tetrazole, pyran, tetrahydropyran, thiopyran, tetrahydrothiopyran, pyridine, pyrazine, pyrimidine, pyridazine, benzofuran, dibenzofuran, benzothiophene, indole, benzimidazole, benzothiazole, benzoxazole, chromane, isochromane, quinoline, decahydroquinoline, isoquinoline, quinazoline, quinoxaline, purine, pteridine, azetidine, morpholine, thiomorpholine, piperidine, homopiperidine, piperazine, homopiperazine, indoline, isoindoline, phenoxazine, phenazine, phenothiazine, quinuclidine, acridine, carbazole, cinnoline, dioxane, dioxolane, dithiane, dithiazine, dithiazole, dithiolane, indolizine, indazole, isoindole, isoxazole, naphthyridine, oxathiazole, oxathiazolidine, oxazine, oxadiazine, phthalazine, quinolizine, tetrahydrofuran, tetrazine, thiadiazine, thiatriazole, thiazine, thianaphthalene, triazine, 1,3-dioxane, 2,5-dihydrofuran, oxazoline, trithiane, piperidin-2-one, 3H-isobenzofuran-1-one, *epsilon*-caprolactam, 2-furanone, 2-pyrrolidone, tetrahydro-3H-pyrazol-3-one, piperazin-2-one, coumarin, tetrahydro-2-pyrimidinone, glutarimide and morpholine-3,5-dione.

“Arylalkyl” used herein is a group comprising a combination of the aryl and the alkyl. Examples thereof include, but are not limited to, benzyl, phenethyl, (2-naphthyl)-methyl, 3-phenylpropyl, 4-phenylbutyl and 5-(1-naphthyl) pentyl.

“Heterocyclylalkyl” is a group comprising a combination of the heterocyclyl and the alkyl. Examples thereof include, but are not limited to, 2-pyridylmethyl,

3-pyridylmethyl, 4-pyridylmethyl, 3-furilmethyl, 2-(3-indolyl)ethyl, 2-morpholinoethyl, 2-piperidinoethyl, 2-(4-pyridyl)-ethyl, 3-(1-piperidinyl)-propyl, 3-(2-thienyl)-propyl, and 2-(1-imidazole)ethyl.

“Arylalkenyl” is a group comprising a combination of the aryl and the alkenyl. Examples thereof include, but are not limited to, styryl, cinnamyl and 4-phenyl-2-butenyl. When they have cis and trans geometrical isomers, both isomers are included.

“Heterocyclalkenyl” used herein is a group comprising a combination of the heterocycl and the alkenyl. Examples thereof include, but are not limited to, (3-pyridyl)vinyl, 3-(3-thienyl)propene-2-yl, 3-(4-morpholinyl)-1-propenyl and 4-(1-piperidyl)-2-butenyl. When they have cis and trans geometrical isomers, both isomers are included.

“Arylalkynyl” used herein is a group comprising a combination of the aryl and the alkynyl. Examples thereof include, but are not limited to, phenylethynyl and 4-phenyl-2-butyne.

“Heterocyclalkynyl” used herein is a group comprising a combination of the heterocycl and the alkynyl. Examples thereof include, but are not limited to, 4-(4-pyridyl)-2-butyne and 5-(1-piperazinyl)-2-pentyne.

Halogen means F, Cl, Br or I.

Suitable substituents include F, Cl, Br, I, -CN, -NO₂, -CHO, -G-R⁴⁶ {G is a bond, -C(=O)-, or -O-C(=O)-; R⁴⁶ is optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C6-C14 aryl, optionally substituted heterocycl, -OR⁴⁷ or -NR⁴⁷R⁴⁸}, -NR⁴⁷C(=O)R⁴⁸, -NR⁴⁷C(=O)OR⁴⁸, -NR⁴⁷C(=O)NR⁴⁸R⁴⁹,

$-\text{NR}^{47}\text{SO}_2\text{R}^{48}$, $-\text{S(O)}_m\text{R}^{47}$, $-\text{NR}^{47}\text{SO}_2\text{R}^{48}$ or $-\text{SO}_2\text{NR}^{47}\text{R}^{48}$; wherein optionally substituted C1-C8 alkyl means C1-C8 alkyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{47}$, $-\text{NR}^{47}\text{R}^{48}$, $-\text{NR}^{47}\text{C(=O)R}^{43}$, $-\text{COOR}^{47}$, $-\text{CONR}^{47}\text{R}^{48}$ and $-\text{S(O)}_m\text{R}^{47}$;

wherein optionally substituted C2-C8 alkenyl means C2-C8 alkenyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{50}$, $-\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{50}\text{C(=O)R}^{51}$, $-\text{COOR}^{50}$, $-\text{CONR}^{50}\text{R}^{51}$ and $-\text{S(O)}_m\text{R}^{50}$;

wherein optionally substituted C2-C8 alkynyl means C2-C8 alkynyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{50}$, $-\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{50}\text{C(=O)R}^{51}$, $-\text{COOR}^{50}$, $-\text{CONR}^{50}\text{R}^{51}$ and $-\text{S(O)}_m\text{R}^{50}$;

wherein optionally substituted C3-C8 cycloalkyl means C3-C8 cycloalkyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{50}$, $-\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{50}\text{C(=O)R}^{51}$, $-\text{COOR}^{50}$, $-\text{CONR}^{50}\text{R}^{51}$ and $-\text{S(O)}_m\text{R}^{50}$;

wherein optionally substituted C6-C14 aryl means C6-C14 aryl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{50}$, $-\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{50}\text{C(=O)R}^{51}$, $-\text{COOR}^{50}$, $-\text{CONR}^{50}\text{R}^{51}$ and $-\text{S(O)}_m\text{R}^{50}$;

wherein optionally substituted heterocyclyl means heterocyclyl which may be optionally substituted with one or more F, Cl, Br, I, -CN, -NO₂, -CHO, heterocyclyl, $-\text{OR}^{50}$, $-\text{NR}^{50}\text{R}^{51}$, $-\text{NR}^{50}\text{C(=O)R}^{51}$, $-\text{COOR}^{50}$, $-\text{CONR}^{50}\text{R}^{51}$ and $-\text{S(O)}_m\text{R}^{50}$;

R^{47} , R^{48} , R^{49} , R^{50} and R^{51} , which may be the same or different, are hydrogen, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C14 aryl, heterocyclyl, arylalkyl or heterocyclylalkyl; $m=0, 1$ or 2 .

R^1 is preferably hydrogen or C1-C6 optionally substituted alkyl. More preferably R^1 is hydrogen.

R^2 is preferably selected from hydrogen, halogen, -CN, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, -OR⁸ (R⁸ is hydrogen or C1-C8 optionally substituted alkyl), -NR⁹R¹⁰ (R⁹ and R¹⁰, which may be the same or different, hydrogen or C1-C8 optionally substituted alkyl), -C(=O)NR⁹R¹⁰ (R⁹ and R¹⁰, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)R¹² (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹² is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)OR¹³ (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹³ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)NR¹³R¹⁴ (R⁹ and R¹³, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl; R¹⁴ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹SO₂R¹³ (R⁹ is hydrogen or C1-C8 optionally substituted alkyl; R¹³ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -SR⁹ (R⁹ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) or -SO₂R⁹ (R⁹ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl).

More preferably R^2 is hydrogen, halogen, -CN or -SCH₃. Still more preferably R^2 is hydrogen;

R^3 is preferably selected from C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} {G is a bond or -C(=O)-; R^{15} is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclalkyl) or -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)}, -NR¹⁷C(=O)R¹⁹ (R^{17} is hydrogen or C1-C8 optionally substituted alkyl; R^{19} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and -S(O)_mR¹⁷ (R^{17} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl; m is 0 or 2)], unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{23} {G is a bond or -C(=O)-; R^{23} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) or -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)}, -NR²⁴C(=O)R²⁵ (R^{24} is hydrogen or C1-C8 optionally substituted alkyl;

R^{25} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and $-S(O)_m R^{24}$ (R^{24} is C1-C8 optionally substituted alkyl or C3-C8 optionally substituted cycloalkyl; m is 0 or 2)].

More preferably R^3 is substituted phenyl [As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkynyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl) and -C(=O)NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)], unsubstituted bicyclic heteroaryl, substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NHC(=O)R¹⁹ (R^{19} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and -SR¹⁷ (R^{17} is C1-C8 optionally substituted alkyl)].

R^4 is preferably selected from hydrogen, C1-C8 optionally substituted alkyl,

C3-C8 optionally substituted cycloalkyl, optionally substituted aryl. More preferably R^4 is hydrogen, methyl or ethyl.

R^5 is preferably selected from C3-C8 substituted cycloalkyl [As substituents of C3-C8 cycloalkyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, $-OR^{30}$ (R^{30} is hydrogen or C1-C8 optionally substituted alkyl), $-NR^{30}R^{31}$ (R^{30} and R^{31} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl) and $-NHC(=O)R^{32}$ (R^{32} is C1-C8 optionally substituted alkyl, C3-C8 substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)], unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, $-OR^{16}$ (R^{16} is hydrogen or C1-C8 optionally substituted alkyl), $-NR^{17}R^{18}$ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl) and $-NHC(=O)R^{41}$ (R^{41} is C1-C8 optionally substituted alkyl, C3-C8 substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)].

More preferably R^5 is preferably selected from cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl -OH and $-NH_2$], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl -OH and $-NH_2$].

Still more preferably R^5 is 4-amino-cyclohexyl, piperidin-3-yl, piperidin-4-yl or pyrrolidin-3-yl.

R^6 is preferably selected from hydrogen and C1-C8 optionally substituted alkyl.

More preferably R⁶ is hydrogen.

As preferred combinations of the groups mentioned as preferred examples of R¹ - R⁶ in formula I according to the invention, there may be mentioned the following combinations 1) to 10).

- 1) In formula I, wherein R¹ is hydrogen, R² is hydrogen, R³ is C6-C14 aryl group substituted by C6-C14 optionally substituted aryl or optionally substituted heterocyclyl [wherein C6-C14 aryl group as R³ may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R⁴ is C1-C8 optionally substituted alkyl, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R⁶ is hydrogen.
- 2) In formula I, wherein R¹ is hydrogen, R² is hydrogen, R³ is C6-C14 aryl group substituted by -OR¹⁶ (R¹⁶ is C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) [wherein C6-C14 aryl group as R³ may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R⁴ is C1-C8 optionally substituted alkyl, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more

selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

3) In formula I, wherein R¹ is hydrogen, R² is hydrogen, R³ is C6-C14 aryl group substituted by -G-R¹⁵ {G is -(CO)-; R¹⁵ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) or -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)} [wherein C6-C14 aryl group as R³ may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R⁴ is C1-C8 optionally substituted alkyl, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

4) In formula I, wherein R^1 is hydrogen, R^2 is hydrogen, R^3 is unsubstituted bicyclic heteroaryl or substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclalkyl), -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NH(CO)R¹⁹ (R^{19} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and -SR¹⁷ (R^{17} is C1-C8 optionally substituted alkyl)], R^4 is C1-C8 optionally substituted alkyl, R^5 is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R^6 is hydrogen.

5) In formula I, wherein R^1 is hydrogen, R^2 is F, R^3 is C6-C14 aryl group substituted by C6-C14 optionally substituted aryl or optionally substituted heterocyclyl [wherein C6-C14 aryl group as R^3 may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R^4 is hydrogen, R^5 is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally

substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

6) In formula I, wherein R¹ is hydrogen, R² is F, R³ is C6-C14 aryl group substituted by -OR¹⁶ (R¹⁶ is C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) [wherein C6-C14 aryl group as R³ may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R⁴ is hydrogen, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

7) In formula I, wherein R¹ is hydrogen, R² is F, R³ is C6-C14 aryl group substituted by -G-R¹⁵ {G is -(CO)-; R¹⁵ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl) or -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)} [wherein C6-C14 aryl group as

R^3 may be substituted by one or more substituents selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl)], R⁴ is hydrogen, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R⁶ is hydrogen.

8) In formula I, wherein R¹ is hydrogen, R² is F, R³ is unsubstituted bicyclic heteroaryl or substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ (R¹⁶ is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), -NH(CO)R¹⁹ (R¹⁹ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) and -SR¹⁷ (R¹⁷ is C1-C8 optionally substituted alkyl)], R⁴ is hydrogen, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected

from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

9) In formula I, wherein R¹ is hydrogen, R² is halogen, -CN or -SCH₃, R³ is C₆-C₁₄ optionally substituted aryl, optionally substituted bicyclic heteroaryl, R⁴ is hydrogen, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

10) In formula I, wherein R¹ is hydrogen, R² is halogen or -CN, R³ is C₆-C₁₄ optionally substituted aryl, optionally substituted bicyclic heteroaryl, R⁴ is C1-C8 optionally substituted alkyl, R⁵ is cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclyl or substituted saturated heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂] and R₆ is hydrogen.

The compounds of the first aspect may be provided as a salt, preferably as a pharmaceutically acceptable salt of the compounds of formula I. Examples of pharmaceutically acceptable salts of these compounds include those derived from organic acids such as acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, mandelic acid, methanesulphonic acid, benzenesulphonic acid,

trifluoroacetic acid and *p*-toluenesulphonic acid, mineral acids such as hydrochloric and sulphuric acid and the like, giving methanesulphonate, benzenesulphonate, *p*-toluenesulphonate, hydrochloride and sulphate, and the like, respectively or those derived from bases such as organic and inorganic bases. Examples of suitable inorganic bases for the formation of salts of compounds for this invention include the hydroxides, carbonates, and bicarbonates of ammonia, lithium, sodium, calcium, potassium, aluminium, iron, magnesium, zinc and the like. Salts can also be formed with suitable organic bases. Such bases suitable for the formation of pharmaceutically acceptable base addition salts with compounds of the present invention include organic bases which are non-toxic and strong enough to form salts. Such organic bases are already well known in the art and may include amino acids such as arginine and lysine, mono-, di-, or trihydroxyalkylamines such as mono-, di-, and triethanolamine, choline, mono-, di-, and trialkylamines, such as methylamine, dimethylamine, and trimethylamine, guanidine; *N*-methylglucosamine; *N*-methylpiperazine; morpholine; ethylenediamine; *N*-benzylphenethylamine; tris(hydroxymethyl) aminomethane; and the like.

Salts may be prepared in a conventional manner using methods well known in the art. Acid addition salts of said basic compounds may be prepared by dissolving the free base compounds of the invention in aqueous or aqueous alcohol solution or other suitable solvents containing the required acid. Where a compound of the invention contains an acidic function, a base salt of said compound may be prepared by reacting said compound with a suitable base. The acid or base salt may separate directly or can be obtained by concentrating the solution *e.g.* by evaporation. The compounds of this

invention may also exist in solvated or hydrated forms.

























The invention also extends to a prodrug of the aforementioned compounds such as an ester or amide thereof. A prodrug is any compound that may be converted under physiological conditions or by solvolysis to any of the compounds of the invention or to a pharmaceutically acceptable salt of the compounds of the invention. A prodrug may be inactive when administered to a subject but is converted *in vivo* to an active compound of the invention.

The compounds of the invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. The compounds of the invention may exist in trans or cis form. The first aspect of the invention covers all of these compounds.

























As specific examples of compounds of the formula I above there may be mentioned compounds listed in Table A below.

Wherein "Me", "Et", "*n*-Pr", "*i*-Pr", "*n*-Bu", "*t*-Bu" and "Ph" mean "methyl group", "ethyl group", "*n*-propyl group", "isopropyl group", "*n*-butyl group", "*tert*-butyl group" and "phenyl group" respectively.

Table A

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
1	H	CN	H		
2	H	Br	H		
3	Me	H	H		
4	<i>t</i> -Bu	H	H		
5	Ph	H	H		
6	Me	Br	H		
7	H	Cl	H		
8	<i>t</i> -Bu	Br	H		
9	H	COOEt	H		
10	H	H	Me		
11	H	H	<i>n</i> -Pr		
12	H	H	Ph		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
13	H	Br	H		
14	H	Br	<i>n</i> -Pr		
15	H	H	Me		
16	H	H	Et		
17	H	H			
18	H	Br	Me		
19	H	H			
20	H	Br	Me		
21	H	H	Ph	Me	
22	H	H			
23	H	H	Et		
24	H	H			



























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
25	H	H	Et		
26	H	H	Et		
27	H	H	Et		
28	H	H	Et		
29	H	H	Et		
30	H	H	Et		
31	H	H	Et		
32	H	H	Me		
33	H	H	Et		
34	H	H	Et		
35	H	H	Et		
36	H	H	Et		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
37	H	H	Et		
38	H	H	Et		
39	H	H	Et		
40	H	H	Et		
41	H	H	Et		
42	H	H	Et		
43	H	H	Et		
44	H	H	Et		
45	H	H	Et		
46	H	H	Et		
47	H	I	H		
48	H	I	H		
























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
49	H	I	H		
50	H	Br	H		
51	H	H			
52	H	H			
53	H	H			
54	H	H	Et		
55	H	H	Et		
56	H	H	Et		
57	H	H	Et		
58	H	H	Et		
59	H	H	Et		
60	H	H	Et		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
61	H	H	Et		
62	H	H	Et		
63	H	H	Et		
64	H	CN	H		
65	H	H	Me		
66	H	H	Me		
67	H	H	Me		
68	H	H	Me		
69	H	H	Et		
70	H	H	Et		
71	H	H	Et		
72	H	H	Et		


























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
73	H	H	Et		
74	H	H	Et		
75	H	H	Et		
76	H	H	Me		
77	H	H	Me		
78	H	SMe	H		
79	H	H	Me		
80	H	H	Me		
81	H	H	Me		
82	H	H	Me		
83	H	H	Me		
84	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
85	H	H	Me		
86	H	H	Me		
87	H	H	Me		
88	H	H	Me		
89	H	H	Me		
90	H	H	Me		
91	H	H	Me		
92	H		Me		
93	H	H	Et		
94	H		Me		
95	H	H	Me		
96	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
97	H	H	Me		
98	H	H	Me		
99	H	H	Me		
100	H	H	Me	<i>t</i> -Bu	
101	H	H	Me		
102	H	H	Me	Ph	
103	H	H	Me		
104	H	H	Me		
105	H	H	Me		
106	H	H	Me		
107	H	H	Me		
108	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
109	H	H	Me		
110	H	H	Me		
111	H	H	Me		
112	H	H	Me		
113	H	H	Et		
114	H	H	<i>i</i> -Pr		
115	H	H	<i>i</i> -Pr		
116	H	H	Et		
117	H	H	Et		
118	H	H	Me		
119	H	H	Me		
120	H	H	Me	Ph	

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
121	H	H	Me		
122	H	H	Me		
123	H	H	Me		
124	H	H	Et		
125	H	H	Et		
126	H	H	Me		
127	H	H	Me		
128	H	H	Et		
129	H	H	Me		
130	H	H	Me		
131	H	H	Me		
132	H		Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
133	H	H	Me		
134	H	H	Me		
135	H	H	Me		
136	H	H	Et		
137	H	H	Et		
138	H	H	Me		
139	H	H	Et		
140	H	H			
141	H	H	Et		
142	H	H	Me		
143	H	H	Me		
144	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
145	H	H	Me		
146	H	H	Me		
147	H	H	Me		
148	H	H	Me		
149	H	H	Me		
150	H	H	Me		
151	H	H	Et		
152	H	H	Me		
153	H	H	Me		
154	H	Et	Me		
155	H	H	Me		
156	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
157	H	H	Ph		
158	H	Et	Me		
159	H	H	Et		
160	H	H	Et		
161	H	H	Me		
162	H	H	Me		
163	H		Me		
164	H		Me		
165	H	<i>i</i> -Pr	Me		
166	H	<i>i</i> -Pr	Me		
167	H	H	Et	Ph	
168	H	H	Et		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁴ R ⁶
169	H	Cl	Et		
170	H	CN	H		
171	H	H	OMe		
172	H	H	OMe		
173	H	H	OMe		
174	H	H	Me		
175	H	H	Et		
176	H	H	Me		
177	H	H	Me		
178	H	H	Me		
179	H	H	Me		
180	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
181	H	H	Me		
182	H	H	Me		
183	H	H	Me		
184	H	H	Me		
185	H	H	Me		
186	H	H	Me		
187	H	H	Me		
188	H	H	Me		
189	H	H	Me		
190	H	H	Me		
191	H	H	Me		
192	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
193	H	H	Me		
194	H	H	Me		
195	H	H	Me		
196	H	H	Me		
197	H	H	Me		
198	H	H	Me		
199	H	H	Me		
200	H	H	Me		
201	H	H	Me		
202	H	H	Me		
203	H	H	Me		
204	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
205	H	H	Me		
206	H	H	Me		
207	H	H	Me		
208	H	H	Me		
209	H	H	Me		
210	H	H	Me		
211	H	H	Me		
212	H	H	Me		
213	H	H	Me		
214	H	H	Me		
215	H	H	Me		
216	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
217	H	H	Me		
218	H	H	Me		
219	H	H	Me		
220	H	H	Me		
221	H	H	Me		
222	H	H	Me		
223	H	H	Me		
224	H	H	Me		
225	H	H	Me		
226	H	H	Me		
227	H	H	Me		
228	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
229	H	H	Me		
230	H	H	Me		
231	H	H	Me		
232	H	H	Me		
233	H	H	Me		
234	H	H	Me		
235	H	H	Me		
236	H	H	Me		
237	H	H	Me		
238	H	H	Me		
239	H	H	Me		
240	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
241	H	H	Me		
242	H	H	Me		
243	H	H	Me		
244	H	H			
245	H	H			
246	H	H	Me		
247	H	H	Me		
248	H	H	Me		
249	H	H	Me		
250	H	H	Me		
251	H	H	Me		
252	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
253	H	H	Me		
254	H	H	Me		
255	H	H	Me		
256	H	H	Me		
257	H	H	Me		
258	H	H	Me		
259	H	H	Me		
260	H	H	Me		
261	H	H	Me		
262	H	H	Me		
263	H	H	Me		
264	H	H	Me		




































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
265	H	H	Me		
266	H	H	Me		
267	H	H	Me		
268	H	H	Me		
269	H	H	Me		
270	H	H	Me		
271	H	H	Me		
272	H	H	Me		
273	H	H	Me		
274	H	H	Me		
275	H	H	Me		
276	H	H	Me		

































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
277	H	H	Me		
278	H	H	Me		
279	H	H	Me		
280	H	H	Me		
281	H	H	Me		
282	H	H	Me		
283	H	H	Me		
284	H	H	Me		
285	H	H	Me		
286	H	H	Me		
287	H	H	Me		
288	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
289	H	H	Me		
290	H	H	Me		
291	H	H	Me		
292	H	H	Me		
293	H	CN	Me		
294	H	CN	Me		
295	H	CN	Me		
296	H	H	Me		
297	H	I	H		
298	H	H	Me		
299	H	H	Me		
300	H	H	Me		






























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
301	H	H	Me		
302	H	H	Me		
303	H	H	Me		
304	H	H	Me		
305	H	H	Me		
306	H	H	Me		
307	H	H	Me		
308	H	H	Me		
309	H	H	Me		
310	H	H	Me		
311	H	H	Me		
312	H	H	Me		
































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
313	H	H	Me		
314	H	H	Me		
315	H	H	Me		
316	H	H	Me		
317	H	H	Me		
318	H	H	Me		
319	H	H	Me		
320	H	H	Me		
321	H	H	Me		
322	H	H	Me		
323	H	H	Me		
324	H	H	Me		

































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
325	H		Me		
326	H		Me		
327	H	COOH	Me		
328	H		Me		
329	H		Me		
330	H		Me		
331	H		Me		
332	H		Me		
333	H		Me		
334	H		Me		
335	H		Me		
336	H		Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
337	H		Me		
338	H		Me		
339	H		Me		
340	H	H	Me		
341	H	H	Me		
342	H	H	Me		
343	H	NH ₂	Me		
344	H		Me		
345	H		Me		
346	H		Me		
347	H		Me		
348	H		Me		




























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
349	H		Me		
350	H	H	Me		
351	H	H	Me		
352	H	H	Me		
353	H	H	Me		
354	H	H	Me		
355	H	H	Me		
356	H	H	Me		
357	H	H	Me		
358	H		Me		
359	H		Me		
360	H		Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
361	H		Me		
362	H		Me		
363	H		Me		
364	H		Me		
365	H		Me		
366	H	H	Me		
367	H	H	Me		
368	H	H	Me		
369	H	H	Me		
370	H	H	Me		
371	H	H	Me		
372	H	H	Me		
































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
373	H	H	Me		
374	H	H	Me		
375	H	H	Me		
376	H	H	Me		
377	H	H	Me		
378	H		Me		
379	H		Me		
380	H		Me		
381	H		Me		
382	H		Me		
383	H		Me		
384	H		Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
385	H		Me		
386	H		Me		
387	H		Me		
388	H		Me		
389	H		Me		
390	H		Me		
391	H		Me		
392	H		Me		
393	H	H	Me		
394	H	H	Me		
395	H	H	Me		
396	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
397	H	H	Me		
398	H	H	Me		
399	H	H	Me		
400	H	H	Me		
401	H	H	Me		
402	H	H	Me		
403	H	H	Me		
404	H	H	Me		
405	H	H	Me		
406	H	H	Me		
407	H	H	Me		
408	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
409	H	H	Me		
410	H	H	Me		
411	H	H	Me		
412	H	H	Me		
413	H	Me	Me		
414	H	Me	Me		
415	H		Me		
416	H		Me		
417	H		Me		
418	H	H	Me		
419	H	H	Me		
420	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
421	H	H	Me		
422	H	H	Me		
423	H	H	Me		
424	H	H	Me		
425	H	OMe	Me		
426	H		Me		
427	H		Me		
428	H		Me		
429	H		Me		
430	H		Me		
431	H		Me		
432	H		Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
433	H		Me		
434	H		Me		
435	H		Me		
436	H		Me		
437	H		Me		
438	H		Me		
439	H		Me		
440	H	COOH	Me		
441	H	F	Me		
442	H	H	Me		
443	H	H	Me		
444	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
445	H	H	Me		
446	H	H	Me		
447	H	H	Me		
448	H	H	Me		
449	H	H	Me		
450	H	H	Me		
451	H	H	Me		
452	H	H	Me		
453	H	H	Me		
454	H	H	Me		
455	H	H	Me		
456	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
457	H	H	Me		
458	H	H	Me		
459	H	H	Me		
460	H	H	Me		
461	H	H	Me		
462	H	H	Me		
463	H	H	Me		
464	H	H	Me		
465	H	H	Me		
466	H	H	Me		
467	H	H	Me		
468	H	H	Me		









































Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
469	H	H	Me		
470	H	H	Me		
471	H	H	Me		
472	H	H	Me		
473	H	H	Me		
474	H	H	Me		
475	H	H	Me		
476	H	H	Me		
477	H	H	Me		
478	H	H	Me		
479	H	H	Me		
480	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
481	H	H	Me		
482	H	H	Me		
483	H	H	Me		
484	H	H	Me		
485	H	H	Me		
486	H	H	Me		
487	H	H	Me		
488	H	H	Me		
489	H	H	Me		
490	H	H	Me		
491	H	H	Me		
492	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
493	H	H	Me		
494	H	H	Me		
495	H	H	Me		
496	H	H	Me		
497	H	H	Me		
498	H	H	Me		
499	H	H	Me		
500	H	H	Me		
501	H	H	Me		
502	H	H	Me		
503	H	H	Me		
504	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
505	H	H	Me		
506	H	H	Me		
507	H	H	Me		
508	H	H	Me		
509	H	H	Me		
510	H	H	Me		
511	H	H	Me		
512	H	H	Me		
513	H	H	Me		
514	H	H	Me		
515	H	H	Me		
516	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
517	H	H	Me		
518	H	H	Me		
519	H	H	Me		
520	H	H	Me		
521	H	H	Me		
522	H	H	Me		
523	H	H	Me		
524	H		H		
525	Me		Me		
526	H		OMe		
527	H		Et		
528	H				

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
529	H				
530	H				
531	H		Me		
532	H		H		
533	H		Et		
534	H		OMe		
535	H		Me		
536	H		Me		
537	H				
538	H		H		
539	H		Et		
540	H				

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
541	H		Me		
542	H		Et		
543	Me		OMe		
544	H		H		
545	H		Me		
546	H				
547	H		H		
548	H		H		
549	H				
550	H		Et		
551	H		H		
552	H		Et		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
553	H		OMe		
554	H		H		
555	H		Et		
556	H		Me		
557	H		Me		
558	Me		OMe		
559	H				
560	H		Et		
561	H				
562	H		Me		
563	H		H		
564	H		Me		




























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
565	H		H		
566	H		Me		
567	H		Et		
568	H		H	Ph	
569	H	H	Me		
570	H	H	Me		
571	H	F			
572	H	Br	H		
573	H		Me		
574	H	F	Et		
575	H	H	Me		
576	H				

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
577	H	F	Me		
578	H	H	Me		
579	H	H	Me		
580	H		Me		
581	H	Br	H		
582	H	H	Me		
583	H		H		
584	H	F	H		
585	H	F	OMe		
586	H	Me	H		
587	H	F	Me		
588	H		H		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
589	H	F	OMe		
590	H	H			
591	H		Me		
592	H	F			
593	H	F	H		
594	H	Me			
595	H		Me		
596	H	F	H		
597	H	F	H		
598	H	F	H		
599	H	H	OMe		
600	H		Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
601	H	F	Me		
602	H	F	Me		
603	H		H		
604	H	H	Me		
605	H	F	Me		
606	H	F	Me		
607	H	F	H		
608	H	H	Et		
609	H		H		
610	H	NH ₂			
611	H	F	Me		
612	H		Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
613	H	F	H		
614	H	Me	Me		
615	H	F	H		
616	H	H	Me		
617	H	H	Me		
618	H	H			
619	H	H	Me		
620	H	F	Me		
621	H	NH ₂	H		
622	H	F	Et		
623	H	H	Me		
624	H	NH ₂	H		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
625	H	F			
626	H		H		
627	H	Br	Me		
628	H	H			
629	H	H	Me		
630	H	H	Me		
631	H	H	Me		
632	H	H	Me		
633	H	H	Me		
634	H	H	Me		
635	H	H	Me		
636	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
637	H	H	Me		
638	H	H	Me		
639	H	H	Me		
640	H	H	Me		
641	H	H	Me		
642	H	H	Me		
643	H	H	Me		
644	H	H	Me		
645	H	H	Me		
646	H	H	Me		
647	H	H	Me		
648	H	H	Me		

























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
649	H	H	Me		
650	H	F	Me		
651	H	F	Me		
652	H	H	Et		
653	H	H	Me		
654	H	H	Me		
655	H	H	Me		
656	H	H	Me		
657	H	F	Me		
658	H	H	Me		
659	H	F	Me		
660	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
661	H	H	Me		
662	H	F	Me		
663	H	H	Me		
664	H	F	Me		
665	H	F	Me		
666	H	F	Et		
667	H	H	Me		
668	H	F	Me		
669	H	H	Me		
670	H	H	Me		
671	H	F	Me		
672	H	H	Me		





























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
673	H	F	Me		
674	H	H	Me		
675	H	H	Me		
676	H	H	Me		
677	H	H	Me		
678	H	F	Me		
679	H	H	Me		
680	H	H	Me		
681	H	H	Me		
682	H	H	Me		
683	H	F	Me		
684	H	H	Me		




























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
685	H	H	Me		
686	H	H	Me		
687	H	H	Me		
688	H	H	Me		
689	H	H	Me		
690	H	H	Me		
691	H	F	Me		
692	H	H	Me		
693	H	F	Et		
694	H	H	Me		
695	H	F	Me		
696	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
697	H	F	Me		
698	H	H	Me		
699	H	F	Me		
700	H	H	Me		
701	H	F	Me		
702	H	H	Et		
703	H	F	Me		
704	H	H	Me		
705	H	F	Et		
706	H	H	Me		
707	H	F	Me		
708	H		Me		




























Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
709	H	Cl	H		
710	H	Cl	H		
711	H	Cl	H		
712	H	Cl	H		
713	H	Cl	H		
714	H	Cl	H		
715	H	Cl	H		
716	H	Cl	Me		
717	H	Cl	H		
718	H	Cl	H		
719	H	Br	H		
720	H	Br	H		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
721	H	Br	H		
722	H	Br	H		
723	H	Br	H		
724	H	Br	H		
725	H	Br	H		
726	H	Br	H		
727	H	I	H		
728	H	I	H		
729	H	I	H		
730	H	I	H		
731	H	I	H		
732	H		H		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
733	H		H		
734	H	Me	H		
735	H	Me	H		
736	H		H		
737	H		H		
738	H		H		
739	H	CN	H		
740	H	CN	H		
741	H	CN	H		
742	H	CN	H		
743	H	CN	H		
744	H	CN	H		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
745	H	CN	H		
746	H	CN	H		
747	H		H		
748	H		H		
749	H		H		
750	H	SMe	H		
751	H	SMe	H		
752	H	SMe	H		
753	H	SMe	H		
754	H	SMe	H		
755	H	SMe	H		
756	H	SMe	H		







Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
757	H	SMe	H		
758	H	OMe	H		
759	H	H	Me		
760	H	H	Me		
761	H	H	Me		
762	H		Me		
763	H		Me		
764	H		Me		
765	H		Me		
766	H		Me		
767	H		Me		
768	H		Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
769	H		Me		
770	H		Me		
771	H		Me		
772	H	H	Me		
773	H	H	Me		
774	H	H	Me		
775	H	H	Me		
776	H	H	Me		
777	H	H	Me		
778	H	H	Me		
779	H	H	Me		
780	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
781	H	H	Me		
782	H	H	Me		
783	H	H	Me		
784	H	H	Me		
785	H	H	Me		
786	H	H	Me		
787	H	H	Me		
788	H	H	Me		
789	H	H	Me		
790	H		Me		
791	H		Me		
792	H	H	Me		


Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
793	H	H	Me		
794	H	H	Me		
795	H	H	Me		
796	H	H	Me		
797	H	H	Me		
798	H	H	Me		
799	H	H	Me		
800	H	H	Me		
801	H	H	Me		
802	H	H	Me		
803	H	H	Me		
804	H	H	Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
805	H	H	Me		
806	F	F	Me		
807	H	H	Me		
808	H	H	Me		
809	H	H	Me		
810	H	H	Me		
811	H	H	Me		
812	H	H	Me		
813	H	H	Me		
814	H	H	Me		
815	H		Me		
816	H		Me		

Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶
817	H		Me		
818	H		Me		

In a second aspect, the present invention provides a compound of formula II-26, III-01 and IV which are useful as synthetic intermediates for a compound of formula I:

1) A compound of the formula II-26




wherein $R^1 - R^6$ are as defined for formula I above; R^{45} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H;

R^{45} is preferably *tert*-butyl or benzyl.

2) A compound of the formula III-01




wherein $R^1 - R^6$ are as defined for formula I above; R^{45} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H;

R⁴⁵ is preferably *tert*-butyl or benzyl.

3) A compound of the formula IV




wherein R¹ - R⁶ are as defined for formula I above;

with the provisos:


that R¹, R² and R⁴ are not all H;

that R⁴ is not optionally substituted aryl or optionally substituted heteroaryl.

The pyrazolo[1,5-*a*]pyrimidine derivatives represented by formula I above exist as tautomers represented by the following formula X and XI:



wherein R¹ - R⁶ are as defined for formula I above;




wherein R¹ - R⁶ are as defined for formula I above;

These tautomers are also encompassed within the scope of the present invention.

In a third aspect, the present invention provides a process for the manufacture of a compound of the invention by reaction of a compound of formula II, III, IV, V, VI,


VII, V-01, IV-01, II-01, II-03, II-04, II-06, II-08, II-13, II-15, II-18, II-20, II-22, II-24, I-26, I-28 or V-04 as follows, wherein R^1 - R^6 are as defined above:

- 1) reacting a compound of the formula II




with acid *e.g.* trifluoroacetic acid for removal of *t*-butoxycarbonyl groups of a compound (for example as described in *Protective Groups in Organic Synthesis*, 3rd Ed, John Wiley & Sons Inc)

- 2) reacting a compound of the formula III




with a compound of the formula R^5R^6NH either in the absence or presence of transition metal catalyst under *e.g.* Buchwald conditions (for example as described in *J. Am. Chem. Soc.* 1994, 116, 7901.)

- 3) reacting a compound of the formula IV




with a compound of the formula R⁵R⁶NH

- 4) reacting a compound of the formula IV




with a compound of the formula di *t*-butyl dicarbonate (for example as described in Protective Groups in Organic Synthesis, 3rd Ed, John Wiley & Sons Inc)

- 5) reacting a compound of the formula V




with a compound of the formula R³NH₂ or R³NHAc in the presence of base *e.g.* triethylamine and sodium hydride

- 6) reacting a compound of the formula VI




with a halogenating agent *e.g.* phosphorus oxychloride or phenyl phosphonic dichloride (for example as described in US 3907799 (CA 1975, 84, 4998p), J. Med. Chem. 1977, 20, 296, Monatsh Chem. 1986, 117, 1305.)

7) reacting a compound of the formula VII




with a compound of the formula $R^4CH(CO_2Me)_2$ or $R^4CH(CO_2Et)_2$ (for example as described in J. Med. Chem. 1976, 19, 296 and J. Med. Chem. 1977, 20, 296.)

8) reacting a compound of the formula V-01




with a halogenating agent *e.g.* *N*-chlorosuccinimide, *N*-bromosuccinimide (for example as described in J. Med. Chem. 1976, 19, 517.) or iodine monochloride

9) reacting a compound of the formula V-01




with a thiocyanating agent *e.g.* combination of potassium thiocyanate and bromine

10) reacting a compound of the formula V-01




with an acylating agent *e.g.* dimethyl formamide/phosphorus oxychloride or acetyl chloride/aluminium trichloride

11) reacting a compound of the formula IV-01




with a Grignard reagent *e.g.* methyl magnesium chloride

12) reacting a compound of the formula II-01




with an acylating agent *e.g.* trifluoroacetic anhydride

13) reacting a compound of the formula II-01




with fluorinating agent *e.g.* 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2] octane bis(tetrafluoroborate) (J. Chem. Soc. Perkin 1, 1996, 2069.)

14) reacting a compound of the formula II-03



with aqueous sodium hydroxide for the hydrolysis of ester group in compound; R⁶⁷ is methyl or ethyl

15) reacting a compound of the formula II-04




with amine derivatives in the presence of peptide coupling agent *e.g.*

ethyl-3-(3'-dimethylaminopropyl) carbodiimide hydrochloride,


N-hydroxybenzotriazole monohydrate and triethylamine

16) reacting a compound of the formula II-06




with oxidizing agent *e.g.* iodosobenzene diacetate for Hofmann rearrangement in the presence of benzyl alcohol (for example as described in J. Org. Chem. 1979, 44, 1746 and Synthesis 1981, 266.), followed by removal of the benzyloxy carbonyl group by hydrogenolysis in the presence of palladium on carbon (for example as described in Protective Groups in Organic Synthesis, 3rd Ed, John Wiley & Sons Inc)

17) reacting a compound of the formula II-08




with a compound of the formula $R^{12}COCl$, $R^{12}COOH$, $R^{10}SO_2Cl$, $R^{10}NCO$ or $R^{10}NCS$

18) reacting a compound of the formula II-13




with alcohol derivatives in the presence of *e.g.* diisopropyl azodicarboxylate and polymer supported triphenylphosphine under *e.g.* Mitsunobu conditions (for example as described in Synthesis 1981, 1.); Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl

19) reacting a compound of the formula II-15




with boronic acid derivatives in the presence of transition metal catalyst under *e.g.* Suzuki coupling conditions (for example as described in Chem. Rev. 1995, 95, 2457.); Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl

20) reacting a compound of the formula II-15



with a 1-alkyne in the presence of transition metal catalyst under Sonogashira coupling conditions (Synthesis 1980, 627, and Comprehensive Organic Synthesis, Vol. 3, p. 521, 1991.); Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl


21) reacting a compound of the formula II-18



with a compound of the formula R¹⁶R¹⁷NH in the presence of peptide coupling agent;

Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl


22) reacting a compound of the formula II-20



with an alkyl lithium *e.g.* *n*-butyl lithium under Weinreb conditions (for example as described in Tetrahedron Lett. 1981, 22, 3815.)


23) reacting a compound of the formula II-22

141




with alkyl halide *e. g.* methyl iodide in the presence of base, followed by trifluoroacetic acid and sodium hydroxide, respectively, for removal of *t*-butoxycarbonyl and trifluoroacetyl group from a compound

24) reacting a compound of the formula II-08



with an aldehyde *e.g.* benzyl aldehyde in the presence of reducing agent *e.g.* sodium acetoxyborohydride


25) reacting a compound of the formula II-24



with alkyl halide *e. g.* methyl iodide in the presence of base *e. g.* sodium hydride

26) reacting a compound of the formula I-26


142



(I-26)

with H_2 in the presence of $Pd(OH)_2-C$ or *alpha*-chloroethyl chloroformate followed by methanol for removal of R^{60} group from a compound (for example as described in Protective Groups in Organic Synthesis, 3rd Ed, John Wiley & Sons Inc); R^{60} is benzyl or *p*-MeO-benzyl; n is 1, 2 or 3


27) reacting a compound of the formula I-28



(I-28)

with halogenating agent *e.g.* iodine monochloride

28) reacting a compound of the formula V-04



(V-04)

with reducing agent *e.g.* sodium borohydride or with diol derivative *e.g.* propane 1,3-diol and ethane 1,2-diol for formation of acetal.

A compound of formula I may undergo one or more further reactions to provide a different compound of formula I. For example, a compound may undergo a reduction, oxidation, elimination, substitution and/or addition reaction.

Figure 2 - 8 shows a general reaction scheme for the preparation of compounds of Formula I.

The compounds of formula V, VI, VII and VIII are either known or can be prepared by methods analogous to those known for preparing analogous known compounds.

Other methods will be apparent to the chemist skilled in the art, as will the methods for preparing starting materials and intermediates. The Examples also make apparent various methods of preparing compounds of the invention as well as starting materials and intermediates.

In a fourth aspect, the present invention provides a composition comprising a compound of the invention in combination with a pharmaceutically acceptable carrier, diluent or excipient.

The composition may also comprise one or more additional active agents, such as an anti-inflammatory agent (for example a p38 inhibitor, glutamate receptor antagonist, or a calcium channel antagonist), a chemotherapeutic agent and/or an antiproliferative agent.

Suitable carriers and/or diluents are well known in the art and include pharmaceutical grade starch, mannitol, lactose, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, (or other sugar), magnesium carbonate, gelatin, oil, alcohol, detergents, emulsifiers or water (preferably sterile). The composition may be a

mixed preparation of a composition or may be a combined preparation for simultaneous, separate or sequential use (including administration).

The composition according to the invention for use in the aforementioned indications may be administered by any convenient method, for example by oral (including by inhalation), parenteral, mucosal (e.g. buccal, sublingual, nasal), rectal or transdermal administration and the compositions adapted accordingly.

For oral administration, the composition can be formulated as liquids or solids, for example solutions, syrups, suspensions or emulsions, tablets, capsules and lozenges.

A liquid formulation will generally consist of a suspension or solution of the compound or physiologically acceptable salt in a suitable aqueous or non-aqueous liquid carrier(s) for example water, ethanol, glycerine, polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and microcrystalline cellulose.

A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, powders, granules or pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.

Compositions for oral administration may be designed to protect the active

ingredient against degradation as it passes through the alimentary tract, for example by an outer coating of the formulation on a tablet or capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or physiologically acceptable salt in a sterile aqueous or non-aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal or oral administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a pharmaceutically acceptable propellant. The aerosol dosage forms can also take the form of a pump-atomiser.

Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.

Compositions for rectal or vaginal administration are conveniently in the form of suppositories (containing a conventional suppository base such as cocoa butter), pessaries, vaginal tabs, foams or enemas.

Compositions suitable for transdermal administration include ointments, gels, patches and injections including powder injections.

Conveniently the composition is in unit dose form such as a tablet, capsule or ampoule.

In a fifth aspect, the present invention provides a process for the manufacture of a composition according of the invention which comprises admixing one or more compounds of the invention with one more pharmaceutically acceptable excipients, carriers or diluents. The manufacture can be carried out by standard techniques well known in the art and involves combining a compound according to the first aspect of the invention and the pharmaceutically acceptable carrier or diluent. The composition may be in any form including a tablet, a liquid, a capsule, and a powder or in the form of a food product, *e.g.* a functional food. In the latter case the food product itself may act as the pharmaceutically acceptable carrier.

In a sixth aspect, the present invention provides a compound or composition of the invention, for use in medicine.

The compounds of the present invention are inhibitors of protein kinases such as mitogen-activated protein kinases, particularly mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2), or cyclin dependent kinases (CDK) *e.g.*, CDK1 and CDK2. Preferably, the compounds of the invention inhibit MAPKAP-K2 or CDK selectively (*i.e.*, the compounds of the present invention show greater activity against one kinase than the other). For the purpose of this invention, an inhibitor is any compound which reduces or prevents the activity of a protein kinase.

The compounds are therefore useful for conditions for which inhibition of protein kinase activity is beneficial. Thus, preferably, this aspect provides a compound

of the first aspect, or a composition of the third aspect of the present invention, for the prevention or treatment of a protein kinase-mediated disorder. The compounds of the first aspect of the invention may thus be used for the inhibition of protein kinase.

A "protein kinase-mediated disorder" is any disease or deleterious condition in which protein kinase plays a role. Examples include neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis; stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and thrombin induced platelet aggregation.

The compounds of the present invention are particularly useful for the prevention or treatment of a neurodegenerative disorder. In particular, the neurodegenerative disorder results from apoptosis and/or inflammation. Examples of neurodegenerative disorders are: dementia; Alzheimer's disease; Parkinson's disease; Amyotrophic Lateral Sclerosis; Huntington's disease; senile chorea; Sydenham's chorea; hypoglycemia; head and spinal cord trauma including traumatic head injury; acute and chronic pain; epilepsy and seizures; olivopontocerebellar dementia; neuronal cell death; hypoxia-related neurodegeneration; acute hypoxia; glutamate toxicity including glutamate neurotoxicity; cerebral ischemia; dementia linked to meningitis and/or neurosis; cerebrovascular dementia; or dementia in an HIV-infected patient.

The compounds of the invention can also be used to prevent or treat disorders resulting from inflammation. These include, for example, inflammatory bowel disorder, bronchitis, asthma, acute pancreatitis, chronic pancreatitis, allergies of various types, and possibly Alzheimer's disease. Autoimmune diseases which may also be treated or

prevented by the compounds of the present invention include rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome, psoriatic arthritis, glomerulonephritis, scleroderma, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropaenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

A compound of the present invention may be administered simultaneously, subsequently or sequentially with one or more other active agent, such as an anti-inflammatory agent *e.g.* p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent. For example, for acute treatment, a p38 inhibitor may be administered to a patient prior to administering a compound of the present invention.

The compounds of the invention will normally be administered in a daily dosage regimen (for an adult patient) of, for example, an oral dose of between 1 mg and 2000 mg, preferably between 30 mg and 1000 mg, *e.g.* between 10 and 250 mg or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 50 mg, *e.g.* between 1 and 25 mg of the compound of the formula I, or a physiologically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day. Suitably the compounds will be administered for a period of continuous therapy, for example for a week or more.

In a seventh aspect, the present invention provides a method of treating or preventing a protein kinase-mediated disorder in an individual, which method comprises administering to said individual one or more compounds of the invention or a composition of the invention. The active compound is preferably administered in a

cumulative effective amount. The individual may be in need of the treatment or prevention. Any of the protein kinase-mediated disorders listed above in relation to the fifth aspect may be the subject of treatment or prevention according to the sixth aspect. One or more other active agent may be administered to the individual simultaneously, subsequently or sequentially to administering the compound. The other active agent may be an anti-inflammatory agent such as a p38 inhibitor, glutamate receptor antagonist, calcium channel antagonist, a chemotherapeutic agent or an antiproliferative agent.

In an eighth aspect, the present invention provides the use of a compound of the invention in the manufacture of a medicament for the prevention or treatment of a protein kinase-mediated disorder. The medicament may be used for treatment or prevention of any of the protein kinase-mediated disorders listed above in relation to the fifth aspect. Again, the compounds of the present invention may be administered simultaneously, subsequently or sequentially with one or more other active agent such as a p38 inhibitor.

In a ninth aspect, the present invention provides an assay for determining the activity of the compounds of the present invention, comprising providing a system for assaying the activity and assaying the activity of the compound. Preferably the assay is for the protein kinase inhibiting activity of the compound. The compounds of the invention may be assayed *in vitro*, *in vivo*, *in silico*, or in a primary cell culture or a cell line. *In vitro* assays include assays that determine inhibition of the kinase activity of activated protein kinase. Alternatively, *in vitro* assays may quantitate the ability of a compound to bind protein kinase and may be measured either by radiolabelling the compound prior to binding, then isolating the inhibitor/ protein kinase complex and

determining the amount of the radiolabel bound or by running a competition experiment where new inhibitors are incubated with protein kinase bound to known radioligands. An example of an assay which may be used is Scintillation Proximity Assay (SPA), preferably using radiolabelled ATP. Another example is ELISA. Any type or isoform of protein kinase may be used in these assays.

In a tenth aspect, the present invention provides a method of inhibiting the activity or function of a protein kinase, which method comprises exposing a protein kinase to a compound or a composition of the invention. The method may be performed in a research model, *in vitro*, *in silico*, or *in vivo* such as in an animal model. A suitable animal model may be a kainic acid model in rat or mice, traumatic brain injury model in rat, or MPTP in mice for neurodegenerative disorder and a collagen induced arthritis model in rat or mice, type II collagen-antibodies induced arthritis in mice, or a LPS induced endotoxin shock model in mice for inflammatory disease.

All features of each of the aspects apply to all other aspects *mutatis mutandis*.

Examples

The invention will now be explained in greater detail by the following examples, with the understanding that the scope of the invention is not in any sense restricted by these examples. The numbers assigned to each of the compounds in the examples correspond to the Compound Nos. of the compounds listed as specific examples in Tables A above. Structures of isolated novel compounds were confirmed by ^1H NMR and/or other appropriate analyses.

Compounds were characterised by mass spectrometry using single quadrupole instrumentation with an electrospray source. M+H indicates values obtained for

compound molecular mass (M) with proton (H) capture and M-H compound molecular mass (M) with proton (H) loss. Melting points (mp) are uncorrected; (d) denotes decomposition at or near the melting point. Compounds which were not solids were gums. The $^1\text{H-NMR}$ spectra (400 MHz, DMSO- d_6 or CDCl_3) of selected compounds of the invention were measured. The data for the chemical shifts (δ : ppm) and coupling constants (J : Hz) are shown. The "HPLC retention time" data for the compounds synthesized in the examples are the retention time for the compounds in HPLC analysis carried out under the following conditions.

HPLC (High Performance Liquid Chromatography) conditions

System: Hewlett-Packard 1100 HPLC

Column: Cadenza CD-C18 (Imtakt) 100 mm x 4.6 mmf

[Method A]

Solvent: A: H_2O /acetonitrile = 95/5

0.05% TFA (trifluoroacetic acid)

B: H_2O /acetonitrile = 5/95

0.05% TFA (trifluoroacetic acid)

Flow rate: 1.0 mL/min

Gradient:

0-1 min, solvent B: 10% solvent A: 90%

1-13 min, solvent B: 10% \rightarrow 70% solvent A: 90% \rightarrow 30%

13-14 min, solvent B: 70% \rightarrow 100% solvent A: 30% \rightarrow 0%

14-16 min, solvent B: 100% solvent A: 0%

16-19 min, solvent B: 100% \rightarrow 10% solvent A: 0% \rightarrow 90%

Calculation of purity: Area % of UV absorption (254 nm)

[Method B]

Solvent: A: H₂O/acetonitrile = 95/5

0.05% TFA (trifluoroacetic acid)

B: H₂O/acetonitrile = 5/95

0.05% TFA (trifluoroacetic acid)

Flow rate: 1.0 mL/min

Gradient:

0-1 min, solvent B: 5% solvent A: 95%

1-13 min, solvent B: 5% → 55% solvent A: 95% → 45%

13-14 min, solvent B: 55% → 100% solvent A: 45% → 0%

14-17 min, solvent B: 100% solvent A: 0%

17-18 min, solvent B: 100% → 5% solvent A: 0% → 95%

Calculation of purity: Area % of UV absorption (254 nm)

[Method C]

Solvent: A: H₂O/acetonitrile = 95/5

0.05% TFA (trifluoroacetic acid)

B: H₂O/acetonitrile = 5/95

0.05% TFA (trifluoroacetic acid)

Flow rate: 1.5 mL/min

Gradient:

0-1 min, solvent B: 2% solvent A: 98%

1-9 min, solvent B: 2% → 30% solvent A: 98% → 70%

9-13 min, solvent B: 30% → 100% solvent A: 70% → 0%

13-16 min, solvent B: 100% solvent A: 0%

16-17.5min, solvent B: 100% → 2% solvent A: 0% → 98%

Calculation of purity: Area % of UV absorption (254 nm)

[Method D]

Solvent: A: H₂O/acetonitrile = 95/5

0.1% NEt₃ (triethyl amine)

B: H₂O/acetonitrile = 5/95

0.1% NEt₃ (triethyl amine)

Flow rate: 1.5 mL/min

Gradient:

0-1 min, solvent B: 10% solvent A: 90%

1-14 min, solvent B: 10% → 100% solvent A: 90% → 0%

14-16 min, solvent B: 100% solvent A: 0%

16-17 min, solvent B: 100% → 10% solvent A: 0% → 90%

17-20min, solvent B: 10 solvent A: 90%

Calculation of purity: Area % of UV absorption (254 nm)


EXAMPLE 1

[General Procedure for the Synthesis of Pyrazolo[1,5-a]pyrimidines of General Formula (VI)]

To a stirred solution of sodium ethoxide (50 mmol) in ethanol (100 mL) was added the appropriately 2-substituted malonic acid diester (20 mmol) and appropriately substituted 3-aminopyrazole (VII) (20 mmol). The mixture was heated at reflux for 18 h, during which a precipitate formed.* The reaction was cooled to room temperature and the mixture was filtered through an A4 sinter (whilst washing with a minimum of cool

ethanol). The residue was dried under vacuum. The dried precipitate was dissolved in water (ca. 100 mL) and the resulting solution was acidified (pH 2) with concentrated HCl. This rendered a pale-white precipitate (VI), which was filtered and dried. Typical unoptimised yields ranged from 20-40%.

*In several cases where the substituent was an alkyl chain, little or no precipitate was formed. In these situations, the ethanol was removed under reduced pressure. The residue was partitioned between water and ethyl acetate. The aqueous phase was acidified (pH 2) with concentrated HCl and back-extracted with ethyl acetate. The organic phase was washed (water and saturated aqueous NaCl) and dried (MgSO₄) to give the desired bis-hydroxy compound (VI).




Compound No.	R ¹	R ²	R ⁴	mp (°C)
VI-01	Me	H	H	240 (d)
VI-02	H	H	Ph	285
VI-03	H	H	Et	260

EXAMPLE 2

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V)]

To a suspension of bis-hydroxy compound (VI) (2 g) in *N,N*-dimethylaniline (2

mL) was added phosphorous oxychloride (or phenyl phosphonic dichloride) (20 mL). The mixture was heated at reflux for 18 h, and excess phosphorus oxychloride (or phenyl phosphonic dichloride) was removed *in vacuo*. The residue was poured onto ice (50 g) and extracted with CH₂Cl₂ (5 x). The organic phase was adsorbed onto neutral (activity I) alumina and chromatographed (typically using petrol→ 30% ethyl acetate/petrol as eluent). To gave the appropriately substituted 5,7-dichloropyrazolo[1,5-*a*]pyrimidine intermediate (V) in yields of *ca.* 40 % values.



Compound No.	R ¹	R ²	R ⁴	mp (°C) or ¹ H-NMR (400MHz, CDCl ₃) <i>d</i> (ppm)
V-07	Me	H	H	92 - 95
V-08	H	H	Ph	182 - 186
V-09	H	H	Et	60 - 62
V-10	H	H	Me	2.55 (s, 3H, CH ₃), 6.7 (s, 1H, Het-H), 8.12 (s, 1H, Het-H).

EXAMPLE 3

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V-02)]

A solution of the 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V-01) (0.01 mol) in


chloroform (50 mL) was treated with *N*-chlorosuccinimide, *N*-bromosuccinimide or iodine monochloride (0.011 mol) at room temperature. The mixture was boiled under reflux until all solids were dissolved and no starting material remained (by TLC). The mixture was poured onto ice/water and the organic layer was separated, washed with aqueous Na₂CO₃, dried over MgSO₄, and the solvent removed *in vacuo*. The residual material was purified by chromatography over silica gel to provide the 3-halo-5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V-02).

Compound No.	R ¹	R ²	R ⁴	¹ H-NMR (400MHz, CDCl ₃) <i>d</i> (ppm)
V-11	H	Br	H	8.2 (s, 1H, Het-H), 7.05 (s, 1H, Het-H).
V-12	H	I	H	8.15 (s, 1H, Het-H), 2.60 (s, 3H, 6-Me).

EXAMPLE 4

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V-03)]

Synthesis of {5,7-dichloro(pyrazolo[1,5-*a*]pyrimidin-7-yl)}thiocarbonitrile.




To a solution of powdered potassium thiocyanate (2.66 g) in acetic acid (20 mL) was added slowly a solution of bromine (0.72 mL) in acetic acid (3 mL) whilst maintaining the temperature between 10 - 15 °C. 5,7-Dichloropyrazolo[1,5-*a*]pyrimidine (2.5 g) in acetic acid (30 mL) was added and the resulting solution was stirred at 15 °C for 30 min and then room temperature for 3 h

after which, the solvent was removed under reduced pressure. Water and ethyl acetate were added and the product was extracted with ethyl acetate (3x). The combined organic phase was dried (Na_2SO_4), evaporated and subjected to flash chromatography to give the title compound (780 mg, 73 % pure by $^1\text{H-NMR}$); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.27 (1H, s, 2-H), 7.10 (1H, s, 6-H).

EXAMPLE 5

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V-04)]

Synthesis of 5,7-dichloro-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carbaldehyde.




To *N,N*-dimethyl formamide (9 mL) under nitrogen at room temperature was added POCl_3 (3mL) and the resulting slurry was stirred for 5 min. 5,7-Dichloro-6-methylpyrazolo[1,5-*a*]pyrimidine (5g) was slowly added and resulting thick mixture was heated at 70°C for 3 h. The mixture was poured onto ice and basified with sodium hydroxide (5g). The residue was filtered and the dried precipitate chromatographed on silica gel (eluting with $\text{CH}_2\text{Cl}_2 \rightarrow 20\%$ ethyl acetate/ CH_2Cl_2) to give the title compound (3.74 g); mp $137\text{-}139^\circ\text{C}$.

EXAMPLE 6

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V-05)]

Synthesis of {5,7-dichloro-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}methanol.




To 5,7-dichloro-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carbaldehyde (200 mg) in ethanol (20 mL) was added sodium borohydride (70mg) and the reaction mixture was stirred at room temperature for 15 min. Saturated aqueous NH_4Cl (1 mL) was added and the reaction mixture was stirred for a further 10 min then the solvent was removed under reduced pressure. Water and ethyl acetate were added and the product was extracted with ethyl acetate (3x). The combined organic phase was washed (water, saturated aqueous NaCl) and dried (MgSO_4) to give the title compound (150 mg); $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.22 (1H, s, 2-H), 4.90 (1H, s, CH_2OH).

EXAMPLE 7

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (V-06)]

Synthesis of 2-{5,7-dichloro-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}-1,3-dioxane.



To 5,7-dichloro-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carbaldehyde (290 mg) in toluene (40 mL) was added pyridinium *p*-toluenesulfonate (60 mg) and propan-1,3-diol. The mixture was then heated under reflux for 2h, with azeotropic removal of water. The

solution was cooled and evaporated under reduced pressure. The residue was chromatographed on silica gel using ethyl acetate/petroleum ether 2/3 as eluent to give the title compound (310 mg) as a white solid; $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 8.32 (1H, s, 2-H), 5.97 (1H, s, CHO_2R), 4.25 (2H, br dd, OCH_{eq}), 4.05 (2H, br t, OCH_{ax}), 2.50 (3H, s, 6-Me), 2.25 (1H, m, CCH_{eq}HC), 1.48 (1H, br d, CCHH_{ax}C).

EXAMPLE 8

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (IV) and (IV-01)]

a) To a solution of (appropriately substituted) 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V) or {5,7-dichloro(pyrazolo[1,5-*a*]pyrimidin-7-yl)}thiocarbonitrile and triethylamine (2 equivalents) in 2-propanol (20 mL) was added the amine R^3NH_2 (1 or 1.1 equivalents) and the mixture was stirred at room temperature overnight. The mixture was concentrated *in vacuo* and the residue was then partitioned between water and CH_2Cl_2 . The organic phase was washed twice with water and the combined aqueous phases back-extracted with CH_2Cl_2 . The organic layer was combined, washed with saturated aqueous NaCl and dried over Na_2SO_4 . Removal of the solvent *in vacuo* yielded the precursor (IV). [Purification performed - normally the products did not require any further purification, if they did, they were recrystallised. Analysis performed - $^1\text{H-NMR}$, HPLC and MS].

Should the above room-temperature reaction not occur satisfactorily, the following may be applied:


b) To a solution of the 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V) (2 g) in 2-propanol (25 mL) containing *N,N*-diisopropylethylamine (2 equivalents) was added the amine

R^3NH_2 (1.2 equivalents). The reaction was heated overnight at 80 °C and the solvent removed *in vacuo*. The residue was partitioned between water and CH_2Cl_2 and the organic phase was washed with water, saturated aqueous NaCl and dried over $MgSO_4$. Removal of the solvent *in vacuo* yielded the product (IV).




c) To a stirred suspension of sodium hydride (50 mmol) in *N,N*-dimethylformamide (30 mL) was added appropriately substituted aniline derivative (25 mmol) and then appropriately substituted 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V) (25 mmol) in tetrahydrofuran (50 mL). The resulting mixture was stirred at 50 °C for 2 h. The reaction was quenched with saturated aqueous NH_4Cl . After extraction with ethyl acetate, the combined organic layer was washed with saturated aqueous NaCl and dried over $MgSO_4$. The solvent was removed *in vacuo* to give the crude title compound (IV). Typical unoptimised yields for d) 60 – 80 %.

d) To a solution of 2-chloroacetanilide (2.2 mmol) in toluene (3 mL) at room temperature was added sodium hydride (3 mmol) after the addition the mixture was heated until effervescence ceased and the solution became homogenous. The appropriately substituted 5,7-dichloropyrazolo[1,5-*a*]pyrimidine (V) (1 mmol) was added and the mixture heated at reflux for 5 h. (The solution became heterogeneous during this time). Upon cooling, acetic acid (1 mL) and water (1 mL) were cautiously added and the mixture was stirred for 15 min. The solvent was removed *in vacuo* and the residual acetic acid removed by azeotropic evaporation with toluene (3x). The residue was partitioned between water and ethyl acetate. The organic phase was washed (water and saturated aqueous NaCl) and dried. The solvent was removed *in vacuo* and the residue was chromatographed to afford the desired compound (IV). Typical unoptimised yields for c) 50 – 70 %. The R_f of starting material (V) and product (IV)

are chromatographically indistinguishable, making complete reaction difficult to determine. It appears that at least 5 h is required for significant reaction to occur.



Compound No.	R ¹	R ²	R ⁴	R ³	mp (°C) or ¹ H-NMR (400MHz) <i>d</i> (ppm)
IV-03	H	H	Me		(CDCl ₃) 1.91 (s, 3H, CH ₃), 6.5 (s, 1H, Het-H), 7.05 (d, 1H, ArH), 7.15 (t, 1H, ArH), 7.27 (t, 1H, ArH), 7.45 (d, 1H, ArH).
IV-04	H	Cl	H		184 - 186
IV-05	H	COOEt	CH ₃		(DMSO-d ₆) 1.27-1.35 (m, 6H), 1.78 (s, 3H), 4.02 (q, <i>J</i> =6.84Hz, 2H), 4.27 (q, <i>J</i> =7.08Hz, 2H), 6.92 (d, <i>J</i> =8.80Hz, 2H), 7.15 (d, <i>J</i> =8.80Hz, 2H), 8.62 (s, 1H), 9.95 (s, 1H).
IV-06	H	CN	H		(CDCl ₃) 8.31 (s, 1H), 7.48 (dd, <i>J</i> =2.44, 6.24Hz, 1H), 7.35 (m, 1H), 6.33 (s, 1H).


IV-07	H	H	CH ₃		(CDCl ₃) 8.07 (s, 1H), 8.00 (d, J=2.2Hz, 1H), 7.46-7.35 (m, 5H), 7.12 (d, J=9.04Hz, 2H), 7.00 (d, J=9.04Hz, 2H), 6.49 (d, J=2.2Hz, 1H), 5.09 (s, 2H), 1.90 (s, 3H).
IV-08	H	H	CH ₃		(CDCl ₃) 8.01 (d, J=2.2Hz, 1H), 7.98 (brs, 1H), 7.18 (m, 2H), 7.01 (m, 1H), 6.54 (d, J=2.2Hz, 1H), 1.96 (s, 3H).
IV-09	H	CN	CH ₃		(CDCl ₃) 8.25 (s, 1H), 8.16 (brs, 1H), 7.14 (d, J=8.8Hz, 2H), 6.94 (d, J=8.8Hz, 2H), 4.07 (q, J=7.08Hz, 2H), 1.89 (s, 3H), 1.45 (t, J=6.84Hz, 3H).

EXAMPLE 9

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (IV-02)]

Synthesis of (3-chloro-4-fluorophenyl)

{5-chloro-3-methylthio(pyrazolo[1,5-*a*]pyrimidin-7-yl)}amine.




Methyl magnesium chloride (0.25 mL, 3M solution) was added cautiously to a solution of {5-chloro-7-[(3-chloro-4-fluorophenyl)amino]-6-methylpyrazolo[1,5-*a*]pyrimidin-3-yl}thiocarbonitrile (100 mg) in dry tetrahydrofuran (5 mL) while maintaining the temperature between 0 – 4 °C for 2 h. Acetic acid (2 equivalents.) was added and the solvent was removed under reduced pressure. Water and ethyl acetate were added and the product was extracted with ethyl acetate (3x). The combined organic phase was dried (Na₂SO₄) and evaporated to give the title compound (98 mg); mp 156-158 °C.





EXAMPLE 10

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (III)]

To a solution of the precursor (IV) formed above (2 g) in 1,4-dioxane (10 mL) was added di-*tert*-butyl dicarbonate (2 equivalents) in 1,4-dioxane (10 mL) followed by a catalytic amount of 4-dimethylaminopyridine. The reaction was stirred at room temperature overnight and if starting material was detected by TLC, the reaction was left for longer. The mixture was concentrated *in vacuo* and the residue was then partitioned between water and CH₂Cl₂. The organic phase was washed with 10% citric acid, water and saturated aqueous NaCl and then dried over MgSO₄. Removal of the solvent *in vacuo* gave the Boc protected intermediate (III). [Purification performed - filter column to remove any residual 4-dimethylaminopyridine. Analysis performed - ¹H-NMR, HPLC and MS].



Compound No.	R ¹	R ²	R ⁴	R ³	mp (°C) or ¹ H-NMR (400MHz) <i>d</i> (ppm)
III-01	H	H	Me		(CDCl ₃) 1.94 (br s, 9H, C(CH ₃) ₃), 2.55 (s, 3H, CH ₃), 6.68 (s, 1H, Het-H), 7.05 (d, 1H, ArH), 7.15 (t, 1H, ArH), 7.24 (t, 1H, ArH), 7.5 (d, 1H, ArH), 8.12 (s, 1H, Het-H).
III-02	H	Br	H		136 – 138
III-03	H	Cl	H		130 – 132
III-04	H	COOEt	CH ₃		(DMSO-d ₆) 1.10-1.50 (m, 15H), 2.22 (s, 3H), 3.98 (q, <i>J</i> =7.08Hz, 2H), 4.30 (q, <i>J</i> =7.08Hz, 2H), 6.87 (d, <i>J</i> =8.80Hz, 2H), 7.22 (d, <i>J</i> =9.04Hz, 2H), 8.68 (brs, 1H).
III-05	H	H	CH ₃		(CDCl ₃)

					8.12 (d, $J=2.2\text{Hz}$, 1H), 7.78 (d, $J=8.8\text{Hz}$, 1H), 7.73 (br, 1H), 7.31 (br, 1H), 6.69 (d, $J=2.2\text{Hz}$, 1H), 2.78 (s, 3H), 2.31 (brs, 3H), 1.35 (brs, 9H).
III-06	H	H	CH ₃		(CDCl ₃) 8.12 (d, $J=2.2\text{Hz}$, 1H), 7.78 (d, $J=8.8\text{Hz}$, 1H), 7.71 (br, 1H), 7.31 (br, 1H), 6.69 (d, $J=2.2\text{Hz}$, 1H), 3.34 (q, $J=7.56\text{Hz}$, 1H), 2.31 (brs, 3H), 1.47 (t, $J=7.32\text{Hz}$, 3H), 1.35 (brs, 9H).
III-07	H	H	CH ₃		(CDCl ₃) 8.12 (d, $J=2.2\text{Hz}$, 1H), 7.79 (d, $J=8.8\text{Hz}$, 1H), 7.82 (br, 1H), 7.31 (br, 1H), 6.69 (d, $J=2.2\text{Hz}$, 1H), 4.06 (sevenfold, $J=6.84\text{Hz}$, 1H), 2.32 (brs, 3H), 1.49 (d, $J=6.84\text{Hz}$, 6H), 1.35 (brs, 9H).
III-08	H	CH ₃	CH ₃		(CDCl ₃) 7.94 (s, 1H), 7.17 (d, $J=9.04\text{Hz}$, 2H), 6.80 (d, 2H), 3.98 (q, $J=7.08\text{Hz}$, 2H), 2.35 (brs, 3H), 2.29 (brs, 3H), 1.38 (t, $J=7.08\text{Hz}$, 3H), 1.25 (brs, 9H).
III-09	H	H	CH ₃		(CDCl ₃) 8.09 (d, $J=2.44\text{Hz}$, 1H), 7.98 (d,

					$J=9.04\text{Hz}$, 2H), 7.27 (d, $J=8.53\text{Hz}$, 2H), 6.69 (d, 1H), 3.89 (s, 3H), 2.24 (s, 3H), 1.36 (s, 9H).
--	--	--	--	--	--

EXAMPLE 11


[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (II)]

a) An intimate mixture (III) (100 mg) and amine (HNR^5R^6) (1.5 g) were heated together at 80 – 85 °C for 18 h, then cooled. The crude material was then partitioned between ethyl acetate and saturated aqueous NaHCO_3 . The organic phase was then separated, washed with water and dried over MgSO_4 and concentrated *in vacuo*. The crude material was then subjected to column chromatography over silica gel. CH_2Cl_2 was used as eluent, then gradient elution up to 95% CH_2Cl_2 + 5% (10 M NH_3 in methanol). Typical purified yield 20 mg.

b) A solution of the Boc intermediate (III) (0.248 mmol), the amine (HNR^5R^6) (0.496 mmol), copper iodide (0.496 mmol), and potassium carbonate (0.496 mmol) in DMSO (0.8 mL) was stirred at 85 °C for 2 days. The reaction mixture was cooled to room temperature, followed by quenched with saturated aqueous NH_4Cl . The mixture was extracted with Et_2O . The combined extract was washed with saturated aqueous NaCl , dried over Na_2SO_4 , filtered, and evaporated. The residue was purified by column chromatography (5~10% $\text{MeOH-CH}_2\text{Cl}_2$) to give the title compound (II).

c) Synthesis of


4-{7-[tert-Butoxycarbonyl-(4-ethoxy-phenyl)-amino]-6-methyl-pyrazolo[1,5-*a*]pyrimidin-5-ylamino}-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester



A solution of the Boc intermediate (0.248 mmol), the (S)-4-amino L-proline (114 mg, 0.496 mmol), copper iodide (94.4 mg, 0.496 mmol) and potassium carbonate (68.5 mg, 0.496 mmol) in DMSO (0.8 mL) was stirred at 85 °C for 2 days. The reaction mixture was cooled to room temperature, followed by quenched with saturated aqueous NH_4Cl . The mixture was extracted with Et_2O . The combined extract was washed with saturated aqueous NaCl , dried over Na_2SO_4 , filtered, and evaporated. The residue was purified by column chromatography (5~10% $\text{MeOH-CH}_2\text{Cl}_2$) to give coupling compound (66.0 mg, 44.6%). The title compound was obtained.

The $^1\text{H-NMR}$ for this compound was shown below.

$^1\text{H-NMR}$ (400 MHz, CD_3OD) $d(\text{ppm})$: 1.25 (t, $J=7.1\text{Hz}$, 3H), 1.34 (s, 18H), 1.95 (m, 1H), 2.56 (m, 1H), 3.44 (m, 1H), 3.69 (m, 1H), 3.89 (q, $J=7.1\text{Hz}$, 2H), 4.16 (m, 1H), 6.05 (m, 1H), 6.74 (d, $J=7.1\text{Hz}$, 2H), 7.14 (d, $J=8.5\text{Hz}$, 2H), 7.68 (s, 1H).



Compound No.	R ¹	R ²	R ⁴	R ³	NR ⁵ R ⁶	$^1\text{H-NMR}$ (400MHz) $d(\text{ppm})$
II-26	H	COOEt	CH ₃			(DMSO- <i>d</i> ₆) 1.03-1.51 (m, 19H),

						1.74-2.08 (m, 7H),
						2.50-2.58 (m, 1H), 3.96
						(q, $J=7.08\text{Hz}$, 2H),
						4.01-4.13 (m, 1H), 4.19
						(q, $J=7.08\text{Hz}$, 2H), 6.85
						(d, $J=9.04\text{Hz}$, 2H), 6.91
						(d, $J=7.32\text{Hz}$, 1H), 7.18
						(d, $J=8.56\text{Hz}$, 2H), 8.17
						(brs, 1H).

EXAMPLE 12

[General Procedures for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I)]

a) An intimate mixture of the Boc intermediate (III) (100 mg) and the amine (HNR^5R^6) (1.5 g) were heated together at 80 – 85 °C for 90 min, then cooled. The crude material was then partitioned between CH_2Cl_2 and saturated aqueous NaHCO_3 . The organic phase was then separated and washed with water, dried over MgSO_4 and concentrated *in vacuo*. The crude material dissolved in CH_2Cl_2 (10 mL) and trifluoroacetic acid (5 mL). The mixture was stirred for 1 h at room temperature, then evaporated *in vacuo*. The residue was partitioned between saturated aqueous NaHCO_3 and CH_2Cl_2 , the organic phase was separated, dried over MgSO_4 then subjected to column chromatography over silica gel. CH_2Cl_2 was used as eluent, then gradient elution up to 95% CH_2Cl_2 + 5% (10 *M* NH_3 in methanol). Typical purified yield 20 mg.

b) The Boc intermediate (III) (0.1 mmol) was dissolved in toluene (1 ml) and the amine


(HNR^5R^6) (1.2 equivalents) was added. Tris(dibenzylideneacetone)dipalladium (0) (2 mol %), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (4 mol %) and sodium *tert*-butoxide (1.2 equivalents) were added sequentially under an atmosphere of nitrogen. The reaction was heated and agitated overnight at 80 °C following which the reaction was filtered through a 0.45 micron filter. The solvent was removed *in vacuo* and the residue was resuspended in CH_2Cl_2 (0.2 mL). Trifluoroacetic acid (0.8 mL) was added and the reactions allowed to stand for 1 h at room temperature. The mixture was evaporated to dryness, *in vacuo*, and the resultant residue was dissolved in *N,N*-dimethylformamide (1 mL), filtered and purified by preparative HPLC to give the product (I). [Analysis performed - LC/MS].

EXAMPLE 13

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-01)]

Synthesis of

1-{5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-iodophenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}-2,2,2-trifluoroethan-1-one (compound No: 417).



To a solution of

N-{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*

-butoxy)-*N*-(4-iodophenyl)carboxamide (50 mg) in 1,2-dichloroethane (1.8 mL) was added trifluoroacetic anhydride (1.8 mL). The resulting mixture was stirred at 45 °C for 3 h and then the solvent was removed *in vacuo*. The residue was dissolved in CH₂Cl₂ (1.25 mL). To this stirred solution was added trifluoroacetic acid (0.53 mL). The resulting mixture was stirred at room temperature for 3 h, and then the solvent was removed *in vacuo*. The residue was dissolved in tetrahydrofuran (1.6 mL) and methanol (0.18 mL). To this stirred solution was added 2mol/L aqueous NaOH (0.18 mL). The resulting mixture was stirred at room temperature for 15 h. The reaction was quenched with aqueous 1N HCl. After extraction with CH₂Cl₂, the combined organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄ and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (33.0 mg, yield 41% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.38-1.56 (m, 4H), 1.79 (s, 3H), 1.97-2.12(m, 4H), 3.04(brs, 1H), 4.09(brs, 1H), 6.73(d, *J*=8.52Hz, 2H), 7.11(d, *J*=7.32Hz, 1H), 7.57(d, *J*=8.04Hz, 2H), 7.86(brs, 3H), 8.34(s, 1H), 9.27(s, 1H).

HPLC retention time (method A): 14.7 min.

ESI/MS: 559.3 (M+H, C₂₁H₂₂F₃N₆O).


EXAMPLE 14

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-02)]

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl

))(4-iodophenyl)amine (compound No: 441).



N-{5-[(*trans*-4-aminocyclohexyl)amino]-6-methylpyrazolo[1,5-*a*]pyrimidin-7-yl}-(*tert*-butoxy)-*N*-(4-iodophenyl)carboxamide (20mg) was dissolved in tetrahydrofuran (300 μ L). To this solution was added 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2,2,2]octane bis(tetrafluoroborate) (63 mg). The resulting mixture was stirred for 19 h at 40 °C. The reaction was quenched with saturated aqueous NaHCO₃. After extraction with CH₂Cl₂, the combined organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, and the solvent was removed *in vacuo* to give the crude Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (2.0 mL). To this solution was added trifluoroacetic acid (0.2 mL). After stirring for 4 h, the solvent was removed *in vacuo*. The residue was purified on preparative TLC to give the title compound (1.5 mg, 9 % yield). The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, CDCl₃) δ (ppm): 1.25(m, 2H), 1.36(m, 2H), 1.72(s, 3H), 1.99(m, 2H), 2.22(m, 2H), 2.72(m, 1H), 4.14(m, 1H), 6.73(m, 2H), 7.32(brs, 1H), 7.60(m, 2H), 7.69(d, *J*=3.40Hz, 1H).

HPLC retention time (method A): 12.9 min.


ESI/MS: 481.4 (M+H, C₁₉H₂₃FIN₆).

EXAMPLE 15

[General Procedure for the Synthesis of Pyrazolo[1,5-a]pyrimidines of General Formula (II-04)]

Synthesis of

5-({trans-4-[(tert-butoxy)carbonylamino]cyclohexyl}amino)-7-[(tert-butoxy)-N-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylic acid.



To a stirred suspension of ethyl

5-({trans-4-[(tert-butoxy)carbonylamino]cyclohexyl}amino)-7-[(tert-butoxy)-N-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate (5.55 g) in 2-propanol (136 mL) was added 2 mol/L aqueous NaOH (34 mL). The resulting mixture was stirred at 50 °C for 40 h, and then at 80 °C for 4 h. The mixture was acidified (pH 4) with 1 mol/L aqueous HCl and concentrated *in vacuo*. The residue was suspended in water (150mL) and slowly stirred for 1 h. The precipitate was filtered and dried *in vacuo* to give the title compound (5.35g, yield 78%) as a white solid. The ¹H-NMR and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) *d*(ppm): 1.19-1.28(br, 4H), 1.29(t, *J*=7.08Hz, 3H), 1.38(s, 18H), 1.73-1.86(br, 2H), 1.86-2.04(br, 5H), 3.15-3.33(m, 1H), 3.97(q, *J*=7.08Hz, 2H), 4.02-4.08(m, 1H), 6.43(brs, 1H), 6.82(d, *J*=8.80Hz, 1H), 6.86(d, *J*=8.76Hz, 2H), 7.20(d, *J*=7.80Hz, 2H), 7.93(brs, 1H).


ESI/MS: 625.5 (M+H, C₃₂H₄₄N₆O₇).

EXAMPLE 16

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (II-05)]

Synthesis of

5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide.



To a stirred solution of

5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carboxylic acid (1.25 g) in *N,N*-dimethylformamide (20 mL) were added ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (1.92 g), *N*-hydroxybenzotriazole monohydrate (0.31 g), triethylamine (2.8 mL) and ammonia (5.0 mL, 2.0 mol/L in methanol). The resulting mixture was stirred at room temperature for 24 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the combined organic layer was washed with water, dried over MgSO₄, and the solvent was removed *in vacuo* to give the crude title compound (1.25 g) as a white solid. This crude product was used in the next reaction without further purification. ESI/MS data for this compound are shown below.


ESI/MS: 624.6 (M+H, C₃₂H₄₅N₇O₆).

EXAMPLE 17

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (II-07)]

Synthesis of

N-[5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-*a*]pyrimidin-3-yl)](phenylmethoxy)carboxamide.



To a stirred solution of crude

5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-*a*]pyrimidine-3-carboxamide (1.25 g) in benzyl alcohol (5.0 mL) was added potassium *tert*-butoxide (0.561 g). The resulting mixture was stirred at room temperature for 10 min. and then at 0 °C for 10 min. To this stirred solution was added iodobenzene diacetate (0.773 g), stirred at 0 °C for 10 min., and allowed to warm room temperature. The resulting mixture was stirred at room temperature for 12 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the combined organic layer was dried over MgSO₄, and solvent

was removed *in vacuo* to give the crude title compound (1.46 g) as pale red oil. This crude product was used in the next reaction without further purification. The $^1\text{H-NMR}$ and ESI/MS data for this compound are shown below.


$^1\text{H-NMR}$ (400MHz, $\text{DMSO-}d_6$) δ (ppm): 1.18-1.30(brs, 4H), 1.29(t, $J=7.08\text{Hz}$, 3H), 1.38(s, 18H), 1.75-1.86(m, 2H), 1.87-1.97(m, 2H), 2.00(brs, 3H), 3.15-3.28(m, 1H), 3.97(t, $J=7.08\text{Hz}$, 2H), 3.85-4.10(m, 1H), 5.12(s, 2H), 6.43-6.53(m, 1H), 6.75(d, $J=7.56\text{Hz}$, 2H), 6.86(d, $J=8.80\text{Hz}$, 2H), 7.15-7.50(m, 7H), 7.83(brs, 1H), 8.86(brs, 1H).
ESI/MS: 730.7 ($\text{M}+\text{H}$, $\text{C}_{39}\text{H}_{51}\text{N}_7\text{O}_7$).

EXAMPLE 18

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (II-08)]

Synthesis of

N-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide.



To a stirred solution of the crude

N-[5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)](phenylmethoxy)carboxamide (1.46 g) in ethanol (100 mL) and acetic acid (0.46 mL) was added Pd/C (0.29 g, 10% on carbon). The resulting mixture was stirred at room temperature for 2

days under hydrogen atmosphere, and Pd/C was filtered off. The solvent was removed *in vacuo*. The residue was purified by silica gel column chromatography (elute with ethyl acetate/*n*-hexane = 3/1) to give the title compound (0.560 g, yield 47% for 2 steps) as a pale yellow solid. The ¹H-NMR and ESI/MS data for this compound are shown below.


¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.20-1.35(brs, 4H), 1.29(t, *J*=7.08Hz, 3H), 1.38(s, 18H), 1.75-1.90(brs, 3H), 1.90-2.05(m, 4H), 3.22(brs, 1H), 3.92-4.00(m, 3H), 6.21(brs, 1H), 6.77(d, *J*=8.04Hz, 1H), 6.83-6.87(m, 3H), 7.20(brs, 3H), 7.45(brs, 1H).

ESI/MS: 596.6 (M+H, C₃₁H₄₅N₇O₅).

EXAMPLE 19

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-09)]

Synthesis of *N*-{5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}acetamide (compound No: 378).



To acetyl chloride (7.1 μ L) were added

N-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide (14.9 mg) in CH₂Cl₂ (250 μ L) and triethylamine (13.9 μ L). The resulting mixture was stirred at room

temperature for 1 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (175 μ L). To this solution was added trifluoroacetic acid (75 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (9.04 mg, yield 46% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.30(t, *J*=6.84Hz, 3H), 1.32-1.55 (m, 4H), 1.63 (s, 3H), 1.85-2.05(m, 4H), 2.05(s, 3H), 3.00(brs, 1H), 3.97(q, *J*=6.80Hz, 2H), 4.05(brs, 1H), 6.24(brs, 1H), 6.85(d, *J*=9.00Hz, 2H) , 6.90(d, *J*=8.80Hz, 2H), 7.78(brs, 3H), 8.00(s, 1H), 8.54(brs, 1H) , 9.40(brs, 1H).


HPLC retention time (method A): 8.4 min.

ESI/MS: 438.4 (M+H, C₂₃H₃₁N₇O₂).

EXAMPLE 20

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-10)]

Synthesis of {5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}(methylsulfonyl)amine (compound No: 386).



To methanesulfonyl chloride (11.5 mg) were added

N-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methylpyrazolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide (14.9 mg) in CH₂Cl₂ (250 μ L) and triethylamine (13.9 μ L). The resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (175 μ L). To this solution was added trifluoroacetic acid (75 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (2.43 mg, yield 12% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.26(t, *J*=7.08Hz, 3H), 1.30-1.45 (m, 4H), 1.60 (s, 3H), 1.87-2.03(m, 4H), 2.93(brs, 1H), 3.06(s,3H), 3.85-3.98(m, 3H), 6.24(d, *J*=7.32Hz, 1H), 6.81(d, *J*=9.28Hz, 2H) , 6.86(d, *J*=9.04Hz, 2H), 7.68(s, 1H), 7.72(brs, 3H), 8.56(s, 1H) , 8.75(s, 1H).


HPLC retention time (method A): 10.5 min.

ESI/MS: 474.4 (M+H, C₂₂H₃₁N₇O₃S).

EXAMPLE 21

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-11)]

Synthesis of *N*-{5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}(phenylamino)carboxamide (compound No: 389).



To phenyl isocyanate (11.9 mg) were added

N-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide (14.9 mg) in CH₂Cl₂ (250 μ L) and triethylamine (13.9 μ L). The resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (175 μ L). To this stirred solution was added trifluoroacetic acid (75 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was

purified by preparative HPLC to give the title compound (6.59 mg, yield 31% as 3 trifluoroacetic acids salt) as a white solid. The $^1\text{H-NMR}$, HPLC retention time and ESI/MS data for this compound are shown below.

$^1\text{H-NMR}$ (400MHz, $\text{DMSO-}d_6$) δ (ppm): 1.30(t, $J=7.08\text{Hz}$, 3H), 1.36-1.47(m, 4H), 1.65(s, 3H), 1.90-2.10(m, 4H), 2.98(brs, 1H), 3.97(q, $J=7.08\text{Hz}$, 2H), 4.03(brs, 1H), 6.13(brs, 1H), 6.82-6.96(m, 5H), 7.25(t, $J=8.28\text{Hz}$, 2H), 7.45(d, $J=7.60\text{Hz}$, 2H), 7.76(brs, 3H), 7.86(brs, 1H), 7.95(s, 1H), 8.58(brs, 1H), 8.76(brs, 1H).


HPLC retention time (method A): 10.9 min.

ESI/MS: 515.6 ($\text{M}+\text{H}$, $\text{C}_{28}\text{H}_{34}\text{N}_8\text{O}_2$).

EXAMPLE 22

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-12)]

Synthesis of ({5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-3-yl)}amino)(methylamino)methane-1-thione (compound No: 390).



To methyl thioisocyanate (7.3 mg) were added

N-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide (14.9 mg) in

CH₂Cl₂ (250 μ L) and triethylamine (13.9 μ L). The resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (175 μ L). To this stirred solution was added trifluoroacetic acid (75 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (8.32 mg, yield 41% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.30(t, *J*=6.84Hz, 3H), 1.33-1.50(m, 4H), 1.64(s, 3H), 1.88-2.05(m, 4H), 2.91(d, *J*=4.40Hz, 3H), 2.98(brs, 1H), 3.88(brs, 1H), 3.97(q, *J*=6.80Hz, 2H), 6.27(d, *J*=7.08Hz, 1H), 6.80-6.95(m, 4H), 7.67(s, 1H), 7.70-7.90(m, 4H), 8.61(s, 1H), 9.06(s, 1H).

HPLC retention time (method A): 10.3 min.


ESI/MS: 469.4 (M+H, C₂₃H₃₂N₈OS).

EXAMPLE 23

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-14)]

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}[4-(methylethoxy)phenyl]amine (compound No: 197).



A solution of

N-{5-[(4-aminocyclohexyl)amino]-6-methyl(8-hydropyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*-butoxy)-*N*-[4-(phenylmethoxy)phenyl]carboxamide (3.68 g) and Pd/C (0.78 g, 10% on carbon) in methanol (140 mL) was stirred under hydrogen atmosphere for 23 h. The catalyst was filtered off and the solvent was removed *in vacuo* to give the crude intermediate (2.93 g) as a pale brown solid. This crude intermediate was used in the next reaction without further purification.

A suspension of crude intermediate (22.7 mg), 2-propanol (19 μ L) and polymer-supported triphenylphosphine resin (3.0 mmol/g, 83.5 mg) in CH₂Cl₂ (1.0 mL) was shaken for 0.5 h at room temperature. To this suspension was added a solution of diisopropylazodicarboxylate (39.3 μ L) in CH₂Cl₂ (1.1 mL) and then shaken at room temperature for 10 h. The reaction mixture was filtrated and the residual resin was washed with CH₂Cl₂ (3 x 1.0 mL). The combined filtrate was evaporated *in vacuo* to give the crude Boc protected intermediate. This crude product was used in the next reaction without further purification.


The crude product was dissolved in CH₂Cl₂ (1.0 mL). To this solution was added trifluoroacetic acid (0.87 mL). The resulting mixture was stirred at room temperature for 2.3 h and the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (7.3 mg, 37 % yield as 3 trifluoroacetic acids salt). The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method A): 7.6 min.

ESI/MS: 395.0 (M+H, C₂₂H₃₀N₆O).

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}[3-(2-piperazinylethoxy)phenyl]amine (compound No: 259)



A solution of

N-{5-[(4-aminocyclohexyl)amino]-6-methyl(8-hydropyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*-butoxy)-*N*-[3-(phenylmethoxy)phenyl]carboxamide (11.6 g) and Pd/C (0.62 g, 10% on carbon) in methanol (150 mL) was stirred under hydrogen atmosphere for 23 h. The catalyst was filtered off and the solvent was removed *in vacuo* to give the crude intermediate (10.7 g) as a pale brown solid. This crude intermediate was used in the next reaction without further purification.

A suspension of crude intermediate (33.9mg), 4-(2-hydroxyethyl)piperazinecarboxylate (86.4mg) and polymer-supported triphenylphosphine resin (3.0 mmol/g, 125 mg) in CH₂Cl₂ (1.75 mL) was shaken for 0.5 h at room temperature. To this suspension was added a solution of diisopropylazodicarboxylate (59.0 μ L) in CH₂Cl₂ (1.0 mL) and then shaken at room temperature for 17.5 h. The reaction mixture was filtrated and the residual resin was washed with CH₂Cl₂ (3 x 1.0 mL). The combined filtrate was evaporated *in vacuo* to

give the crude Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH_2Cl_2 (1.0 mL). To this solution was added trifluoroacetic acid (0.87 mL). The resulting mixture was stirred at room temperature for 2.3 h and the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (20.6 mg, 34% yield as 3 trifluoroacetic acids salt). The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method B): 2.3min.


ESI/MS: 465.7 (M+H, $\text{C}_{25}\text{H}_{36}\text{N}_8\text{O}$).

EXAMPLE 24

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-16)]

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(4-phenylphenyl)amine (compound No: 284).



A mixture of

N-{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*-butoxy)-*N*-(4-iodophenyl)carboxamide (30 mg), phenylboronic acid (7.2 mg), Na_2CO_3

(67.8 mg), palladium (II) acetate (3.6 mg) and triphenylphosphine (12.5 mg) in *n*-propanol (1.08 mL) and H₂O (0.217 mL) was stirred for 19.3 h at 80 °C. The reaction mixture was filtrated and the filtrate was evaporated *in vacuo* to give the crude Boc protected intermediate. This crude product was used in the next reaction without further purification.


The crude product was dissolved in CH₂Cl₂ (1.0 mL). To this solution was added trifluoroacetic acid (0.87 mL). The resulting mixture was stirred for 1.8 h, the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (9.1 mg, 23% yield as 3 trifluoroacetic acids salt). The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method B): 10.8min.

ESI/MS: 413.3 (M+H, C₂₅H₂₈N₆).

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(3-(3-*p*iridyl)phenyl)amine (compound No: 450).



The title compound and Boc protected intermediate were synthesised in the same manner as above using *N*-{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*

-butoxy)-*N*-(3-iodophenyl)carboxamide, pyridine-3-boronic acid, Na₂CO₃ palladium (II) acetate and triphenylphosphine. The title compound (6.1 mg, 15% yield as 3 trifluoroacetic acids salt) was obtained. The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method A): 6.0 min.


ESI/MS: 414.1 (M+H, C₂₄H₂₇N₇).

EXAMPLE 25

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-17)]

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}[4-(2-phenylethynyl)phenyl]amine (compound No: 375).



To a mixture of

N-{5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(*tert*-butoxy)-*N*-(4-iodophenyl)carboxamide (30 mg), palladium (II) acetate (6.0 mg), triphenylphosphine (7.0 mg) in tetrahydrofuran (0.5mL) was added ethynylbenzene (17.6 μ L) and triethylamine (26 μ L). The resulting mixture was stirred for 15 min. To this mixture was added copper (I) iodide (3.0 mg) and stirred for 1 h at 50 °C. The

reaction mixture was filtrated and the filtrate was evaporated *in vacuo* to give the crude Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (1.0 mL). To this solution was added trifluoroacetic acid (0.87 mL). After stirring for 4 h, the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (11.4 mg, 27% yield as 3 trifluoroacetic acids salt). The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method A): 12.7 min.


ESI/MS: 437.2 (M+H, C₂₇H₂₈N₆).

EXAMPLE 26

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-19)]

Synthesis of

4-({5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}amino)phenyl pyrrolidinyl ketone (compound No.792).



To a stirred solution of

4-({(*tert*-butoxy)-*N*-[5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)]carbonylamino}benzoic acid (50 mg) in

N,N-dimethylformamide (1.0 mL) was added carbonyldiimidazole (69 mg) and stirred at room temperature for 30 minutes. The resulting mixture was added to pyrrolidine (100 μ L) and stirred at room temperature for 15 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH₂Cl₂, the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (700 μ L). To this stirred solution was added trifluoroacetic acid (300 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (39.43 mg, yield 59% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.37-1.53 (m, 4H), 1.73-1.88 (m, 7H), 1.92-2.07 (m, 4H), 2.95-3.05 (m, 1H), 3.43 (t, *J*=6.60Hz, 4H), 3.89-4.00 (m, 1H), 6.07 (s, 1H), 6.49 (brs, 1H), 6.86 (d, *J*=8.28Hz, 2H), 7.45 (d, *J*=8.56Hz, 2H), 7.73-7.91 (m, 4H), 9.18 (brs, 1H).

HPLC retention time (method A): 6.9 min.

ESI/MS: 434.1 (M+H, C₂₄H₃₁N₇O).


EXAMPLE 27

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-21)]

Synthesis of

1-{5-[(*trans*-4-aminocyclohexyl)amino]-7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo

[1,5-*a*]pyrimidin-3-yl}}pentan-1-one (compound No:362).



(*tert*-Butoxy)-*N*-[5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-3-(*N*-methoxy-*N*-methylcarbonyl)-6-methylpyrazolo[1,5-*a*]pyrimidin-7-yl)]-*N*-(4-ethoxyphenyl)carboxamide (33.4 mg) was dissolved in tetrahydrofuran (500 μ L) and stirred at -78°C for 5 min under nitrogen atmosphere. To this stirred solution was added *n*-butyl lithium (61.5 μ L, 2.44 M in *n*-hexane). The resulting mixture was stirred at -78°C for 1 h, allowed to warm at room temperature and then stirred at room temperature for 23 h. The reaction was quenched with saturated aqueous NH_4Cl . After extraction with ethyl acetate, the combined organic layer was washed with saturated aqueous NaCl, dried over Na_2SO_4 and then the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH_2Cl_2 (175 μ L). To this stirred solution was added trifluoroacetic acid (75 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (2.93 mg, yield 6% for 2 steps as 3 trifluoroacetic acids salt) as a white solid. The ^1H -NMR, HPLC retention time and ESI/MS data for this compound are shown below.

^1H -NMR (400MHz, $\text{DMSO}-d_6$) δ (ppm): 0.91(t, $J=7.32\text{Hz}$, 3H), 1.30(t, $J=7.04\text{Hz}$, 3H),

1.32-1.52 (m, 6H), 1.57-1.67 (m, 5H), 1.90-2.15(m, 4H), 2.96-3.06(m, 3H), 3.92-4.03(m, 3H), 6.57(d, $J=7.32\text{Hz}$, 1H), 6.85(d, $J=9.04\text{Hz}$, 2H), 6.92(d, $J=9.00\text{ Hz}$, 2H), 7.75-7.90(m, 3H), 8.14(s, 1H), 8.78(s, 1H).


HPLC retention time (method A): 14.2min.

ESI/MS: 465.2 (M+H, $\text{C}_{26}\text{H}_{36}\text{N}_6\text{O}_2$).

EXAMPLE 28

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-23)]

Synthesis of {5-[(*trans*-4-aminocyclohexyl)amino]-6-methyl-[3-benzylamino]pyrazolo[1,5-*a*]pyrimidin-7-yl)} (4-ethoxyphenyl)amine (compound No. 436).



To sodium hydride (1.2 mg) was added

N-[5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl)amino)-7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methylpyrazolo[1,5-*a*]pyrimidin-3-yl)]-2,2,2-trifluoroacetamide (20.8 mg) in tetrahydrofuran (300 μL). The resulting mixture was stirred at room temperature for 1 h, to this solution was added benzyl bromide (4.3 μL) and then stirred at room temperature for 15 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH_2Cl_2 , the solvent was removed *in vacuo*. The residue was dissolved in CH_2Cl_2 (210 μL). To this

stirred solution was added trifluoroacetic acid (90 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was dissolved in methanol (300 μ L). To this stirred solution was added aqueous 2 mol/L NaOH (75 μ L). The resulting mixture was stirred at room temperature for 2 h. The reaction was quenched with saturated aqueous NaCl. After extraction with CH_2Cl_2 , the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (12.79 mg, yield 52% as 3 trifluoroacetic acids salt) as a white solid. The ^1H -NMR, HPLC retention time and ESI/MS data for this compound are shown below.


^1H -NMR (400MHz, $\text{DMSO}-d_6$) δ (ppm): 1.30(t, $J=7.08\text{Hz}$, 3H), 1.38-1.55(m, 4H), 1.65(s, 3H), 1.95-2.13(m, 4H), 3.02(brs, 1H), 3.92-4.05(m, 3H), 4.62(s, 2H), 6.50(d, $J=7.02\text{Hz}$, 1H), 6.85(d, $J=9.28\text{Hz}$, 2H), 6.89(d, $J=9.28\text{Hz}$, 2H), 7.38-7.46(m, 5H), 7.80(s, 1H), 7.88-7.97(m, 3H), 8.73(s, 1H).

HPLC retention time (method A): 11.2 min.

ESI/MS: 486.4 ($\text{M}+\text{H}$, $\text{C}_{28}\text{H}_{35}\text{N}_7\text{O}$).

Synthesis of

[5-[(*trans*-4-aminocyclohexyl)amino]-3-([3-(difluoromethoxy)phenyl]methyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](4-ethoxyphenyl)amine (compound No.791).



To a solution of 3-(difluoromethoxy)benzaldehyde (5.1 mg) in

1,2-dichloroethane (340 μ L) and acetic acid (35 μ L) were added *N*-[3-amino-5-({*trans*-4-[(*tert*-butoxy)carbonylamino]cyclohexyl}amino)-6-methyl(pyr azolo[1,5-*a*]pyrimidin-7-yl)](*tert*-butoxy)-*N*-(4-ethoxyphenyl)carboxamide (22.4 mg). The resulting mixture was stirred at 70 °C for 30 min. To this solution was added sodium tetrahydroborate (20 mg) and stirred at room temperature for 10 min. The reaction was quenched with water. After extraction with CH₂Cl₂, the combined organic layer was washed with saturated aqueous NaCl and the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH₂Cl₂ (280 μ L). To this stirred solution was added trifluoroacetic acid (120 μ L). The resulting mixture was stirred at room temperature for 2 h, and then the solvent was removed *in vacuo*. The residue was purified by preparative HPLC to give the title compound (15.58 mg, yield 46% as 3 trifluoroacetic acids salt) as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, DMSO-*d*₆) δ (ppm): 1.30(t, *J*=6.84Hz, 3H), 1.35-1.52(m, 4H), 1.65(s, 3H), 1.95-2.12(m, 4H), 3.01(m, 1H), 3.92-4.00(m, 3H), 4.63(s, 2H), 6.40-6.47(m, 1H), 6.82-6.90(m, 4H), 7.16-7.30(m, 4H), 7.45(t, *J*=8.04Hz, 1H), 7.76(brs, 1H), 7.85(brs, 3H), 8.69(brs, 1H).

HPLC retention time (method A): 10.9 min.


ESI/MS: 552.1 (M+H, C₂₉H₃₅F₂N₇O₂).

EXAMPLE 29

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-25)]

Synthesis of

{7-[(4-ethoxyphenyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-5-yl)}methyl-3-piperidylamine (compound No: 340).



To a solution of *tert*-butyl

3-({7-[(*tert*-butoxy)-*N*-(4-ethoxyphenyl)carbonylamino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-5-yl)}methylamino)piperidinecarboxylate (22.3 mg) in *N,N*-dimethylformamide (0.5 mL) was added sodium hydride (>60 % w/w in oil, 3.1 mg). The resulting mixture was stirred at room temperature for 10 min. To this solution was added methyl iodide (3.7 μ L) and the resulting mixture was stirred for further 15 h. The reaction was quenched with water. After extraction with CH_2Cl_2 , the combined organic layer was washed with saturated aqueous NaCl, dried over Na_2SO_4 , and the solvent was removed *in vacuo* to give the crude di-Boc protected intermediate. This crude product was used in the next reaction without further purification.

The crude product was dissolved in CH_2Cl_2 (1.0 mL). To this solution was added trifluoroacetic acid (0.87 mL) and stirred for 5.5 h. The solvent was removed *in vacuo*. The residue was purified on preparative TLC to give the title compound (14.6 mg, 64% yield). The ^1H -NMR, HPLC retention time and ESI/MS data for this compound are shown below.

$^1\text{H-NMR}$ (400MHz, $\text{DMSO-}d_6$) δ (ppm): 1.42(t, 3H), 1.78(s, 3H), 1.81(m, 3H), 1.96(m, 1H), 2.57(m, 1H), 2.86(s, 3H), 2.89(m, 1H), 3.08(m, 1H), 3.24(m, 1H), 3.49(m, 1H), 3.99(q, 2H), 5.30(brs, 1H), 6.24(d, $J=2.2\text{Hz}$, 1H), 6.91(m, 2H), 6.98(m, 2H), 7.68(brs, 1H), 7.85(d, $J=2.2\text{Hz}$, 1H) HPLC retention time (method A): 9.8 min.


ESI/MS: 381.2 (M+H, $\text{C}_{21}\text{H}_{28}\text{N}_6\text{O}$).

EXAMPLE 30

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-27)]

Synthesis of

{5-[(3*S*)(3-piperidyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)}(4-ethoxyphenyl)amine (compound No: 193).



To a stirred solution of

N-(5-[(3*S*)-1-benzyl(3-piperidyl)amino]-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl))(tert-butoxy)-N-(4-ethoxyphenyl)carboxamide (272 mg) in CH_2Cl_2 (2 mL) was added trifluoroacetic acid (2 mL). After stirring at room temperature for 3 h, the reaction mixture was poured into the saturated aqueous NaHCO_3 and extracted with CH_2Cl_2 . The combined extract was washed with saturated aqueous NaCl , dried over Na_2SO_4 , filtered, and the solvent was removed in vacuo. The residue was purified by silica gel column chromatography (96% CH_2Cl_2 + 4% (2 M NH_3 in methanol) was used as eluent, then

gradient elution up to 90% CH₂Cl₂ + 10% (2.0 M NH₃ in methanol)) to give the intermediate (237 mg).


A solution of this intermediate in ethanol (2 mL) was hydrogenated under hydrogen atmosphere in the presence of Pd(OH)₂/C (125 mg, 10% on carbon). After stirring for 5 h, the reaction mixture was filtered, and evaporated in vacuo. The crude residue was purified by column chromatography (96% CH₂Cl₂ + 4% (2.0 M NH₃ in methanol)) to give the title compound (107 mg, 60%). The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (400MHz, CDCl₃) d(ppm): 7.76 (d, J=2.2Hz, 1H), 7.49 (s, 1H), 7.00 (d, J=9.0Hz, 2H), 6.85 (d, J=8.8Hz, 2H), 6.11 (d, J=2.2Hz, 1H), 4.95 (m, 1H), 4.27 (m, 1H), 4.02 (q, J=7.1Hz, 2H), 3.20 (m, 1H), 2.83 (m, 2H), 2.71 (dd, J=6.2Hz, 11.4Hz, 1H), 1.87 (m, 1H), 1.71 (m, 2H), 1.71 (s, 3H), 1.56 (m, 1H), 1.49 (t, J=7.1Hz, 3H).

HPLC retention time (method A): 8.0 min.

ESI/MS: 367.4 (M+H, C₂₀H₂₆N₆O).

Synthesis of [5-(azaperhydroepin-3-yl amino)-6-methyl(pyrazolo[1,5-*a*]pyrimidin-7-yl)](4-ethoxyphenyl)amine (compound No: 272).



To a solution of

(*tert*-butoxy)-*N*-(4-ethoxyphenyl)-*N*-(6-methyl-5-[[1-benzylazaperhydroepin-3-yl]amino

}(pyrazolo[1,5-*a*]pyrimidine-7-yl))carboxamide (6.6 mg) in CH₂Cl₂ (0.5 mL) was added trifluoroacetic acid (0.3 mL) at 0 °C. After stirring for 16 h at room temperature, the reaction mixture was poured into saturated aqueous NaHCO₃ and extracted with ethyl acetate. The combined organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, and evaporated *in vacuo*. The residue was purified on preparative TLC to give the intermediate (5.0 mg, 91%).

To a stirred solution of this intermediate (2.0 mg) in CH₂Cl₂ (0.3 mL) was added α -chloroethyl chloroformate (2 μ L) at 0 °C. After stirring for 0.5 h, to the reaction mixture was added saturated aqueous NaHCO₃ and then extracted with ethyl acetate. The combined organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, and evaporated *in vacuo*. The residue was dissolved in methanol (0.5 mL). After reflux for 4 h, the reaction mixture was cooled to room temperature and then evaporated *in vacuo*. The residue was purified on preparative TLC (90% CH₂Cl₂ + 10% (2.0 M NH₃ in methanol)) to give the title compound (0.9 mg, 59%). The HPLC retention time and ESI/MS data for this compound are shown below.

HPLC retention time (method A): 4.4 min.


ESI/MS: 381.4 (M+H, C₂₁H₂₈N₆O).

EXAMPLE 31

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-29)]

Synthesis of

{5-[(*trans*-4-aminocyclohexyl)amino]-3-iodo(pyrazolo[1,5-*a*]pyrimidin-7-yl)}[(3-chlorophenyl)methyl]amine (compound No: 297).



To a stirred solution of

{5-[(*trans*-4-aminocyclohexyl)amino](pyrazolo[1,5-*a*]pyrimidin-7-yl)}[(3-chlorophenyl)methyl]amine (41.8 mg) in CH₂Cl₂ (565 μ L) was added ICl (169 μ L, 1.0 M in CH₂Cl₂), and the resulting mixture was stirred at room temperature for 4 h in the dark. The reaction was quenched with saturated aqueous Na₂S₂O₃. The resulting precipitate was collected by filtration. After extraction of filtrate by CH₂Cl₂, the combined organic layer was washed with saturated aqueous NaCl. To this solution, the precipitate collected above was dissolved, and the solvent was removed *in vacuo*. The residue was purified by preparative HPLC, and the fraction contained the title compound was basified (pH 9) with saturated aqueous NaHCO₃. After extraction with CH₂Cl₂, combined organic layer was dried over Na₂SO₄. The solvent was removed *in vacuo*, and the title compound (23.11mg, 41% yield) was obtained as a white solid. The ¹H-NMR, HPLC retention time and ESI/MS data for this compound are shown below.

¹H-NMR (270MHz, DMSO-*d*₆) δ (ppm): 1.00-1.40(m, 4H), 1.70-2.00(m, 4H), 2.71(m, 1H), 3.65(m, 1H), 4.44(brs, 2H), 5.10(s, 1H), 6.76(d, *J*=7.83Hz, 1H), 7.10-7.50(m, 4H), 7.81(s, 1H), 8.05(brs, 1H).

HPLC retention time (method A): 7.6 min.

ESI/MS: 497.4 (M+H, C₁₉H₂₂ ClIN₆).


EXAMPLE 32

[General Procedure for the Synthesis of Pyrazolo[1,5-*a*]pyrimidines of General Formula (I-31)]

To a solution of pyrazolo[1,5-*a*]pyrimidine (I-30) (50 mg) in tetrahydrofuran (5 ml) was added cyclohexanone (1.1 equivalents) and the reaction was heated for 16 h at 60°C. To the cooled mixture was then added sodium cyanoborohydride (5 equivalents) and stirred at room temperature for 2 h. The mixture was evaporated to dryness, *in vacuo*, and the resultant residue dissolved in water and ethyl acetate. The organic layer was separated, dried over MgSO₄ then subjected to column chromatography over silica gel. The eluent was CH₂Cl₂, then gradient elution up to 95% CH₂Cl₂ + 5% (10 M NH₃ in methanol) to give pyrazolo[1,5-*a*]pyrimidine of General Formula (I-31).

EXAMPLE 33

Synthesis of 7-N-(4-Ethoxy-phenyl)-6-methyl-5-N-(4-propyl-piperidin-3-yl)-pyrazolo[1,5-*a*]pyrimidine- 5,7-diamine (compound No:814)



To a stirred solution of 4-allyl 3-oxopiperidine (3.39 g, 12.4 mmol) in tetrahydrofuran (31 mL) was added a solution of lithium tris *sec*-butyl hydroborate in tetrahydrofuran (15 mL; 1M solution) at -78°C. After stirring at -78°C for 3 h, the mixture was acidified with 1 N HCl and extracted with AcOEt. The combined extract was washed with saturated aqueous NaHCO₃, followed by saturated aqueous NaCl. The organic

layer was dried over Na_2SO_4 , filtered and evaporated in vacuo. The residue was purified by column chromatography (20% AcOEt-hexane) to give 4-Allyl-3-hydroxy-piperidine-1-carboxylic acid benzyl ester (3.12 g).

$^1\text{H-NMR}$ (400 MHz, CDCl_3) δ (ppm): 7.35 (m, 5H), 5.79 (m, 1H), 5.13 (m, 2H), 5.09 (m, 1H), 5.04 (m, 1H), 4.22 (br, 2H), 3.83 (m, 1H), 2.92 (m, 1H), 2.77 (br, 1H), 2.21 (m, 1H), 2.05 (m, 1H), 1.57 (m, 2H), 1.48 (br, 1H).

To a stirred solution of 4-Allyl-3-hydroxy-piperidine-1-carboxylic acid benzyl ester (293 mg, 1.06 mmol) were added triphenyl phosphine (362 mg, 1.38 mmol), a solution of diethyl azodicarboxylate in toluene (0.6 mL, 1.38 mmol; 40% solution) and DPPA (297 μL , 1.38 mmol). After stirring for 4h, the mixture was evaporated and the residue was purified by column chromatography (15% AcOEt-hexane) to give 4-Allyl-3-azido-piperidine-1-carboxylic acid benzyl ester.

To a stirred solution of above residue in tetrahydrofuran (3.5 mL)- H_2O (0.35 mL) was added triphenyl phosphine (417 mg, 1.59 mmol). The mixture was stirred under reflux for 16 h, added NaSO_4 , filtered and evaporated. The crude mixture was purified by column chromatography to give 4-Allyl-3-amino-piperidine-1-carboxylic acid benzyl ester (118 mg, 41% in 2 steps).

$^1\text{H-NMR}$ (400 MHz, CD_3OD) δ (ppm): 7.2 (m, 5H), 5.71 (m, 1H), 5.00 (s, 2H), 4.99 (m, 1H), 4.93 (m, 1H), 4.05 (m, 1H), 3.96 (m, 1H), 2.70 (br, 1H), 2.47 (br, 1H), 2.39 (m, 1H), 2.30 (m, 1H), 1.84 (m, 1H), 1.66 (m, 1H), 1.24 (m, 1H), 1.04 (m, 1H).

4-Allyl-3-[7-(4-ethoxy-phenylamino)-6-methyl-pyrazolo[1,5-*a*]pyrimidin-5-ylamino]-piperidine-1-carboxylic acid benzyl ester was prepared by Example 12.

A solution of 4-Allyl-3-[7-(4-ethoxy-phenylamino)-6-methyl-pyrazolo[1,5-*a*]

pyrimidin-5-ylamino]-piperidine-1-carboxylic acid benzyl ester (3.1 mg) in EtOH (1.5 mL) was hydrogenated in the presence of 10% palladium on carbon (7.5 mg) for 45 min. The mixture was filtered through a pad of Celite and evaporated. The residue was purified on preparative TLC to give the title compound (1.4 mg).

¹H-NMR (400 MHz, CDCl₃) δ (ppm): 7.77 (d, $J=2.2$ Hz, 1H), 7.51 (s, 1H), 7.01 (d, $J=8.8$ Hz, 2H), 6.86 (d, $J=9.04$ Hz, 2H), 6.10 (d, $J=2.2$ Hz, 1H), 4.45 (br, 1H), 4.05 (m, 1H), 4.02 (q, $J=6.84$ Hz, 2H), 3.47 (dd, 1H), 3.09 (m, 1H), 2.68 (m, 1H), 2.48 (m, 1H), 2.02 (m, 1H), 1.91-1.43 (m, 3H), 1.69 (s, 3H), 1.42 (t, $J=6.84$ Hz, 3H), 1.26 (m, 2H), 0.89 (t, $J=7.08$ Hz, 3H).

EXAMPLE 34

The compounds of the invention listed in Table B below were synthesized according to the respective methods in Examples 1 to 33 using the corresponding starting materials and reagents. The numbers assigned to each of the compounds in Table B correspond to the Compound Nos. of the compounds listed as specific examples in Table A above. Compounds were characterised by mass spectrometry using single quadrupole instrumentation with an electrospray source. M+H indicates values obtained for compound molecular mass (M) with proton (H) capture and M-H compound molecular mass (M) with proton (H) loss. Melting points (mp) are uncorrected; (d) denotes decomposition at or near the melting point. Compounds which were not solids were gums. The ¹H-NMR spectra (400 MHz, DMSO-*d*₆ or CDCl₃) of selected compounds of the invention were measured. The data for the chemical shifts (δ : ppm) and coupling constants (J : Hz) are shown in Table B. The "HPLC retention time" are the retention time for the compounds in HPLC analysis carried out under the condition of the Method A, B, C or D above. The "method of preparation" in Table B

are the example numbers of the corresponding methods in which the compounds were synthesized.

Table B

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
1	400.2		9.5	A		(DMSO- <i>d</i> ₆) 8.31 (s, 1H), 7.61 (dd, 1H), 7.49 (t, 1H), 7.39 (m, 1H), 7.27 (d, 1H), 5.59 (s, 1H), 3.94 (m, 1H), 2.49 (m, 1H), 1.88 (m, 2H), 1.76 (m, 2h), 1.15 (m, 4H).	12
2	455		10.2	A	222-225		12
3	389				102-105 (d)		12
4	431				102-105 (d)		12
5	451				198-200 (d)		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
6	469		12.1	A	224-226(d)		12
7	409		11.2	A	227-230(d)		12
8	509				234-237(d)		12
9	447				221-223		12
10	389		9.4	A	229-232		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
11	417		10.3	A	196-198	((DMSO- d_6) 7.76 (s, 1H), 7.31 (t, 1H), 6.95 (d, 1H), 6.71 (m, 1H), 6.30 (d, 2H), 6.09 (s, 1H), 4.05 (m, 1H), 2.60 (m, 2H), 2.52 (m, 2H), 1.95 (m, 2H), 1.85 (m, 2H), 1.45 (m, 4H), 1.20 (m, 2H), 0.90 (t, 2H).	12
12	451		10.9	A	Gum		12
13	469	467	10.5	A	Gum		12
14	495		13.2	A	188-191		12
15	371		9.1	A	87-92(d)	(CDCl ₃) 7.79 (s, 1H), 7.42 (d, 2H), 7.15 (t, 1H), 6.98 (t, 1H), 6.80 (d, 1H), 6.25 (s, 1H), 4.35 (m, 1H), 4.18 (m, 1H), 2.71 (m, 1H), 2.21 (m, 2H), 1.92 (m, 1H), 1.72 (s, 3H), 1.35 (m, 2H), 1.25 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
16	385	383	9.4	A	174-176(d)	(CDCl ₃) 7.79 (s, 1H), 7.41(d, 1H), 7.15 (t, 1H), 6.98 (t, 1H), 7.87 (d, 1H), 6.13 (s, 1H), 4.42 (d, 1H), 4.10 (m, 1H), 2.70 (m, 1H), 2.28 (q, 2H), 2.20 (m, 2H), 1.19 (m, 2H), 3.37 (m, 2H), 1.25 (m, 2H), 1.00(t, 3H).	12
17	397		9.9	A	153-155		12
18	469	467			213-216		12
19	415	413	10.3	A	176-178	(CDCl ₃) 7.75 (s, 1H), 7.55 (bs, 1H), 7.10 (m, 2H), 6.92 (m, 1H), 6.13 (s, 1H), 5.65 (m, 1H), 5.18 (d, 1H), 5.15 (d, 1H), 4.62 (d, 1H), 4.02 (m, 1H), 3.00 (d, 2H), 2.70 (m, 1H), 2.18 (m, 2H), 1.90 (m, 2H), 1.45 (bs, 2H), 1.32 (m, 2H), 1.10 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
20	449				220-222		12
21	337				Gum		12
22	447		11.3	A	Gum		12
23	403	401	9.5	A	Gum		12
24	465	463	10.9	A	Gum	(CDCl ₃) 7.80 (s, 1H), 7.49 (s, 1H), 7.25 (m, 3H), 7.09 (m, 3H), 6.90 (m, 2H), 6.18 (s, 1H), 4.21 (d, 1H), 3.90 (m, 1H), 2.55 (m, 1H), 2.03 (s, 2H), 1.97 (d, 2H), 1.80 (d, 2H), 1.28 (m, 1H), 1.25 (m, 2H), 0.85 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
25	369	367	7.7	A	Gum	(CDCl ₃) 7.88 (s, 1H), 7.15 (m, 2H), 7.04 (m, 2H), 6.95 (m, 1H), 6.12 (s, 1H), 4.40 (d, 2H), 4.10 (m, 1H), 2.71 (m, 1H), 2.28 (q, 2H), 2.20 (d, 2H), 1.90 (d, 2H), 1.20~1.50 (m, 6H), 0.90 (t, 3H).	12
26	385	383	8.9	A	Gum	(CDCl ₃) 7.87 (s, 1H), 7.25 (d, 2H), 6.95 (d, 2H), 6.12 (s, 1H), 4.40 (m, 1H), 4.10 (m, 1H), 2.70 (m, 1H), 2.25 (q, 2H), 2.20 (d, 2H), 2.05 (d, 1H), 1.96 (d, 2H), 1.53 (bs, 2H), 1.45~1.15 (m, 4H), 0.97 (t, 3H).	12
27	380		7.7	A	202-204	(CDCl ₃) 7.75 (s, 1H), 7.28 (d, 1H), 7.20 (t, 1H), 6.65 (m, 2H), 6.59 (s, 1H), 6.12 (s, 1H), 4.40 (m, 1H), 4.10 (m, 1H), 3.80 (s, 3H), 2.71 (m, 1H), 2.32 (q, 2H), 2.21 (d, 2H), 1.95 (d, 2H), 1.58~1.18 (m, 6H), 1.02 (t, 3H).	12
28	381		7.9	A	Gum	(CDCl ₃) 7.75 (s, 1H), 7.42 (bs, 1H), 7.11 (d, 2H), 6.82 (d, 2H), 6.12 (s, 1H), 4.31 (d, 1H), 4.08 (m, 1H), 3.81 (s, 3H), 2.70 (m, 1H), 2.20 (m, 3H), 1.92 (m, 2H), 1.60 (bs, 2H), 1.35 (m, 2H), 1.20 (m, 2H), 0.90 (t, 3H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
29	365		8.4	A	176-178	(CDCl ₃) 7.75 (s, 1H), 7.21 (d, 1H), 7.18 (s, 1H), 7.12 (m, 1H), 7.03 (d, 1H), 6.10 (s, 1H), 4.30 (d, 1H), 4.09 (m, 1H), 2.70 (m, 1H), 2.35 (s, 3H), 2.21 (m, 2H), 2.11 (q, 2H), 1.92 (d, 2H), 1.40 (bs, 2H), 1.35 (m, 2H), 1.21 (m, 2H), 0.85 (t, 3H).	12
30	379		10.5	A	Gum		12
31	395		9.8	A	131-133		12
32	381		9.0	A	163-165		12
33	443		11.2	A	147-149	(CDCl ₃) 7.75 (s, 1H), 7.50 (bs, 1H), 7.30 (t, 2H), 7.1 (m, 3H), 7.02 (d, 2H), 6.98 (d, 2H), 6.11 (s, 1H), 4.35 (d, 1H), 4.11(m, 1H), 2.70 (m, 1H), 2.29 (q, 2H), 2.25 (m, 2H), 1.95 (m, 2H), 1.50 (bs, 2H), 1.35 (m, 2H), 1.25 (m, 2H), 0.95 (t, 3H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
34	394		6.1	A	60-62	(CDCl ₃) 7.75 (s, 1H), 7.35 (s, 1H), 7.12 (t, 1H), 6.49 (d, 1H), 6.39 (m, 2H), 6.12 (s, 1H), 4.35 (d, 1H), 4.08 (m, 1H), 2.92 (s, 6H), 2.70 (m, 1H), 2.29 (q, 2H), 2.20 (m, 2H), 1.90 (m, 2H), 1.46 (bs, 2H), 1.36 (m, 2H), 1.22 (m, 2H), 0.95 (t, 3H).	12
35	457		11.3	A	120-122	(CDCl ₃) 7.78 (s, 1H), 7.48-7.29 (m, 5H), 7.10 (d, 2H), 6.90 (d, 2H), 6.12(s, 1H), 5.30 (s, 1H), 5.05 (s, 2H), 4.30 (d, 1H), 4.10 (m, 1H), 2.70 (m, 1H), 2.20 (m, 4H), 1.80 (m, 2H), 1.35 (m, 4H), 1.25 (m, 2H), 0.90 (t, 3H).	12
36	397		9.5	A	190-192	(CDCl ₃) 7.75 (s, 1H), 7.35 (bs, 1H), 7.20 (d, 2H), 6.98 (d, 2H), 6.12 (s, 1H), 4.41 (d, 1H), 4.15 (m, 1H), 2.72 (m, 1H), 2.49 (s, 3H), 2.24 (m, 4H), 1.95 (d, 2H), 1.50 (bs, 2H), 1.40 (m, 2H), 1.27 (m, 2H), 0.96 (t, 3H).	12
37	385		7.5	A	183-184		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
38	399		9.8	A	63-65		12
39	379				127-129		12
40	417		9.4	A	Gum		12
41	315		6.5	A	Gum		12
42	381				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
43	389	387	10.7	A	Gum	(CDCl ₃) 7.76 (s, 1H), 7.20 (s, 1H), 7.10 (m, 2H), 6.95 (m, 1H), 6.12 (s, 1H), 4.30 (br, 1H), 3.12 (m, 1H), 2.85 (m, 2H), 2.75 (m, 1H), 2.32 (q, 2H), 1.90~1.50 (m, 6H), 1.03 (t, 3H).	12
44	389	387	9.2	A	148-154		12
45	371	369			Gum		12
46	329	327	7.8	A	91-93		12
47	483	481	10.5	A	Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
48	493	491	9.4	A	240-241		12
49		499			153-155		12
50	441-444	437-439	11.4	A	Gum		12
51	411	409	7.2	A	65-68		12
52	441	439			162-165	(CDCl ₃) 7.76 (s, 1H), 7.40 (s, 1H), 6.78 (d, 1H), 6.70 (s, 1H), 6.68 (d, 1H), 6.11 (s, 1H), 5.55 (m, 1H), 4.05 (m, 1H), 3.88 (s, 3H), 3.82 (s, 3H), 3.41 (m, 1H), 2.69 (m, 1H), 2.32 (m, 2H), 2.18 (m, 2H), 2.0 (m, 2H), 1.92 (m, 2H), 1.45 (t, 2H), 1.40 ~1.15 (m, 6H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
53	453	451	10.2	A	116-118		12
54	441	439			166-168		12
55	415	413			189-192	(CDCl ₃) 7.75 (s, 1H), 7.39 (s, 1H), 7.14 (s, 1H), 7.02 (d, 1H), 6.87 (d, 1H), 6.12 (s, 1H), 4.32 (d, 1H), 4.10 (m, 1H), 3.90 (s, 3H), 2.71 (m, 1H), 2.20 (m, 4H), 1.94 (d, 2H), 1.45~1.15 (m, 6H), 0.92 (t, 3H).	12
56	423	421	11.9	A	144-148		12
57	457	455			102-104		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
58	411	409			181-185		12
59	429-432	427-430	9.7	A	197-199	(CDCl ₃) 7.76 (s, 1H), 7.32 (s, 1H), 7.21 (d, 1H), 7.15 (d, 1H), 6.95 (d, 1H), 6.15 (s, 1H), 4.41 (d, 1H), 4.10 (m, 1H), 2.75 (m, 1H), 2.27 (q, 2H), 2.22 (m, 2H), 1.93 (m, 2H), 1.42 (br, 2H), 1.40 ~1.20 (m, 4H), 1.00 (t, 3H).	12
60	477	475	9.5	A	199-201	(CDCl ₃) 7.76 (s, 1H), 7.49 (bs, 1H), 7.35 (d, 1H), 7.30 (s, 1H), 7.00~6.90 (m, 2H), 6.15 (s, 1H), 4.42 (d, 1H), 4.08 (m, 1H), 2.71 (m, 1H), 2.32 (q, 2H), 2.20 (m, 2H), 1.92 (m, 2H), 1.55 (bs, 2H), 1.42~1.20 (m, 4H), 1.01 (t, 3H).	12
61	395	393			150-152	(CDCl ₃) 7.76 (s, 1H), 7.32 (s, 1H), 7.17 (t, 1H), 6.60 (d, 1H), 6.55 (s, 1H), 6.13 (s, 1H), 4.38 (d, 1H), 4.08 (m, 1H), 3.98 (q, 2H), 2.70 (m, 1H), 2.31 (q, 2H), 2.20 (m, 2H), 1.92 (m, 2H), 1.46 (br, 2H), 1.38 (q, 3H), 1.38~1.19 (m, 4H), 0.95 (q, 3H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
62	397				Gum		12
63	443				Gum	(CDCl ₃) 7.77(s, 1H), 7.33 (s, 1H), 7.15 (d, 2H), 7.05 (d, 2H), 6.95 (d, 2H), 6.90 (d, 2H), 6.13 (s, 1H), 5.19 (br, 1H), 4.28 (m, 1H), 3.19 (dd, 1H), 2.83 (m, 1H), 2.72 (m, 2H), 2.31 (s, 3H), 2.30 (q, 2H), 1.90~1.50 (m, 5H), 0.97 (t, 3H).	12
64	392.3		6.4	A		(CDCl ₃) 8.00 (s, 1H), 7.53 (br, 1H), 7.23 (d, 2H), 6.96 (d, 2H), 5.29 (s, 1H), 4.65 (m, 1H), 4.06 (q, 2H), 3.71 (s, 3H), 2.67 (m, 1H), 2.06 (m, 2H), 1.89 (m, 2H), 1.56 (br, 2H), 1.45 (t, 3H), 1.28~1.14 (m, 4H).	12
65	383		8.5	A	185-187	(CDCl ₃) 7.80 (s, 1H), 7.50 (s, 1H), 7.25 (d, 2H), 6.98 (d, 2H), 6.15 (s, 1H), 4.30 (m, 1H), 4.10 (m, 1H), 2.75 (m, 1H), 2.50 (s, 3H), 2.22 (m, 2H), 1.92 (m, 2H), 1.72 (s, 3H), 1.48~1.18 (m, 6H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
66	438	436			Gum		12
67	409		8.7	A	Gum		12
68	409	407			59-60		12
69	452				Gum		12
70	423				Gum	(CDCl ₃) 7.95 (d, 2H), 7.75 (s, 1H), 7.40 (bs, 1H), 6.95 (d, 2H), 6.15 (s, 1H), 4.45 (d, 1H), 4.35 (q, 2H), 4.10 (q, 2H), 2.86 (m, 1H), 2.30 (q, 2H), 2.25 (m, 2H), 2.18 (bs, 2H), 2.03 (s, 3H), 1.95 (m, 2H), 1.37 (m, 4H), 1.28 (t, 3H), 1.00 (t, 3H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
71	423				Gum	(CDCl ₃) 7.78 (s, 1H), 7.77 (d, 1H), 7.65 (s, 1H), 7.38 (t, 1H), 7.25 (s, 1H), 7.20 (d, 1H), 6.13 (s, 1H), 4.41 (m, 1H), 4.40 (q, 2H), 4.10 (m, 1H), 2.71 (m, 1H), 2.21 (m, 4H), 1.12 (m, 2H), 1.51 (bs, 2H), 1.39 (t, 3H), 1.39~1.20 (m, 4H), 1.98 (t, 3H).	12
72	365				Gum	(DMSO- <i>d</i> ₆) 8.35 (bs, 1H), 7.65 (s, 1H), 7.08 (t, 1H), 6.65 (d, 1H), 6.60 (s, 1H), 6.52 (d, 1H), 6.18 (d, 1H), 5.95 (s, 1H), 3.95 (m, 1H), 2.41 (m, 2H), 2.20 (s, 3H), 1.86 (m, 2H), 1.78 (m, 2H), 1.40 (m, 2H), 1.18 (m, 2H), 0.90 (t, 3H).	12
73	433				Gum		12
74	457				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
75	443				Gum		12
76	365		9.0	A	148-149	(CDCl ₃) 7.77 (s, 1H), 7.48 (s, 1H), 7.07 (d, 1H), 6.82 (s, 1H), 6.76 (d, 1H), 6.14 (s, 1H), 4.25 (d, 1H), 4.10 (m, 1H), 2.72 (m, 1H), 2.23 (s, 3H), 2.21 (m, 2H), 1.90 (m, 2H), 1.70 (s, 3H), 1.45 (br, 2H), 1.45~1.20 (m, 4H).	12
77	415		9.0	A	215-216	(CDCl ₃) 7.78 (s, 1H), 7.43 (s, 1H), 7.19 (d, 2H), 7.10 (s, 1H), 6.90 (m, 1H), 6.10 (s, 1H), 4.31 (d, 1H), 4.10 (m, 1H), 2.85 (m, 1H), 2.23 (m, 2H), 1.92 (m, 2H), 1.78 (s, 3H), 1.45~1.20 (m, 6H).	12
78	421	419			225-235		12
79	357	355			120-160		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
80	355		7.3	A	Gum		12
81	381				146-148	(CDCl ₃) 7.75 (s, 1H), 7.50 (bs, 1H), 7.18 (t, 1H), 6.60 (d, 1H), 6.52 (d, 1H), 6.50 (s, 1H), 6.12 (s, 1H), 4.12 (m, 1H), 4.05 (m, 1H), 4.00 (m, 2H), 2.72 (bs, 1H), 2.20 (m, 2H), 1.93 (m, 2H), 1.72 (s, 3H), 1.49 (m, 4H).	12
82	366				Gum		12
83	463		8.7	A	134-136	(CDCl ₃) 7.76 (s, 1H), 7.42 (s, 1H), 7.38 (d, 1H), 7.25 (s, 1H), 7.02 (t, 1H), 6.92 (d, 1H), 6.15 (s, 1H), 4.32 (d, 1H), 4.08 (m, 1H), 2.75 (m, 1H), 2.23 (m, 2H), 1.95 (m, 1H), 1.75 (s, 3H), 1.60 (br, 2H), 1.40 (m, 2H), 1.25 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
84	405	403			198-200	(CDCl ₃) 7.80 (bs, 1H), 7.78 (s, 1H), 7.51 (d, 2H), 6.92 (d, 2H), 6.18 (s, 1H), 4.37 (d, 1H), 4.10 (m, 1H), 2.62 (m, 1H), 2.21 (m, 2H), 1.95 (m, 2H), 1.75 (s, 3H), 1.51 (bs, 2H), 1.32 (m, 2H), 1.28 (m, 2H).	12
85	371		8.5	A	209-212	(CDCl ₃) 7.75 (s, 1H), 7.46 (bs, 1H), 7.25 (s, 1H), 7.20 (t, 1H), 7.02 (d, 1H), 6.92 (s, 1H), 6.85 (d, 1H), 6.15 (s, 1H), 4.31 (d, 1H), 4.06 (m, 1H), 2.72 (m, 1H), 2.20 (m, 2H), 1.92 (m, 2H), 1.75 (s, 3H), 1.52 (bs, 2H), 1.32 (m, 2H), 1.25 (m, 2H).	12
86	331				138-145		12
87	303				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
88	353	351	5.9	A	145-150		12
89	351		13.4	B	Gum	(CDCl ₃) 7.76 (s, 1H), 7.45 (s, 1H), 7.27 (s, 2H), 7.08 (d, 1H), 6.82 (s, 1H), 6.72 (d, 1H), 6.10 (s, 1H), 4.98 (m, 1H), 4.3 (m, 1H), 3.2 (d, 1H), 2.82 (m, 2H), 2.71 (m, 1H), 2.29 (m, 1H), 2.20 (s, 3H), 1.83 (m, 1H), 1.80~1.50 (m, 2H), 1.25 (s, 2H).	12
90	391	389			Gum	(CDCl ₃) 7.80 (s, 1H), 7.55 (d, 2H), 7.50 (s, 1H), 7.00 (d, 2H), 6.15 (s, 1H), 5.20 (m, 1H),	12
91	367				Gum	(CDCl ₃) 7.76 (s, 1H), 7.42 (s, 1H), 7.20 (t, 1H), 6.61 (d, 1H), 6.60 (m, 2H), 6.50 (s, 1H), 6.12 (s, 1H), 4.25 (d, 1H), 4.05 (m, 1H), 3.78 (s, 3H), 2.75 (m, 1H), 2.22 (m, 2H), 1.95 (m, 2H), 1.75 (s, 3H), 1.50~1.12 (m, 6H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
92	411				101-104		12
93	468				Gum		12
94	467	465			120-130		12
95	367		5.3	A	200-202	(DMSO- <i>d</i> ₆) 7.50 (s, 1H), 7.00 (d, 2H), 6.65 (d, 2H), 5.75 (d, 2H), 5.53 (s, 1H), 5.51 (s, 1H), 4.82 (bs, 1H), 4.20 (s, 2H), 3.75 (m, 1H), 3.00 (br, 2H), 2.35 (m, 1H), 2.30 (s, 2 H), 1.71 (m, 2H), 1.51 (d, 2H), 1.50 (s, 3H), 1.15 (m, 2H), 0.95 (m, 2H).	12
96					158-162	(CDCl ₃) 7.76(s, 1H), 7.52 (bs, 1H), 7.27 (d, 2H), 6.95 (d, 2H), 6.15 (s, 1H), 4.32 (d, 1H), 4.10 (m, 1H), 3.82 (s, 2H), 2.72 (m, 1H), 2.22 (m, 2H), 1.95 (m, 2H), 1.70 (bs, 4H), 1.35 (m, 2H), 1.23 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
97	367				97-100	(CDCl ₃) 7.73 (s, 1H), 7.57 (bs, 1H), 7.25 (t, 1H), 7.02 (d, 1H), 6.95 (s, 1H), 6.86 (d, 1H), 6.13 (s, 1H), 4.52 (s, 2H), 4.32 (d, 1H), 4.05 (d, 1H), 2.70 (m, 1H), 2.20 (m, 2H), 1.90 (m, 2H), 1.73 (s, 3H), 1.33 (m, 2H), 1.20 (m, 2H).	12
98	377	375	7.4	A	205-207		12
99	401				Gum		12
100	317				Gum		12
101	392	390			Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
102	337		7.1	A	96-99	(CDCl ₃) 7.80 (s, 1H), 7.50 (bs, 1H), 7.40 (t, 2H), 7.08 (t, 1H), 7.00 (d, 2H), 6.15 (s, 1H), 4.28 (d, 1H), 4.09 (m, 1H), 2.75 (m, 1H), 2.22 (m, 2H), 1.98 (m, 2H), 1.72 (s, 3H), 1.35 (m, 2H), 1.25 (m, 2H).	12
103	463		9.2	A	105-108	(CDCl ₃). 7.78 (s, 1H), 7.60 (d, 2H), 7.46 (bs, 1H), 6.75 (d, 2H), 6.15 (s, 1H), 4.30 (d, 1H), 4.09 (m, 1H), 2.78 (m, 1H), 2.23 (m, 2H), 1.95 (m, 2H), 1.87 (bs, 2H), 1.75 (s, 3H), 1.41 (m, 2H), 1.28 (m, 2H).	12
104	449		10.2	A	Gum	(CDCl ₃) 7.74 (s, 1H), 7.45 (s, 1H), 7.38 (d, 1H), 7.30 (s, 1H), 7.05 (t, 1H), 6.95 (d, 1H), 6.15 (s, 1H), 5.10 (m, 1H), 4.30 (m, 1H), 3.20 (dd, 1H), 2.82 (m, 2H), 2.72 (m, 1H), 1.90 (m, 1H), 1.80 (s, 3H), 1.75 (m, 2H), 1.43 (m, 1H).	12
105	449	447			Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
106	357		9.3	A	Gum		12
107	376	374	7.2	A	207-209	(CDCl ₃) 8.70 (bs, 1H), 7.80 (s, 1H), 7.70 (bs, 1H), 7.35 (s, 1H), 7.20 (s, 1H), 6.95 (d, 1H), 6.45 (s, 1H), 6.15 (s, 1H), 4.22 (d, 1H), 4.05 (m, 1H), 3.45 (s, 3H), 2.71 (m, 1H), 2.20 (d, 2H), 1.90 (d, 2H), 1.51 (s, 3H), 1.35 (m, 2H), 1.24 (m, 2H).	12
108	374				Gum		12
109	388				Gum		12
110	319				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
111	408				95-99	(CDCl ₃) 7.78 (s, 1H), 7.72 (d, 1H), 7.62 (s, 1H), 7.57 (s, 1H), 7.05 (d, 1H), 6.15 (s, 1H), 4.25 (d, 1H), 4.07 (m, 1H), 2.82 (s, 3H), 2.70 (m, 1H), 2.21 (m, 2H), 1.95 (m, 2H), 1.75 (s, 3H), 1.50 (bs, 2H), 1.35 (m, 2H), 1.25 (m, 2H).	12
112	394		6.1	A	100-108		12
113	449	447			181-183		12
114	409		10.0	A	Gum		12
115	417				165-168	(CDCl ₃) 7.76 (s, 1H), 7.19 (bs, 1H), 7.05 (m, 2H), 6.90 (m, 1H), 6.14 (s, 1H), 4.55 (d, 1H), 4.10 (m, 1H), 3.05 (m, 1H), 2.73 (m, 2H), 1.95 (m, 2H), 1.50 (d, 1H), 1.45 (m, 2H), 1.30 (m, 2H), 1.23 (d, 6H), 1.0 (dd, 1H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
116	434				Gum		12
117	436				140-142		12
118	403				210-215	(CDCl ₃) 7.80 (d, 2H), 7.50 (s, 1H), 7.35 (d, 2H), 7.25 (d, 2H), 6.17 (s, 1H), 7.05 (d, 2H), 6.15 (s, 1H), 4.31 (d, 1H), 4.09 (m, 1H), 2.71 (m, 1H), 2.20 (m, 2H), 1.90 (m, 2H), 1.75 (s, 3H), 1.40 (m, 2H), 1.25 (m, 4H).	12
119	338				Gum		12
120	323				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
121	353	351			100-105		12
122	402				Gum		12
123	378	376			155-156		12
124	449	447			Gum	(CDCl ₃) 7.78 (s, 1H), 7.44 (s, 1H), 7.08 (d, 2H), 6.89 (d, 2H), 6.10 (s, 1H), 4.30 (d, 1H), 4.10 (m, 1H), 3.18 (m, 3H), 2.71 (m, 1H), 2.59 (m, 3H), 2.36 (s, 3H), 2.19 (m, 3H), 1.92 (m, 1H), 1.60 (br, 2H), 1.34 (m, 2H), 1.20 (m, 2H), 0.88 (t, 3H).	12
125	434	432			Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
126	395	393			68-72	(CDCl ₃) 7.78 (s, 1H), 7.44 (s, 1H), 6.80 (d, 1H), 6.55 (s, 1H), 6.13 (d, 1H), 4.24 (s, 4H), 4.22 (m, 1H), 4.05 (m, 1H), 2.72 (m, 1H), 2.21 (m, 2H), 1.94 (m, 2H), 1.71 (s, 3H), 1.40~1.15 (m, 6H).	12
127	377	375			60-75		12
128	435	433			Gum		12
129	420	418			58-66	(CDCl ₃) 7.78 (s, 1H), 7.50 (s, 1H), 6.97 (d, 2H), 6.90 (d, 2H), 6.20 (s, 1H), 4.20 (d, 1H), 4.07 (m, 1H), 3.12 (m, 4H), 2.72 (m, 1H), 2.20 (m, 2H), 1.94 (m, 2H), 1.72 (m, 2H), 1.64 (s, 3H), 1.55 (m, 2H), 1.45 (m, 2H), 1.35 (m, 2H), 1.25 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
130	408	406			Gum		12
131	377	375			Gum	(CDCl ₃) 8.00 (s, 1H), 7.79 (s, 1H), 7.66 (d, 1H), 6.91 (d, 1H), 6.89 (s, 1H), 7.78 (m, 1H), 6.65 (m, 1H), 6.15 (s, 1H), 5.32(s, 1H), 4.44 (d, 1H), 4.12 (m, 1H), 3.15 (m, 1H), 2.75 (m, 1H), 2.15 (m, 4H), 1.92 (m, 2H), 1.81 (s, 3H), 1.35 (m, 2H), 1.22 (m, 4H).	12
132	495				70-75		12
133	361				180-183		12
134	381				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
135	361	359			Gum		12
136		571			90-93		32
137	457	455			Gum	(CDCl ₃) 7.85 (d, 1H), 7.75 (s, 1H), 6.95 (s, 1H), 6.85 (d, 1H), 6.18 (s, 1H), 4.50 (d, 1H), 4.35 (q, 2H), 4.12 (m, 1H), 2.73 (m, 1H), 2.31 (q, 2H), 2.22 (m, 2H), 1.92 (m, 2H), 1.42 (t, H), 1.42~1.120 (m, 4H), 1.10 (t, 3H).	12
138	395				64-67		12
139	418	416			Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
140	473				Gum	(CDCl ₃) 7.75 (s, 1H), 7.70 (s, 1H), 6.87 (d, 2H), 6.64 (d, 2H), 6.60 (d, 2H), 6.41 (d, 2H), 6.15 (s, 1H), 4.22 (d, 1H), 4.05 (m, 1H), 3.90 (q, 2H), 3.72 (s, 3H), 2.60 (m, 1H), 2.08 (m, 2H), 1.81 (m, 2H), 1.38 (t, 3H), 1.25 (m, 2H), 1.00 (m, 2H).	12
141	412				70-74		12
142	367	365			80-85		12
143	396				Gum		12
144	396				Gum		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
145	393				236-240		12
146	393	391			210-215		12
147	459				230-234		12
148	390	388			Gum	(CDCl ₃) 8.02 (bs, 1H), 7.78 (s, 1H), 7.66 (s, 1H), 7.20 (d, 1H), 6.88 (d, 1H), 6.19(s, 1H), 6.13 (s, 1H), 4.20 (d, 1H), 4.05 (m, 1H), 2.70 (m, 1H), 2.44 (s, 3H), 2.20 (m, 2H), 1.93 (m, 2H), 1.60 (s, 3H), 1.42 (brs, 2H), 1.32 (m, 2H), 1.23 (m, 2H).	12
149	376				Gum	(CDCl ₃) 8.46 (bs, 1H), 7.80 (s, 1H), 7.70 (s, 1H), 7.22 (d, 1H), 7.19 (s, 1H), 7.10 (t, 1H), 6.68 (d, 1H), 6.50 (s, 1H), 6.18 (s, 1H), 4.25 (d, 1H), 4.10 (m, 1H), 2.71 (m, 1H), 2.21 (m, 2H), 1.92 (m, 2H), 1.67 (s, 3H), 1.52 (bs, 2H), 1.38 (m, 2H), 1.28 (m, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
150	421				Gum		12
151		392			206-210		12
152	375	373			Gum		12
153		374			116-125	(CDCl ₃) 8.58 (bs, 1H), 7.80 (s, 1H), 7.70 (s, 1H), 7.55 (d, 1H), 7.19 (d, 1H), 7.07 (s, 1H), 6.90 (d, 1H), 6.55 (s, 1H), 6.15 (s, 1H), 4.25 (d, 1H), 4.05 (m, 1H), 2.72 (m, 1H), 2.20 (m, 2H), 1.93 (m, 2H), 1.62 (s, 3H), 1.60 (bs, 2H), 1.40 (m, 2H), 1.26 (m, 2H).	12
154	409				204-205		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
155	408				210-215	(CDCl ₃) 7.85 (d, 1h), 7.78 (s, 1H), 7.65 (s, 1H), 7.39 (s, 1H), 7.10 (d, 1H), 6.15 (s, 1H), 4.30 (d, 1H), 4.08 (m, 1H), 2.80 (s, 3H), 2.70 (m, 1H), 2.22 (m, 2H), 1.92 (m, 2H), 1.70 (s, 3H), 1.35 (m, 2H), 1.25 (m, 2H).	12
156	341				Gum	(CDCl ₃) 7.78 (s, 1H), 7.40 (bs, 1H), 7.13 (m, 1H), 7.03 (m, 1H), 7.01 (m, 1H), 6.89 (t, 1H), 6.13 (s, 1H), 5.10 (m, 1H), 4.28 (m, 1H), 3.18 (m, 1H), 2.82 (m, 2H), 2.72 (m, 1H), 1.87 (m, 1H), 1.81 (s, 3H), 1.75 (m, 2H), 1.68 (m, 1H), 1.59 (m, 1H).	12
157	363				120-123		12
158	395				64-65		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
159	429				184-187	(CDCl ₃) 7.78 (s, 1H), 7.15 (m, 4H), 6.98 (d, 1H), 6.15 (s, 1H), 4.40 (d, 1H), 4.10 (m, 1H), 2.72 (m, 1H), 2.28 (q, 2H), 2.20 (m, 2H), 1.92 (m, 2H), 1.40 (m, 2H), 1.25 (m, 2H), 1.01 (t, 3 H).	12
160	415				Gum		12
161	326	324			114-116		12
162	324	322			92-94		12
163	421	419			68-69		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
164	407	405			55-60		12
165	423	421			63-65		12
166	409	407			63-66		12
167	351				Gum		12
168	477				104-106		12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
169	497				Gum		12
170	382.2		7.1	A		(DMSO-d6) 8.34 (s, 1H), 7.66 (dd, 1H), 7.52 (dd, 1H), 7.47 (td, 1H), 7.41 (td, 1H), 7.32 (d, 1H), 5.06 (s, 1H), 3.77 (m, 1H), 2.99 (m, 1H), 1.94 (m, 4H), 1.40 (m, 2H), 1.19 (m, 2H).	12
171	391				Gum		12
172	405				Gum		12
173	383				Gum	(CDCl ₃) 7.79 (s, 1H), 7.52 (s, 1H), 7.15 (d, 2H), 6.85 (d, 2H), 6.10 (s, 1H), 5.50 (m, 1H), 4.15 (m, 1H), 4.05 (q, 2H), 3.20 (s, 3H), 2.90 (m, 1H), 2.75 (m, 2H), 2.62 (m, 1H), 2.30 (m, 1H), 1.95 (m, 1H), 1.75~1.53 (m, 3H), 1.42 (t, 2H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
174	379	377			Gum	(CDCl ₃) 7.85 (d, 1H), 7.78 (s, 1H), 7.59 (bs, 1H), 7.07 (d, 1H), 6.93 (s, 1H), 5.30 (m, 1H), 5.22 (s, 2H), 4.35 (m, 1H), 3.15 (dd, 1H), 2.88 (m, 3H), 2.00~1.82 (m, 4H), 1.92 (s, 3H), 1.62 (m, 1H).	12
175	394	392			Gum	(CDCl ₃) 7.78 (s, 1H), 7.70 (d, 2H), 7.50 (bs, 1H), 6.90 (d, 2H), 6.70 (m, 1H), 6.15 (s, 1H), 4.45 (d, 1H), 4.08 (m, 1H), 3.15 (m, 1H), 2.75 (m, 2H), 2.32 (q, 2H), 2.22 (m, 2H), 1.95 (m, 2H), 1.52~1.18 (m, 6H), 1.03 (t, 3H).	12
176	443.3		8.9	A		(DMSO- <i>d</i> ₆) 7.80 (s, 1H), 7.45~7.32 (m, 5H), 6.95 (s, 1H), 6.05 (s, 1H), 5.06 (s, 2H), 3.90 (m, 1H), 2.98 (m, 1H), 1.98 (m, 4H), 1.62 (s, 3H), 1.43 (t, 4H).	12
177	393.3		9.0	A			12
178	380.3		5.8	B			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
179	421.3		8.1	A			12
180	385.3		7.6	A			12
181	315.3		5.9	A			12
182	319.4		7.4	B			12
183	331.4		7.4	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
184	351.3		6.7	A			12
185	372.3		5.2	B			12
186	381.3		11.4	B			12
187	367.3		6.6	B			12
188	357.3		8.6	B			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
189	381.3		9.6	B			12
190	395.3		10.7	B		(CDCl ₃) 7.72 (d, 1H), 7.11 (d, 2H), 6.83 (dd, 2H), 6.05 (d, 1H), 5.82 (t, 1H), 4.12 (d, 1H), 4.04 (m, 1H), 3.78 (s, 3H), 3.68 (q, 2H), 2.89 (t, 2H), 2.70 (m, 1H), 2.19 (m, 1H), 2.17 (m, 1H), 2.04 (s, 3H), 1.93 (m, 1H), 1.90 (m, 1H), 1.52 (br, 2H), 1.34 (m, 2H), 1.23 (m, 2H).	12
191	375.2		12.7	B			12
192	381.3		10.8	B			12
194	395.7		8.9	B			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
195	382.7		8.1	B			12
196	353.3		5.0	B		(DMSO- <i>d</i> ₆) 9.33 (br, 1H), 7.83 (s, 1H), 6.89 (d, 2H), 6.71 (d, 2H), 6.08 (bs, 1H), 3.88 (m, 1H), 2.98 (m, 1H), 1.97 (m, 4H), 1.58 (s, 3H), 1.43 (m, 4H).	23
198	367.3		7.4	A			12
199	415.2		7.1	A			23
200	411.3		5.9	A			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
201	395.3		7.9	A			23
202	435.3		9.1	A			23
203	367.3		5.9	A			23
204	458.3		4.8	A			23
205	458.3		5.2	A			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
206	458.3		6.4	A			23
207	473.3		7.6	A			23
208	473.2		8.6	A			23
209	457.3		8.1	A			23
210	457.2		7.9	A			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
211	477.2		9.5	A			23
212	477.2		9.4	A			23
213	477.2		9.3	A			23
214	435.3		9.6	A			23
215	463.3		10.9	A			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
216	421.3		8.6	A			23
217	450.3		5.4	C			23
218	450.3		5.4	C			23
219	437.3		6.4	A			23
220	444.2		4.4	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
221	466.3		3.8	B			23
222	444.2		4.3	B			23
223	464.2		4.3	B			23
224	444.2		4.8	B			23
225	458.2		4.4	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
226	464.2		4.6	B			23
227	464.2		4.4	B			23
228	458.1		4.5	B			23
229	422.7		4.7	C			23
230	465.7		3.9	C			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
231	464.8		6.3	C			23
232	450.7		6.1	C			23
233	450.7		6.3	C			23
234	447.7		5.2	C			23
235	436.7		5.3	C			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
236	436.7		5.3	C			23
237	449.7		14.1	C			23
238	463.3		10.1	B			23
239	421.3		8.0	B			23
240	435.3		8.9	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
241	435.3		8.6	B			23
242	449.3		9.6	B			23
243	443.3		8.2	B			23
244	435.4		8.2	B			12
245	421.4		9.2	B			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
246	458.4		5.3	B			23
247	477.3		9.1	B			23
248	477.3		9.1	B			23
249	437.4		6.2	B			23
250	477.3		8.9	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
251	450.7		6.3	C			23
252	473.2		8.2	B			23
253	457.2		8.6	B			23
254	457.2		8.4	B			23
255	464.8		7.0	C			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
256	437.7		9.1	C			23
257	427.7		5.9	C			23
258	436.7		3.9	B			23
260	464.7		4.7	B			23
261	450.7		4.5	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
262	436.7		4.0	B			23
263	450.7		4.1	B			23
264	464.7		4.8	B			23
265	450.7		4.5	B			23
266	422.7		3.4	B			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
267	447.7		3.9	B			23
268	450.7		3.9	B			23
269	464.7		4.3	B			23
270	464.7		4.5	B			23
271	501.7		5.4	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
273	444.7		6.8	C			23
274	444.7		7.0	C			23
275	444.7		7.6	C			23
276	458.7		5.1	B			23
277	466.7		5.9	C			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
278	464.7		6.8	C			23
279	458.7		7.1	C			23
280	458.7		7.0	C			23
281	437.7		10.4	C			23
282	427.7		6.9	C			23

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
283	435.7		7.2	A			12
285	443.3		11.1	B			24
286	443.3		11.1	B			24
287	443.3		11.1	B			24
288	428.3		6.8	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
289	469.2		12.8	B			24
290	453.2		12.2	B			24
291	419.2		10.6	B			24
292	469.2		12.5	B			24
293	406.3		12.7	B			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
294	392.3		11.9	B			12
295	414.2		11.8	B			12
296	381.3		9.6	A			12
298	457.3		9.8	A			12
299	414.4		5.3	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
300	414.4		5.5	B			24
301	428.3		6.4	B			24
302	447.2		11.8	B			24
303	431.3		11.0	B			24
304	431.3		11.0	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
305	431.3		10.8	B			24
306	429.2		8.6	B			24
307	429.2		8.9	B			24
308	429.2		9.3	B			24
309	403.3		9.7	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
310	447.2		9.1	D			24
311	415.3		5.9	D			24
312	447.3		11.8	B			24
313	447.3		11.1	B			24
314	456.3		7.5	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	¹ H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
315	456.4		7.3	B			24
316	497.3		12.4	B			24
317	497.3		12.3	B			24
318	438.3		9.8	B			24
319	438.3		9.9	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
320	427.4		11.5	B			24
321	427.4		11.2	B			24
322	427.4		11.5	B			24
323	481.3		11.6	B			24
324	481.3		12.0	B			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
325	463.4		9.4	A			12
326	449.4		11.5	A			12
327	425.3		8.3	A			15
328	453.3		9.6	A			12
329	424.2		7.9	A			16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
330	438.3		8.1	A			16
331	452.3		8.4	A			16
332	482.3		8.4	A			16
333	495.3		7.2	A			16
334	481.3		7.9	A			16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
335	500.3		10.0	A			16
336	514.3		9.5	A			16
337	452.3		7.3	A			16
338	478.3		7.6	A			16
339	464.3		8.4	A			16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
341	395.2		11.1	A			29
342	457.2		12.7	A			29
343	501.2		9.3	A			18
344	509.3		9.5	A			16
345	535.4		10.1	A			16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
346							16
347	507.3		9.5	A			16
348	514.3		12.1	A			16
349	543.3		10.6	A			16
350	481.3		10.0	A			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
351	505.3		7.2	A			24
352	443.3		6.6	A			24
353	443.3		6.8	A			24
354	457.3		8.4	A			24
355	461.3		7.5	A			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
356	457.4		9.2	A			24
357	433.3		10.5	D			24
358	521.3		9.8	A			16
359	501.2		11.5	A			16
360	501.2		10.6	A			16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
361	501.2		10.6	A			16
363	454.3		8.6	A			19
364	468.2		9.5	A			19
365	530.2		13.2	A			17
366	370.3		14.1	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
367	384.2		15.2	A			12
368	382.2		14.0	A			12
369	418.2		13.8	A			12
370	342.3		11.2	A			12
371	356.2		12.6	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
372	418.2		14.8	A			12
373	391.2		7.3	A			25
374	404.3		5.3	A			25
376							25
377	390.3		4.6	A			25

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
379	452.2		9.2	A			19
380	464.2		9.6	A		(DMSO- d_6) 9.66 (brs, 1H), 8.65 (brs, 1H), 7.94 (s, 1H), 7.76 (brs, 3H), 6.87 (d, 2H), 6.81 (d, 2H), 4.07~3.87 (m, 3H), 2.96 (brs, 1H), 2.05~1.80 (m, 4H), 1.59 (s, 3H), 1.50~1.35 (m, 4H), 1.26 (t, 3H), 0.79~0.65 (m, 4H).	19
381	496.2		9.5	A			19
382	498.2		9.3	A			19
383	500.2		10.7	A		(DMSO- d_6) 9.76 (brs, 1H), 8.67 (brs, 1H), 7.97-8.03 (m, 3H), 7.72 (brs, 3H), 7.46-7.63 (m, 3H), 6.82-6.96 (m, 4H), 3.92-4.03 (m, 3H), 2.97 (brs, 1H), 1.90-2.08 (m, 4H), 1.66 (s, 3H), 1.35-1.48 (m, 4H), 1.31 (t, 3H).	19

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) d(ppm)	Method of Preparation
	M+H	M-H					
384	514.2		10.5	A		(DMSO-d6) 9.44 (brs, 1H), 8.56 (brs, 1H), 7.94 (s, 1H), 7.76 (brs, 3H), 7.18-7.35 (m, 5H), 6.78-6.87 (m, 4H), 6.13 (brs, 1H), 4.02 (brs, 1H), 3.93 (q, 2H), 3.64 (s, 2H), 2.96 (brs, 1H), 1.89-2.03 (m, 4H), 1.60 (s, 3H), 1.32-1.48 (m, 4H), 1.26 (t, 3H).	19
385	492.1		11.8	A			19
387	536.1		12.3	A			20
388	481.2		9.3	A		(DMSO-d6) 8.66 (brs, 1H), 7.70-7.80 (m, 4H), 6.78-6.90 (m, 2H), 6.30 (brs, 1H), 3.82-3.97 (m, 3H), 2.90-3.05 (m, 3H), 1.88-2.02 (m, 4H), 1.58 (s, 3H), 1.32-1.46 (m, 6H), 1.26 (t, 3H), 0.82 (t, 3H).	21

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
391	531.1		12.3	A			22
392	468.2		9.7	A			16
393	328.3		9.5	A			12
394	342.3		9.7	A			12
395	356.2		10.2	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
396	404.2		13.3	A			12
397	416.3		13.6	A			12
398	416.3		13.2	A			12
399	356.3		10.8	A			12
400	327.2		9.0	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
401	341.2		9.0	A			12
402	341.2		8.4	A			12
403	369.2		10.3	A			12
404	355.3		8.0	A			12
405	381.2		10.2	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
406	381.2		11.0	A			12
407	381.2		9.1	A			12
408	357.2		8.1	A			12
409	394.2		8.6	A			30
410	353.3		9.1	A			30
411	443.2		12.9	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
412	353.3		8.9	A			30
413	395.3		8.7	A		(CDCl ₃) 8.25 (s, 1H), 8.21 (bs, 1H), 7.61 (s, 1H), 7.06 (d, 2H), 6.88 (d, 2H), 4.23 (m, 1H), 4.02 (q, 2H), 3.11 (m, 1H), 2.15 (s, 3H), 2.11 (m, 4H), 1.62 (s, 3H), 1.61 (m, 4H), 1.41 (t, 3H).	12
414	381.3		9.9	A		(CDCl ₃) 10.3 (br, 1H), 10.1 (br, 1H), 8.32 (s, 1H), 7.68 (s, 1H), 7.06 (d, 2H), 6.91 (d, 2H), 4.95 (m, 1H), 4.05 (q, 2H), 3.48 (m, 2H), 3.28 (m, 1H), 2.94 (m, 1H), 2.35 (s, 3H), 2.05 (m, 2H), 1.99 (m, 2H), 1.68 (s, 3H), 1.44 (t, 3H).	12
415	471.3		12.4	A		(CDCl ₃) 8.21 (br, 2H), 8.14 (s, 1H), 7.51 (s, 1H), 7.22 (s, 2H), 7.21 (s, 2H), 7.13 (m, 1H), 7.02 (d, 2H), 6.87 (d, 2H), 4.13 (m, 1H), 4.01 (q, 2H), 3.99 (s, 2H), 3.09 (m, 1H), 2.07 (m, 4H), 1.61 (m, 1H), 1.60 (s, 3H), 1.44 (m, 1H), 1.41 (t, 3H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
416	457.2		1.7	A		(CDCl ₃) 10.2 (br, 1H), 9.91 (br, 1H), 8.26 (s, 1H), 7.58 (s, 1H), 7.43 (br, 1H), 7.31-7.16 (m, 5H), 7.05 (d, 2H), 6.89 (d, 2H), 4.92 (m, 1H), 4.22 (s, 2H), 4.03 (q, 2H), 3.44 (m, 2H), 3.22 (m, 1H), 2.98 (m, 1H), 2.35 (s, 2H), 2.06-1.99 (m, 4H), 1.68 (s, 3H), 1.42 (t, 3H).	12
418	443.2		12.4	A			12
419	457.2		12.0	A			24
420	457.2		11.0	A			24
421	433.2		11.3	A			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
422	403.3		6.5	A			24
423	452.2		11.0	A			24
424	438.3		14.3	A			12
425	411.2		9.0	A		(CDCl ₃) 7.61(1H, s), 7.42(brs, 1H), 6.97(m, 2H), 6.85(m, 2H), 4.14(m, 1H), 4.02(q, 2H), 3.98(s, 3H), 2.73(m, 1H), 2.22(m, 2H), 1.94(m, 2H), 1.65(s, 3H), 1.42(t, 3H), 1.35(m, 2H), 1.23(m, 2H).	12
426	424.5		10.4	A		(DMSO- <i>d</i> ₆) 8.93 (s, 1H), 8.74 (brs, 2H), 8.12 (s, 1H), 7.73 (d, 1H), 6.95 (d, 2H), 6.86 (d, 2H), 6.69 (d, 1H), 4.39 (brs, 1H), 3.98 (q, 2H), 3.38~3.47 (m, 1H), 3.21~3.30 (m, 1H), 2.93~3.03 (m, 1H), 2.82~3.03 (m, 4H), 1.99~2.09 (m, 1H), 1.88~1.97 (m, 1H), 1.57~1.83 (m, 4H), 1.31 (t, 3H).	16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
427	438.6		10.9	A			16
428	464.6		13.1	A			16
429	468.5		11.4	A			16
430	481.6		9.0	A			16
431	486.6		14.4	A		(DMSO- <i>d</i> ₆) 9.05 (s, 1H), 8.70~8.90 (m, 2H), 8.26 (s, 1H), 7.68 (d, 2H), 7.37 (t, 2H), 7.09 (t, 1H), 6.99 (d, 2H), 6.88 (d, 2H), 6.81 (d, 1H), 4.45~4.55 (m, 1H), 3.99 (q, 2H), 3.37~3.45 (m, 1H), 3.15~3.30 (m, 2H), 2.87~2.98 (m, 1H), 2.18~2.27 (m, 1H), 1.88~2.00 (m, 1H), 1.55~1.82 (m, 5H), 1.31 (t, 3H).	16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
432	487.5		12.7	A			16
433	487.5		11.0	A		((DMSO- <i>d</i> ₆) 9.07 (s, 1H), 8.85 (d, 1H), 8.72 (brs, 2H), 8.35 (dd, 1H), 8.25~8.32 (m, 2H), 7.47~7.52 (m, 1H), 6.99 (d, 2H), 6.88 (d, 2H), 6.82 (d, 1H), 4.48~4.60 (m, 1H), 3.99 (q, 2H), 3.33~3.42 (m, 1H), 3.12~3.30 (m, 2H), 2.85~2.97 (m, 1H), 2.17~2.25 (m, 1H), 1.89~2.00 (m, 1H), 1.57~1.80 (m, 5H), 1.31 (t, 3H).	16
434	487.6		10.0	A		((DMSO- <i>d</i> ₆) 9.14 (s, 1H), 8.68~8.82 (m, 2H), 8.65 (d, 2H), 8.39 (s, 1H), 8.00 (d, 2H), 6.98 (d, 2H), 6.83~6.92 (m, 3H), 4.48~4.58 (m, 1H), 3.99 (q, 2H), 3.36~3.45 (m, 1H), 3.15~3.25 (m, 2H), 2.89~3.01 (m, 1H), 2.12~2.21 (m, 1H), 1.88~1.98 (m, 1H), 1.62~1.77 (m, 5H), 1.31 (t, 3H).	16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
435	500.6		12.4	A		((DMSO- <i>d</i> 6) 8.96 (s, 1H), 8.54~8.75 (m, 2H), 8.27~8.34 (m, 1H), 8.16 (s, 1H), 7.30~7.35 (m, 4H), 7.22~7.29 (m, 1H), 6.96 (d, 2H), 6.87 (d, 2H), 6.68 (d, 1H), 4.77 (dd, 1H), 4.41 (dd, 1H), 4.25~4.35 (m, 1H), 3.98 (q, 2H), 2.98~3.27 (m, 3H), 2.79~2.92 (m, 1H), 1.83~1.92 (m, 1H), 1.38~1.75 (m, 6H), 1.31 (t, 3H).	16
437	410.6		10.1	A			28
438	454.6		9.9	A			28
439	439.6		14.8	A		59Db0011 ((DMSO- <i>d</i> 6) 8.65~8.90 (m, 3H), 8.19 (s, 1H), 6.94 (d, 2H), 6.87 (d, 2H), 6.63 (d, 1H), 4.36~4.46 (m, 1H), 4.16~4.26 (m, 2H), 3.99 (q, 2H), 3.40~3.48 (m, 1H), 3.06~3.24 (m, 2H), 2.85~2.97 (m, 1H), 1.86~2.10 (m, 2H), 1.62~1.78 (m, 5H), 1.27~1.35 (m, 6H).	12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
440	411.6		11.1	A		59Db0021 ((DMSO- <i>d</i> 6) 8.87~8.97 (brs, 1H), 8.58~8.78 (m, 2H), 8.16 (s, 1H), 6.82~6.97 (m, 4H), 6.70 (d, 1H), 4.31~4.45 (m, 1H), 3.98 (q, 2H), 3.35~3.45 (m, 1H), 2.74~3.25 (m, 3H), 1.86~2.03 (s, 3H), 1.60~1.77 (m, 5H), 1.31 (t, 3H).	15
442	414.1		7.0	A			24
443	405		13.1	A			24
444	414.1		7.9	A			24
445	429.1		9.8	A			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
446	413.1		11.1	A			24
447	428.1		7.3	A			24
448	428.1		7.6	A			24
449	414.1		5.7	A			24
451	461		10.1	A			24

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
452.	381.1		9.3	A			12
453	416		7.5	A			12
454	384.1		9.5	A			12
455	383.1		10.2	A			12
456	427.1		10.8	A			12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
457	413.1		12.8	A			12
458	416		10.9	A			12
459	423		12.2	A			12
460	394.1		6.0	B			Ex.26
462	420		7.2	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
463	448		9.9	B			Ex.26
465	476.1		13.0	B			Ex.26
466	424.1		4.6	A			Ex.26
467	438		7.0	B			Ex.26
468	464		8.7	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
469	451.1		5.5	B			Ex.26
470	477.1		6.5	B			Ex.26
471	493.1		6.1	B			Ex.26
472	426		7.8	B			Ex.26
473	462		10.2	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
474	442		8.7	B			Ex.26
475	454		9.6	B			Ex.26
476	465		6.3	B			Ex.26
477	437.1		6.1	B			Ex.26
478	452		7.5	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
480	465.1		5.9	B			Ex.26
481	507.1		5.9	B			Ex.26
483	480.1		10.6	B			Ex.26
488	474		11.5	B			Ex.26
489	474		12.0	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
490	474		12.3	B			Ex.26
492	481.1		11.8	B			Ex.26
493	481.1		11.8	B			Ex.26
494	486.1		12.4	B			Ex.26
495	486.1		11.2	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
496	486.1		10.8	B			Ex.26
503	499.1		9.9	B			Ex.26
504	499.1		7.4	B			Ex.26
505	499.1		7.9	B			Ex.26
506	507		8.1	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
510	470.1		9.3	A			Ex.26
511	460		9.4	B			Ex.26
512	476		10.3	B			Ex.26
513	471.1		4.3	A			Ex.26
514	471		6.2	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
515	471		5.8	B			Ex.26
518	484		12.3	B			Ex.26
519	485		6.5	B			Ex.26
520	485		6.5	B			Ex.26
521	488.1		6.1	B			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
522	474.1		6.3	B			Ex.26
759	452.1		5.5	A			Ex.23
760	430		6.5	A			Ex.23
761	397		9.4	A			Ex.23
762	459		10.9	A		(CDCl ₃) 8.04(s, 1H), 7.87(brs, 2H), 7.54(brs, 1H), 6.99(d, J=8.8Hz, 2H), 6.85(d, J=9.0Hz, 2H), 4.02(q, J=7.0Hz, 2H), 3.60~4.30(m, 3H), 3.26(s, 3H), 3.15~3.30(m, 1H), 2.10~2.30(m, 4H), 1.50~1.75(m, 2H), 1.60(s, 3H), 1.42(t, J=6.9Hz, 3H), 1.30~1.50(m, 2H).	Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
763	445.1		11.7	A		(CDCl ₃) 9.33(brs, 1H), 8.80(brs, 1H), 8.07(s, 1H), 7.63(brs, 1H), 7.03(d, J=8.8Hz, 2H), 6.89(d, J=8.8Hz, 2H), 5.20~5.60(m, 1H), 4.52(brs, 1H), 4.04(q, J=7.0Hz, 2H), 3.60~3.70(m, 1H), 3.20(s, 3H), 3.15~3.30(m, 3H), 2.00~2.15(m, 2H), 1.80~2.00(m, 2H), 1.65(s, 3H), 1.43(t, J=7.0Hz, 3H).	Ex.12
764	490		12.0	A			Ex.16
765	490		10.7	A			Ex.16
766	491		11.2	A			Ex.16
767	492		12.8	A			Ex.16

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
768	468.1		11.9	A			Ex.16
769	482.1		10.7	A			Ex.16
770	454		11.2	A			Ex.16
771	468.1		11.1	A			Ex.16
772	397		10.0	A		(CDCl ₃) 8.42 (s, 1H), 7.84 (s, 1H), 7.74 (m, 1H), 7.11 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H), 6.36 (s, 1H), 5.06 (m, 1H), 4.48 (m, 1H), 4.04 (q, J = 6.84, 2H), 3.87 (m, 1H), 3.63 (m, 1H), 2.98 (m, 1H), 2.42 (m, 1H), 1.42 (t, J = 6.86 Hz, 3H).	Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
773	447		10.0	A			Ex.24
774	395.1		9.4	A			Ex.12
775	430		6.3	A			Ex.12
776	456		11.1	B			Ex.26
777	397		8.4	A			Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
778	441		10.0	A			Ex.12
779	415		5.5	A			Ex.12
780	427.1		11.8	A			Ex.12
781	430		9.4	A			Ex.12
782	437		12.6	A			Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
783	401.1		10.2	A			Ex.12
784	454.2		11.2	A			Ex.12
785	455		11.4	A			Ex.12
786	458.1		10.7	A			Ex.12
787	484		12.1	A			Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
788	379.1		6.7	A			Ex.12
789	361.1		8.6	A			Ex.12
790	516.1		10.2	A			Ex.28
791	552.1		10.9	A			Ex.28
792	434.1		6.9	A			Ex.26

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
793	450.1		10.5	B			Ex.26
794	408.1		7.2	B			Ex.26
795	398		8.4	A			Ex.12
796	442.1		11.1	A			Ex.12
797	387.1		11.9	A			Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
798	437.2		12.6	A			Ex.12
799	440.2		12.0	A			Ex.12
800	441.0		12.6	A			Ex.12
801	444.1		10.9	A			Ex.12
802	470.1		12.8	A			Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
803	365.2		8.1	A			Ex.12
804	347.1		9.8	A			Ex.12
805	374.1		4.5	A			Ex.12
806	498.9		15.1	A		(CD ₃ OD) 7.61~7.58(m, 2H), 7.38~7.29(m, 2H), 4.05~4.00(m, 1H), 3.09~3.07(m, 1H), 2.21~2.18(m, 2H), 2.13~2.09(m, 2H), 1.99(s, 3H), 1.58~1.49(m, 2H), 1.43~1.34(m, 2H).	Ex.14
807	440.0		8.722	A		(CD ₃ OD) 7.96 (s, 1H), 7.82 (d, 1H), 7.71 (d, 1H), 7.32 (dd, 1H), 3.92 (m, 2H), 3.16 (m, 2H), 2.81 (s, 3H), 2.15 (m, 4H), 1.68 (s, 3H), 1.66 (m, 4H).	Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) δ (ppm)	Method of Preparation
	M+H	M-H					
808	454.0		10.3	A		(CD ₃ OD) 7.96 (s, 1H), 7.83 (d, 1H), 7.71 (d, 1H), 7.32 (dd, 1H), 3.84 (m, 2H), 3.38 (q, 2H), 3.16 (m, 2H), 2.16 (m, 4H), 1.68 (s, 3H), 1.66 (m, 4H), 1.49 (t, 3H).	Ex.12
809	468.0		11.8	A		(CD ₃ OD) 7.96 (s, 1H), 7.84 (d, 1H), 7.71 (d, 1H), 7.32 (dd, 1H), 4.09 (m, 1H), 3.92 (m, 2H), 3.16 (m, 2H), 2.81 (s, 3H), 2.15 (m, 4H), 1.68 (s, 3H), 1.66 (m, 4H).	Ex.12
810	426.0		9.6	A		(CD ₃ OD) 7.84 (s, 1H), 7.75 (d, 1H), 7.46 (d, 1H), 7.16 (dd, 1H), 4.42 (m, 1H), 3.64 (m, 1H), 3.38 (m, 1H), 3.30 (m, 2H), 2.97 (m, 1H), 2.79 (s, 3H), 2.16 (m, 1H), 2.07 (m, 1H), 1.89 (m, 1H), 1.80 (s, 3H).	Ex.12
811	440.0		10.7	A		(CD ₃ OD) 7.87 (s, 1H), 7.77 (d, 1H), 7.50 (d, 1H), 7.19 (dd, 1H), 4.39 (m, 1H), 3.64 (m, 1H), 3.38 (m, 1H), 3.36 (q, 2H), 3.30 (m, 2H), 2.98 (m, 1H), 2.79 (s, 3H), 2.17 (m, 1H), 2.08 (m, 1H), 1.89 (m, 1H), 1.78 (s, 3H), 1.47 (t, 3H).	Ex.12

Compound No.	ESI/MS		HPLC Retention Time (min.)	HPLC Method	Mp (°C)	1H-NMR(400MHz) <i>d</i> (ppm)	Method of Preparation
	M+H	M-H					
812	454.0		11.9	A		(CD ₃ OD) 7.88 (s, 1H), 7.79 (d, 1H), 7.51 (d, 1H), 7.20 (dd, 1H), 4.39 (m, 1H), 4.04 (m, 1H), 3.65 (m, 1H), 3.38 (m, 1H), 3.00 (m, 2H), 2.98 (m, 1H), 2.17 (m, 1H), 2.09 (m, 1H), 1.92 (m, 1H), 1.78 (s, 3H), 1.49 (d, 6H).	Ex.12
813	541.2		16.1	A		(CDCl ₃) 7.79 (d, J = 2.2 Hz, 1H), 7.54 (s, 1H), 7.37-7.29 (m, 5H), 7.00 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 9.04 Hz, 2H), 6.09 (brs, 1H), 5.79 (m, 1H), 5.14 (d, J = 2.72 Hz, 2H), 5.04 (s, 1H), 5.01 (m, 1H), 4.44 (br, 1H), 4.26 (br, 1H), 4.12 (br, 1H), 4.02 (q, J = 6.84 Hz, 2H), 2.94 (br, 1H), 2.76 (br, 1H), 2.41 (m, 1H), 2.06 (m, 1H), 1.83 (br, 1H), 1.64 (s, 3H), 1.42 (t, J = 7.08 Hz, 3H).	Ex.12
815	449.4		13.9	A			Ex.12
816	435.5		13.7	A			Ex.12
817	499.3		15.6	A			Ex.12
818	485.2		14.9	A			Ex.12

EXAMPLE 35[General Procedure for Measurement of MAPKAP-K2 Enzyme Activity Inhibition](Compound preparation)

Compounds were dissolved in DMSO at a concentration of 10 mM and stored in aliquots at -20°C. Compounds in DMSO from these stock aliquots were diluted in DMSO to produce the required range of 30x stock solutions. These stock solutions were then subjected to 1:3 dilutions in order to prepare the required range of 10x stock solutions and 5 μ L of each solution was used per 50 μ L reaction. A final DMSO concentration of 3% was maintained throughout all compound dilution series to maximise compound solubility. Compounds were routinely tested at final concentrations ranging from 300 μ M to 0.001 μ M, but may have been tested at lower concentrations depending upon their activity.

(MAPKAP-K2 Assay)

The kinase reaction was conducted in a round-bottomed polypropylene 96-well plate. MAPKAP-Kinase 2 was diluted to 0.5 mU/ μ L in diluent buffer (50 mM Tris/HCl, pH7.5, 0.1 mM EGTA, 0.1% (v/v) β -mercaptoethanol, 1 mg/mL BSA). 5 μ L compound or 30% DMSO was added to each well followed by 25 μ L substrate cocktail (final concentration: 10 μ M ATP, 30 μ M peptide (KKLNRTLVA), 0.5 μ Ci 33P- γ -ATP in 50 mM Tris pH7.5, 0.1 mM EGTA, 10mM Mg-acetate and 0.1% β -mercaptoethanol). The reaction was initiated with the addition of 20 μ L enzyme solution per well or 20 μ L diluent buffer without enzyme. The plate was shaken for 10 seconds and then left at room temperature for 30 minutes. The reaction was terminated with 50 μ L 150 mM phosphoric acid. 90 μ L of the reaction mixture was then transferred into a 96-well P81

filter plate (Whatmann) and incubated at room temperature for 5 minutes. The filter plate was then washed 4 times with 200 μ L 75 mM phosphoric acid per well on a plate vacuum manifold (Millipore) and dried in an oven for 2-3 hours. Packard MicroScint 'O' (30 μ L) was then added to each well, the plate was mixed for 30 minutes and subjected to liquid scintillation counting on a Packard TopCount.

After adding 25 μ L of peptide substrate solution [60 μ M substrate peptide, 20 μ M ATP, 50 mM Tris buffer (pH 7.5), 0.1 mM EGTA, 0.1 % β -mercaptoethanol, 20 mM magnesium acetate, 0.1 μ Ci [γ -33P]ATP (specific activity: approximately 110 TBq/mmol)] to 5 μ L of the test compound using 5% dimethylsulfoxide as the solvent, reaction was initiated by further addition of 20 μ L of a MAPKAP-K2 enzyme solution [10 mU recombinant human MAPKAP-K2, 50 mM Tris buffer (pH 7.5), 0.1 mM EGTA, 0.1 % β -mercaptoethanol, 0.1% BSA]. After conducting the reaction for 30 minutes at room temperature, an equivalent volume of a 200 mM phosphoric acid solution was added to suspend the reaction, and 90 μ L of the reaction product was adsorbed onto a MultiScreen PH plate (Millipore) and rinsed with a 100 mM phosphoric acid solution. After drying the plate, 30 μ L of MicroScint-O (Packard BioScience) was added, and the cpm was measured with a scintillation counter to determine the inhibiting activity. Substrate peptide is Lys-Lys-Leu-Asn-Arg-Thr-Leu-Ser-Val-Ala.

(Interpretation)

$$\% \text{ Control} = (X-B)/(Tot-B) \times 100$$

$$\% \text{ Inhibition} = 100 - \% \text{ Contr}$$

X = cpm of the test compound wells

B = cpm of wells without enzyme

Tot = cpm of wells with DMSO vehicle only

(MAPKAP-K2 inhibitory activity)

The efficacy of the compounds in Table A against MAPKAP-K2 is shown in Table C below.

(The activity is presented as +, ++, or +++ representing active, more active and very active based on assays conducted at typically 1 – 100 μ M).

Table C

Compound No	activity	Compound No	activity
1	++	36	+++
2	++	37	+++
7	++	38	++
10	+++	39	++
11	+++	40	++
12	+++	41	++
13	+	42	++
14	++	43	+++
15	+++	44	++
16	+++	45	++
17	+++	46	++
18	++	47	++
19	+++	48	++
20	++	49	++
21	++	50	++
22	++	51	+++
23	+++	52	+++
24	+++	53	+++
25	+++	54	++
26	+++	55	+++
27	+++	56	+++
28	+++	57	+++
29	+++	58	++
30	+++	59	+++
31	+++	60	+++
32	+++	61	+++
33	+++	62	++
34	+++	63	+++
35	+++	64	+++

Compound No	activity
65	+++
66	++
67	+++
68	+++
69	++
70	+++
71	++
72	+++
73	++
74	++
75	++
76	+++
77	+++
79	++
80	+++
81	+++
82	++
83	+++
84	+++
85	+++
86	++
87	++
88	+++
89	+++
90	+++
91	++
93	++
94	++
95	+++

Compound No	activity
96	+++
97	+++
98	+++
100	++
102	+++
103	+++
104	+++
105	+++
106	+++
107	+++
110	+
111	+++
112	+++
113	++
114	+++
115	+++
116	++
117	++
118	+++
119	+
120	++
121	++
122	++
124	++
125	++
126	+++
127	+
128	++
129	+++

Compound No	activity
130	++
131	+++
135	+
137	+++
139	+
140	+++
141	++
142	+
145	++
146	++
148	+++
149	+++
150	+++
151	++
152	++
153	+++
155	+++
156	+++
157	++
159	+++
160	++
167	++
168	++
169	++
170	+++
171	++
172	++
173	+++
174	+++

Compound No	activity
175	+++
176	+++
177	++
178	+++
179	+++
180	++
181	++
182	+
183	++
184	++
187	++
190	+
191	+++
192	++
193	+++
195	+
196	+++
197	+++
198	+++
199	+++
200	+++
201	+++
202	+++
203	+++
204	++
205	+++
206	++
207	++
208	+++

Compound No	activity
209	++
210	++
211	+++
212	++
213	+++
214	+++
215	++
216	+++
217	++
218	+++
219	+++
220	++
221	+++
222	+++
223	+++
224	+++
225	+++
226	+++
227	++
228	+++
229	+++
230	+++
231	++
232	+++
233	++
234	+++
235	++
236	++
237	++

Compound No	activity
238	++
239	++
240	++
241	++
242	++
243	++
244	++
245	+++
246	++
247	++
248	++
249	++
250	++
251	+++
252	++
253	+++
254	+++
255	++
256	+++
257	++
258	++
259	++
260	++
261	++
262	++
263	++
264	++
265	++
266	++

Compound No	activity
267	++
268	++
269	++
270	++
272	++
273	++
274	++
275	++
276	++
277	++
278	++
279	++
280	++
281	++
282	+++
284	+++
285	+++
286	+++
287	+++
288	+++
289	+++
290	+++
291	+++
292	++
293	+++
294	++
295	+++
297	++
299	+++

Compound No	activity
300	+++
301	+++
302	+++
303	+++
304	+++
305	+++
306	+++
307	+++
308	+++
309	+++
310	++
311	+++
312	+++
313	++
314	+++
315	+++
316	+++
317	+++
318	+++
319	+++
320	+++
321	+++
322	+++
323	++
324	+++
325	+
327	+++
329	+
330	++

Compound No	activity
331	+
332	++
333	+
335	++
336	+
337	+
338	+
340	+
341	+
343	++
347	+
349	+
350	+++
351	+++
352	+++
353	+++
354	+++
355	+++
356	+++
357	+++
358	+
359	++
360	++
361	+++
362	++
364	+
365	+
373	+++
374	+++

Compound No	activity
375	+++
376	+++
377	+++
378	+
379	+
381	+
382	+
383	+
384	++
385	++
386	+
387	+
389	++
391	+
393	+
394	+
400	++
401	++
402	++
403	++
404	++
406	+
407	+
408	++
409	+++
410	+++
411	++
412	++
413	++

Compound No	activity
414	++
415	+
417	+
418	++
419	+++
420	++
421	+++
422	+++
423	+++
424	+
427	+
428	+
429	++
430	+
431	++
432	++
433	+
434	++
435	++
436	+
437	+
438	++
440	+++
441	+++
442	+++
443	+++
444	+++
445	+++
446	+++

Compound No	activity
447	+++
448	+++
449	+++
450	+++
451	+++
452	+++
453	+++
454	++
455	++
456	+++
457	+++
458	++
459	+++
460	+++
462	+++
463	+++
465	+++
466	+++
467	+++
468	+++
469	+++
470	+++
471	+++
472	+++
473	+++
474	+++
475	+++
476	+++
477	+++

Compound No	activity
478	+++
480	+++
481	+++
483	+++
488	+++
489	+++
490	+++
492	+++
493	+++
494	+++
495	+++
496	+++
503	+++
504	++
505	+++
506	+++
510	+++
511	+++
512	+++
513	+++
514	+++
515	+++
518	+++
519	+++
520	+++
521	+++
522	+++
759	+++
760	+++

Compound No	activity
761	+++
764	++
765	++
766	+
767	++
768	+
769	++
772	++
773	+++
774	+++
775	+++
776	+++
777	++
778	+++
779	+++
780	+++
781	++
782	+++
783	++
784	+++
785	+++
786	+++
787	+++
788	+++
789	+++
790	+
792	+++
793	+++
794	+++

Compound No	activity
795	++
797	++
799	+++
800	+++
801	+++
802	+++
803	+++
804	+++
805	++
806	+
807	+++
808	+++
809	+++
810	+++
811	+++
812	+++
814	++

EXAMPLE 36**[General Procedure for Measurement of CDK-1 Enzyme Activity Inhibition]****(Compound preparation)**

Compounds were dissolved in DMSO at a concentration of 10 mM and stored in aliquots at -20°C . Compounds in DMSO from these stock aliquots were diluted in DMSO to produce the required range of 30x stock solutions. These stock solutions were then subjected to 1:3 dilutions in order to prepare the required range of 10x stock solutions and 5 μL of each solution was used per 50 μL reaction. A final DMSO concentration of 3% was maintained throughout all compound dilution series to maximise compound solubility. Compounds were routinely tested at final concentrations ranging from 300 μM to 0.001 μM , but may have been tested at lower concentrations depending upon their activity.

(CDK-1 Assay)

The kinase reaction was conducted in a round-bottomed polypropylene 96-well plate. CDK-1 was diluted to 0.5 U/ μL in diluent buffer (50 mM Tris/HCl, pH7.5, 0.1 mM EGTA, 0.1% (v/v) β -mercaptoethanol, 1 mg/mL BSA). 5 μL compound or 30% DMSO was added to each well followed by 25 μL substrate cocktail (final concentration: 10 μM ATP, 50 μM peptide (HSTPPKKKAK), 0.5 μCi ^{33}P - γ -ATP in 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 2 mM DTT, 10 mM MgCl_2 , 0.01% Brij-35). The reaction was initiated with the addition of 20 μL enzyme solution per well or 20 μL of diluent buffer without enzyme. The plate was shaken for 10 seconds and then left at room temperature for 15 minutes. The reaction was terminated with 50 μL 150 mM phosphoric acid. 90 μL of the reaction mixture was then transferred into a 96-well P81

filter plate (Whatmann) and incubated at room temperature for 5 minutes. The filter plate was then washed 4 times with 200 μ L 75 mM phosphoric acid per well on a plate vacuum manifold (Millipore) and dried in an oven for 2-3 hours. Packard MicroScint '0' (30 μ L) was then added to each well, the plate was mixed for 30 minutes and subjected to liquid scintillation counting on a Packard TopCount.

(Interpretation)

$$\% \text{ Control} = (X-B)/(Tot-B) \times 100$$

$$\% \text{ Inhibition} = 100 - \% \text{ Control}$$

X = cpm of the test compound wells

B = cpm of wells without enzyme

Tot = cpm of wells with DMSO vehicle only

(CDK-1 inhibitory activity)

Compounds that inhibit CDK-1 ($IC_{50} < 100 \mu M$) are; 2, 7, 9, 10, 11, 12, 14, 15, 16, 17, 18, 19, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 35 and 36.

EXAMPLE 37

[General Procedure for Measurement of CDK-2 Enzyme Activity Inhibition]

(Compound preparation)

Compounds were dissolved in DMSO at a concentration of 10 mM and stored in aliquots at $-20^{\circ}C$. Compounds in DMSO from these stock aliquots were diluted in DMSO to produce the required range of 30x stock solutions. These stock solutions were then subjected to 1:3 dilutions in order to prepare the required range of 10x stock

solutions and 5 μL of each solution was used per 50 μL reaction. A final DMSO concentration of 3% was maintained throughout all compound dilution series to maximise compound solubility. Compounds were routinely tested at final concentrations ranging from 300 μM to 0.001 μM , but may have been tested at lower concentrations depending upon their activity.

(CDK-2 Assay)

a) The kinase reaction was conducted in a round-bottomed polypropylene 96-well plate. CDK-2 was diluted to 0.5 ng/ μL in diluent buffer (50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, 0.1% (v/v) β -mercaptoethanol, 1 mg/ml BSA). 5 μL compound or 30% DMSO was added to each well followed by 25 μL substrate cocktail (final 10 μM ATP, 0.1 mg/ml Histone type III-S, 0.2 μCi ^{33}P - γ -ATP in 50 mM Tris-HCl (pH 7.5), 1 mM EGTA, 2 mM DTT, 10 mM MgCl_2 , 0.01% Brij-35). The reaction was initiated with the addition of 20 μL enzyme solution per well or 20 μL of diluent buffer without enzyme. The plate was shaken for 10 seconds and then left at room temperature for 60 minutes. The reaction was terminated with 50 μL 150 mM phosphoric acid. 90 μL of the reaction mixture was then transferred into a 96-well P81 filter plate (Whatmann) and incubated at room temperature for 5 minutes. The filter plate was then washed 4 times with 200 μL 75 mM phosphoric acid per well on a plate vacuum manifold (Millipore) and dried in an oven for 2-3 hours. Packard MicroScint 'O' (30 μL) was then added to each well, the plate was mixed for 30 minutes and subjected to liquid scintillation counting on a Packard TopCount.

After adding 25 μL of substrate solution [0.2 mg/ml Histone type III-S, 20 μM ATP, 100 mM Tris buffer (pH 7.5), 2 mM EGTA, 4 mM DTT, 0.02 % polyoxyethylene

lauryl ether (23 Lauryl Ether; Brij 35), 20 mM magnesium chloride, 0.2 μCi [γ - ^{33}P]ATP (specific activity: approximately 110 TBq/mmol)] to 5 μL of the test compound using 5% dimethylsulfoxide as the solvent, reaction was initiated by further addition of 20 μL of a CDK2 enzyme solution [2.5 mU recombinant human CDK2/cyclin A, 50 mM Tris buffer (pH 7.5), 0.1 mM EGTA, 0.1 % β -mercaptoethanol, 0.1% BSA]. After conducting the reaction for 15 minutes at room temperature, an equivalent volume of a 70 % trichloroacetic acid (TCA) solution was added to suspend the reaction, and 90 μL of the reaction product was adsorbed onto a MultiScreen HV plate (Millipore) and rinsed with a 25 % TCA solution. After drying the plate, 30 μL of MicroScint-O (Packard BioScience) was added, and the cpm was measured with a scintillation counter to determine the inhibiting activity.

(Interpretation)

$$\% \text{ Control} = (X-B)/(Tot-B) \times 100$$

$$\% \text{ Inhibition} = 100 - \% \text{ Control}$$

X = cpm of the test compound wells

B = cpm of wells without enzyme

Tot = cpm of wells with DMSO vehicle only

(CDK-2 inhibitory activity)

Compounds that inhibit CDK-2 ($\text{IC}_{50} < 100 \mu\text{M}$) are; 1, 2, 6, 7, 10, 11, 12, 13, 14, 15, 16, 23, 28, 31, 32, 35, 37, 38, 41, 42, 43, 44, 46, 47, 48, 49, 50, 51, 52, 53, 55, 56, 57, 58, 59, 60, 61, 63, 64, 65, 68, 70, 71, 72, 74, 75, 76, 77, 78, 80, 81, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93, 95, 97, 98, 102, 103, 105, 107, 111, 112, 113, 114, 115, 116,


118, 125, 126, 128, 129, 131, 137, 140, 148, 149, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 175, 176, 178, 179, 191, 193, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 208, 211, 212, 213, 214, 215, 216, 217, 219, 221, 222, 223, 224, 225, 226, 228, 229, 231, 234, 237, 238, 239, 240, 243, 246, 247, 248, 250, 251, 252, 253, 254, 256, 267, 274, 282, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 297, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 333, 335, 340, 341, 343, 350, 351, 352, 353, 354, 355, 356, 357, 359, 360, 361, 362, 366, 368, 371, 410, 411, 412, 417, 418, 419, 420, 421, 422, 423, 425, 437, 441, 442, 443, 444, 445, 460, 463, 511, 514, 762, 764, 765, 772, 773, 776, 778 and 785.

Industrial Applicability

The Pyrazolo[1,5-a]pyrimidine derivatives represented by formula I and their pharmaceutically acceptable salts exhibit excellent kinase inhibiting activity (particularly MAPKAP-K2 inhibiting activity). Drugs comprising the compounds as effective ingredients are therefore expected to be useful as therapeutic or prophylactic agents for a protein kinase mediated disorder in which kinase is implicated, such as such as inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth.

CLAIMS

1. A compound of formula I:



wherein R¹ is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclylalkynyl;

R² is hydrogen, halogen, -CN, -NO₂, -CHO, -G-R⁷ [G is a bond, -C(=O)- or -O-C(=O)-; and R⁷ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl, -OR⁸ (R⁸ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally

substituted arylalkyl or optionally substituted heterocyclalkyl), $-\text{NR}^9\text{R}^{10}$ (R^9 is as defined for R^8 ; R^{10} is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocycl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl or $-\text{OCH}_3$), $-\text{R}^{11}$ (R^{11} is an optionally substituted saturated heterocycl with 5 to 7 members containing one to four heteroatoms selected from N, O and S), C6-C14 optionally substituted aryl or optionally substituted heteroaryl; provided that when R^7 is C6-C14 optionally substituted aryl or optionally substituted heteroaryl, then G is not a bond], $-\text{NR}^9\text{C}(=\text{O})\text{R}^{12}$ (R^9 is as defined for R^8 ; R^{12} is hydrogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocycl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl), $-\text{NR}^9\text{C}(=\text{X})\text{OR}^{13}$ (R^9 and R^{13} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-\text{NR}^9\text{C}(=\text{X})\text{NR}^{13}\text{R}^{14}$ (R^9 , R^{13} and R^{14} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-\text{NR}^9\text{SO}_2\text{R}^{13}$ (R^9 and R^{13} , which may be the same or different, are as defined for R^8), $-\text{SR}^9$ (R^9 is as defined for R^8) or $-\text{S}(\text{O})_m\text{R}^9$ (R^9 is as defined for R^8 ; m is 1 or 2);

R^3 is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 unsubstituted aryl, C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$,

-CHO, -G-R¹⁵ {G is a bond, -C(=O)- or -O-C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl, -OR¹⁶ (R¹⁶ is as defined for R⁸) or -NR¹⁷R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are as defined for R⁸)}, -NR¹⁷C(=O)R¹⁹ (R¹⁷ is as defined for R⁸; R¹⁹ is as defined for R¹²), -NR¹⁷C(=X)OR¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR¹⁷C(=X)NR¹⁸R²⁰ (R¹⁷, R¹⁸ and R²⁰, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR¹⁷SO₂R¹⁸ (R¹⁷ and R¹⁸, which may be the same or different, are as defined for R⁸), -S(O)_mR¹⁷ (R¹⁷ is as defined for R⁸; m is 0, 1 or 2) and -SO₂NR²¹R²² (R²¹ and R²², which may be the same or different, are as defined for R⁸; R²¹ and R²² together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R²³ {G is a bond, -C(=O)- or -O-C(=O)-; R²³ is as defined for R¹⁵}, -NR²⁴C(=O)R²⁵ (R²⁴ is as defined for R⁸; R²⁵ is as defined for R¹²), -NR²⁴C(=X)OR²⁶ (R²⁴ and R²⁶, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR²⁴C(=X)NR²⁶R²⁷ (R²⁴, R²⁶ and R²⁷, which

may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{24}SO_2R^{26}$ (wherein R^{24} and R^{26} , which may be the same or different, are as defined for R^8), $-S(O)_mR^{24}$ (R^{24} is as defined for R^8 ; m is 0, 1 or 2) and $-SO_2NR^{28}R^{29}$ (R^{28} and R^{29} , which may be the same or different, are as defined for R^8 ; R^{28} and R^{29} together may be taken together with the nitrogen to which they are attached to form a monocyclic or bicyclic heterocycle with 5 - 7 members in each ring and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said monocyclic or bicyclic heterocycle may optionally be substituted with one or more substituents)], optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl or optionally substituted heterocyclalkynyl;

R^4 is hydrogen, halogen, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocycl, optionally substituted arylalkyl, optionally substituted heterocyclalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclalkynyl, $-OR^{30}$ (R^{30} is as defined for R^8), $-SR^{30}$ (R^{30} is as defined for R^8), $-NR^{30}R^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8), $-NR^{30}C(=O)R^{32}$ (R^{30} is as defined for R^8 ; and R^{32} is as defined for R^{12}), $-NR^{30}C(=X)OR^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH), $-NR^{30}C(=X)NR^{31}R^{33}$ (R^{30} , R^{31} and R^{33} , which may be the same or different, are as defined for R^8 ; X is O, S, N-CN or NH)

or $-\text{NR}^{30}\text{SO}_2\text{R}^{31}$ (R^{30} and R^{31} , which may be the same or different, are as defined for R^8);

R^5 is C1-C8 substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 substituted cycloalkyl [As substituents of C3-C8 cycloalkyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R³⁴ {G is a bond, -C(=O)- or -O-C(=O)-; R³⁴ is as defined for R¹⁵}, -NR³⁵C(=O)R³⁶ (R³⁵ is as defined for R⁸; R³⁶ is as defined for R¹²), -NR³⁵C(=X)OR³⁷ (R³⁵ and R³⁷, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR³⁵C(=X)NR³⁷R³⁸ (R³⁵, R³⁷ and R³⁸, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH) and -NR³⁵SO₂R³⁷ (R³⁵ and R³⁷, which may be the same or different, are as defined for R⁸)], unsubstituted heterocyclyl, substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -CHO, -G-R³⁹ {G is a bond, -C(=O)- or -O-C(=O)-; R³⁹ is as defined for R¹⁵}, -NR⁴⁰C(=O)R⁴¹ (R⁴⁰ is as defined for R⁸; R⁴¹ is as defined for R¹²), -NR⁴⁰C(=X)OR⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH), -NR⁴⁰C(=X)NR⁴²R⁴³ (R⁴⁰, R⁴² and R⁴³, which may be the same or different, are as defined for R⁸; X is O, S, N-CN or NH) and -NR⁴⁰SO₂R⁴² (R⁴⁰ and R⁴², which may be the same or different, are as defined for R⁸)], optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, optionally substituted arylalkenyl, optionally substituted heterocyclylalkenyl, optionally substituted arylalkynyl, optionally substituted heterocyclylalkynyl or -NR⁴⁴R⁴⁵ (R⁴⁴ and R⁴⁵, which may be the same or different, are C1-C8 optionally substituted alkyl; R⁴⁴ and R⁴⁵ together may be taken together with the nitrogen to which they are attached to

form a mono heterocycle with 5 - 7 members and optionally containing, in addition to the nitrogen, one or two additional heteroatoms selected from N, O and S, the said mono heterocycle may optionally be substituted with one or more substituents);

R⁶ is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl;

with the provisos:

that R¹, R² and R⁴ are not all H;


that R⁴ is not pentafluorophenyl;

that R⁵ is not a group represented as the following (a):

(a) C1-C6 alkyl or C3-C6 cycloalkyl, in which an alkyl group or a cycloalkyl group optionally may be substituted by phenyl or by one or more fluoro substituents;

and pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs.

2. A compound of formula I-b:



wherein R^{1b} is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl;

R^{2b} is hydrogen, halogen, -CN, -NO₂, -CHO or -G-R⁵² {G is a bond, -C(=O)- or -O-C(=O)-; and R⁵² is C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl, optionally substituted heteroarylalkynyl, -OR⁵³ (R⁵³ is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl), -NR⁵⁴R⁵⁵, -NR⁵⁴C(=O)R⁵⁵, -SR⁵⁴, optionally substituted aryl or

optionally substituted heteroaryl; provided that when R^{52} is optionally substituted aryl or optionally substituted heteroaryl then G is not a bond; wherein R^{54} and R^{55} , which may be the same or different, are as defined for R^{53} ; or wherein R^{54} and R^{55} together form an optionally substituted ring that optionally contains one or more heteroatoms selected from N, O and S};

R^{3b} is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl or optionally substituted heteroarylalkynyl;

R^{4b} is hydrogen, halogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkenyl, optionally substituted arylalkynyl, optionally substituted heteroarylalkynyl, $-OR^{56}$, $-SR^{56}$, $-NR^{56}R^{57}$ or $-NR^{56}C(=O)R^{57}$; wherein R^{56} and R^{57} , which may be the same or different, are as defined for R^{53} ; or wherein R^{56} and R^{57} together form an optionally substituted ring which optionally contains one or more heteroatoms;

R^{5b} is C1-C6 substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally

substituted alkynyl, C3-C8 substituted cycloalkyl, optionally substituted heterocyclyl or optionally substituted heterocyclalkyl;

R^{6b} is hydrogen, C1-C6 optionally substituted alkyl, C2-C6 optionally substituted alkenyl, C2-C6 optionally substituted alkynyl or C3-C8 optionally substituted cycloalkyl;

with the provisos:

that R^{1b}, R^{2b} and R^{4b} are not all H;

that R^{4b} is not pentafluorophenyl;

that R^{5b} is not a group represented as the following (a):

(a) C1-C6 alkyl or C3-C6 cycloalkyl, in which an alkyl group optionally may be substituted by phenyl or by one or more fluoro substituents;

and pharmaceutically acceptable salts, and other pharmaceutically acceptable biohydrolyzable derivatives thereof, including esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents or prodrugs.

3. The compound as claimed in claim 1 wherein R¹ is hydrogen or C1-C8 optionally substituted alkyl.

4. The compound as claimed in claim 1 wherein R^1 is hydrogen.
5. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is $-\text{NO}_2$, $-\text{OC}(=\text{O})\text{R}^7$, $-\text{CO}_2\text{R}^8$ or $-\text{CONR}^9\text{R}^{10}$; wherein R^7 , R^8 , R^9 and R^{10} are as defined in claim 1.
6. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is $-\text{NR}^9\text{C}(=\text{O})\text{R}^{12}$, $-\text{NR}^9\text{C}(=\text{X})\text{OR}^{13}$, $-\text{NR}^9\text{C}(=\text{X})\text{NR}^{13}\text{R}^{14}$, $-\text{NR}^9\text{SO}_2\text{R}^{13}$, $-\text{SR}^9$ or $-\text{S}(\text{O})_m\text{R}^9$; wherein R^9 , R^{12} , R^{13} , R^{14} and X are as defined in claim 1; m is 1 or 2.
7. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl or optionally substituted arylalkyl.
8. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is hydrogen, halogen, $-\text{CN}$ or $-\text{SCH}_3$.
9. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is halogen.
10. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is F.
11. The compound as claimed in any one of claims 1, 3 or 4 wherein R^2 is hydrogen.

12. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C2-C8 optionally substituted alkynyl, C3-C8 optionally substituted cycloalkyl, C6-C14 unsubstituted aryl, C6-C14 substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl.

13. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl.

14. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl {As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} , -NR¹⁷C(=O)R¹⁹ and -S(O)_mR¹⁷; wherein R^{15} , R^{17} , R^{19} or G are as defined in claim 1; m is 0, 1 or 2.}.

15. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G- R^{15} {G is a bond or -C(=O)-; R^{15} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, -OR¹⁶ or -NR¹⁷R¹⁸}, -NR¹⁷C(=O)R¹⁹ and S(O)_mR¹⁷; wherein R^{16} , R^{17} , R^{18} or R^{19} are as defined in claim 1; m is 0, 1 or 2.].

16. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G-R¹⁵ {G is a bond; R¹⁵ is C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclalkyl, -OR¹⁶ or -NR¹⁷R¹⁸}, -NR¹⁷C(=O)R¹⁹ and S(O)_mR¹⁷; wherein R¹⁶, R¹⁷, R¹⁸ or R¹⁹ are as defined in claim 1; m is 0, 1 or 2.].

17. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G-R¹⁵ {G is a bond or -C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, -OR¹⁶ or -NR¹⁷R¹⁸}, -NR¹⁷C(=O)R¹⁹ and S(O)_mR¹⁷; wherein R¹⁶, R¹⁷, R¹⁸ or R¹⁹ are as defined in claim 1; m is 0, 1 or 2.].

18. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G-R¹⁵ {G is a bond or -C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, -OR¹⁶ or -NR¹⁷R¹⁸}, -NR¹⁷C(=O)R¹⁹ and S(O)_mR¹⁷; wherein R¹⁶, R¹⁷, R¹⁸ or R¹⁹, which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl; m is 0, 1 or 2.].

19. The compound as claimed in any one of claims 1, 3 to 11 wherein R^3 is C6-C14 substituted aryl [As substituents of C6-C14 aryl may be mentioned one or more

selected from the group consisting of halogen, -CN, -NO₂ and -G-R¹⁵ {G is -C(=O)-; R¹⁵ is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, -OR¹⁶ or -NR¹⁷R¹⁸}; wherein R¹⁶, R¹⁷ or R¹⁸ are as defined in claim 1.].

20. The compound as claimed in any one of claims 1, 3 to 11 wherein R³ is unsubstituted heterocyclyl.

21. The compound as claimed in any one of claims 1, 3 to 11 wherein R³ is substituted heterocyclyl.

22. The compound as claimed in any one of claims 1, 3 to 11 wherein R³ is substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G-R²³, -NR²⁴C(=O)R²⁵ and -S(O)_mR²⁴; wherein R²³, R²⁴, R²⁵ or G are as defined in claim 1; m is 0, 1 or 2.].

23. The compound as claimed in any one of claims 1, 3 to 11 wherein R³ is unsubstituted bicyclic heteroaryl.

24. The compound as claimed in any one of claims 1, 3 to 11 wherein R³ is substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, -CN, -NO₂, -G-R²³, -NR²⁴C(=O)R²⁵ and -S(O)_mR²⁴; wherein R²³, R²⁴, R²⁵ or G are as defined in claim 1; m is 0, 1 or 2.].

25. The compound as claimed in any one of claims 1, 3 to 24 wherein R^4 is halogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, optionally substituted arylalkyl, optionally substituted heterocyclylalkyl, $-OR^{30}$; wherein R^{30} is as defined in claim 1.
26. The compound as claimed in any one of claims 1, 3 to 24 wherein R^4 is C1-C8 optionally substituted alkyl.
27. The compound as claimed in any one of claims 1, 3 to 24 wherein R^4 is methyl.
28. The compound as claimed in any one of claims 1, 3 to 24 wherein R^4 is hydrogen.
29. The compound as claimed in any one of claims 1, 3 to 28 wherein R^5 is C3-C8 substituted cycloalkyl, unsubstituted heterocyclyl or substituted heterocyclyl.
30. The compound as claimed in any one of claims 1, 3 to 28 wherein R^5 is C3-C8 substituted cycloalkyl [As substituents of cycloalkyl may be mentioned one or more selected from the group consisting of halogen, $-CN$, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and $-NR^{17}R^{18}$; wherein R^{17} or R^{18} is as defined in claim 1].

31. The compound as claimed in any one of claims 1, 3 to 28 wherein R⁵ is substituted cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and -NR¹⁷R¹⁸; wherein R¹⁷ or R¹⁸ is as defined in claim 1].

32. The compound as claimed in any one of claims 1, 3 to 28 wherein R⁵ is 4-amino-cyclohexyl.

33. The compound as claimed in any one of claims 1, 3 to 28 wherein R⁵ is unsubstituted heterocyclyl or substituted heterocyclyl [As substituents of heterocyclyl may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl, C3-C8 optionally substituted cycloalkyl and -NR¹⁷R¹⁸; wherein R¹⁷ or R¹⁸ is as defined in claim 1]

34. The compound as claimed in any one of claims 1, 3 to 28 wherein R⁵ is unsubstituted piperidin-3-yl, unsubstituted piperidin-4-yl or unsubstituted pyrrolidin-3-yl.


35. The compound as claimed in any one of claims 1, 3 to 28 wherein R⁵ is substituted piperidin-3-yl, substituted piperidin-4-yl or substituted pyrrolidin-3-yl.

36. The compound as claimed in any one of claims 1, 3 to 28 wherein R^5 is substituted piperidin-3-yl, substituted piperidin-4-yl or substituted pyrrolidin-3-yl [As their substituents may be mentioned one or more selected from the group consisting of halogen, -CN, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkenyl and C3-C8 optionally substituted cycloalkyl]

37. The compound as claimed in any one of claims 1, 3 to 36 wherein R^6 is hydrogen.

38. The compound as claimed in any one of claims 1, 3 to 36 wherein R^6 is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl.

39. A compound of the formula II-26:




wherein R^1 - R^6 are as defined in claim 1; R^{58} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H.

40. A compound of the formula III-01:




wherein $R^1 - R^4$ are as defined in claim 1; R^{58} is C1-C8 optionally substituted alkyl or optionally substituted arylalkyl;

with the provisos:

that R^1 , R^2 and R^4 are not all H.

41. A compound of the formula IV:



wherein $R^1 - R^4$ are as defined in claim 1;

with the provisos:

that R^1 , R^2 and R^4 are not all H;

that R^4 is not optionally substituted aryl or optionally substituted heteroaryl.

42. The compound as claimed in any one of claims 39, 40 or 41 wherein R^1 is hydrogen.

43. The compound as claimed in any one of claims 39, 40 or 41 wherein R^2 is hydrogen, halogen, -CN, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, -OR⁸ (R^8 is hydrogen or C1-C8 optionally substituted alkyl), -NR⁹R¹⁰ (R^9 and R^{10} , which may be the same or different, hydrogen or C1-C8 optionally substituted alkyl), -C(=O)NR⁹R¹⁰ (R^9 and R^{10} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)R¹² (R^9 is hydrogen or C1-C8 optionally substituted alkyl; R^{12} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)OR¹³ (R^9 is hydrogen or C1-C8 optionally substituted alkyl; R^{13} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), -NR⁹C(=O)NR¹³R¹⁴ (R^9 and R^{13} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl; R^{14} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl),

$-\text{NR}^9\text{SO}_2\text{R}^{13}$ (R^9 is hydrogen or C1-C8 optionally substituted alkyl; R^{13} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl), $-\text{SR}^9$ (R^9 is hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl) or $-\text{SO}_2\text{R}^9$ (R^9 is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl).

44. The compound as claimed in any one of claims 39, 40 or 41 wherein R^3 is substituted phenyl [As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$, C1-C8 optionally substituted alkyl, C2-C8 optionally substituted alkynyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, $-\text{OR}^{16}$ (R^{16} is hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclylalkyl), $-\text{NR}^{17}\text{R}^{18}$ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl) and $-\text{C}(=\text{O})\text{NR}^{17}\text{R}^{18}$ (R^{17} and R^{18} , which may be the same or different, are hydrogen, C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclyl)], unsubstituted bicyclic heteroaryl, substituted bicyclic heteroaryl [As substituents of bicyclic heteroaryl may be mentioned one or more selected from the group consisting of halogen, $-\text{CN}$, $-\text{NO}_2$, C1-C8 optionally substituted alkyl, C6-C14 optionally substituted aryl, optionally substituted heterocyclyl, $-\text{OR}^{16}$ (R^{16} is

hydrogen, C1-C8 optionally substituted alkyl, optionally substituted arylalkyl or optionally substituted heterocyclalkyl), $-NR^{17}R^{18}$ (R^{17} and R^{18} , which may be the same or different, are hydrogen or C1-C8 optionally substituted alkyl), $-NHC(=O)R^{19}$ (R^{19} is C1-C8 optionally substituted alkyl, C3-C8 optionally substituted cycloalkyl, C6-C14 optionally substituted aryl or optionally substituted heterocyclalkyl) and $-SR^{17}$ (R^{17} is C1-C8 optionally substituted alkyl)].

45. The compound as claimed in any one of claims 39, 40 or 41 wherein R^4 is hydrogen, methyl or ethyl.

46. The compound as claimed in claim 39 wherein R^5 is preferably selected from cyclohexyl [As substituents of cyclohexyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂], unsubstituted saturated heterocyclalkyl or substituted saturated heterocyclalkyl [As substituents of heterocyclalkyl may be mentioned one or more selected from the group consisting of halogen, C1-C8 optionally substituted alkyl, -OH and -NH₂].

47. The compound as claimed in claim 39 wherein R^6 is hydrogen.

48. The compound as claimed in any one of claims 39, 40 or 41 wherein R^{58} is *tert*-butyl or benzyl.

49. The compound as claimed in claim 39 wherein R^1 is hydrogen; R^2 is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R^3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R^4 is hydrogen or -CH₃; R^5 is 4-amino-cyclohexyl or piperidin-3-yl; R^6 is hydrogen; R^{58} is *tert*-butyl;


with the provisos that R^1 , R^2 and R^4 are not all H.

50. The compound as claimed in claim 40 wherein R^1 is hydrogen; R^2 is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R^3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R^4 is hydrogen or -CH₃; R^{58} is *tert*-butyl; with the provisos that R^1 , R^2 and R^4 are not all H


51. The compound as claimed in claim 41 wherein R^1 is hydrogen; R^2 is hydrogen, -CN, -SCH₃, -NH₂, -COOH or COCF₃; R^3 is substituted phenyl (As substituents of phenyl may be mentioned one or more selected from the group consisting of halogen, -CN, -OH, -OCH₃, -OEt, -COOH); R^4 is hydrogen or -CH₃; with the provisos that R^1 , R^2 and R^4 are not all H.

52. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein removal of Boc protecting group from compound II.

352




53. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound III




is reacted with a compound of the formula R^5R^6NH .

54. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound IV




is reacted with a compound of the formula R^5R^6NH .

55. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound IV




is reacted with di-*tert*-butyl dicarbonate.

56. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound V




is reacted with a compound of the formula R^3NH_2 or $R^3NH(COCH_3)$.

57. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound VI



is reacted with phosphorus oxychloride or phenyl phosphonic dichloride.


58. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound VII



(VII)

is reacted with a compound of the formula $R^4CH(CO_2Me)_2$ or $R^4CH(CO_2Et)_2$.


59. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound V-01



(V-01)

is reacted with a halogenating, thiocyanating or acylating agent.


60. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound IV-01



(IV-01)


is reacted with a Grignard reagent.

61. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-01



is reacted with a halogenating agent.


62. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-01



is reacted with a compound of the formula $(\text{CF}_3\text{CO})_2\text{O}$.


63. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-03

356




is reacted with hydroxide for a hydrolysis of ester group; R^{67} is methyl or ethyl.

64. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-04




is reacted with a compound of the formula $R^9R^{10}NH$ in the presence of a peptide coupling agent.

65. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-06




is rearranged via isocyanate intermediate under Hofmann rearrangement conditions, followed by removal of carbonate.

66. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-08



is reacted with a compound of the formula $R^{12}COCl$, $R^{12}COOH$, $R^{10}SO_2Cl$, $R^{10}NCO$ or $R^{10}NCS$.


67. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-13



is condensed with an alcohol derivative under Mitsunobu conditions; Ar^1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.


68. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-15

358



is reacted with a boronic acid derivative in the presence of metal catalysis under Suzuki-Miyaura coupling conditions; Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.


69. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-15



is reacted with a 1-alkyne in the presence of metal catalyst under Sonogashira coupling conditions; Ar¹ represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.


70. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-18

359




is reacted with a compound of the formula $R^{16}R^{17}NH$ in the presence of a peptide coupling agent; Ar^1 represents C6-C14 optionally substituted aryl or optionally substituted heteroaryl.

71. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-20




is reacted with an alkyl lithium reagent.

72. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-22




is reacted with alkyl halide, followed by removal of trifluoroacetyl group.

73. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-08



is reacted with an aldehyde in the presence of reducing agent.


74. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound II-24



is reacted with alkyl halide in the presence of sodium hydride

75. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound I-26


361



(I-26)

is reacted with hydrogen in the presence of Palladium on activated carbon or with chloroformate followed by methanol; R60 is benzyl or *p*-MeO-benzyl; n is 1, 2 or 3.

76. A process for the manufacture of a compound as defined in any one of claims 1, 3 to 38 wherein compound V-04



(V-04)

is reacted with reducing agent or diol derivative for formation of acetal.

77. A composition comprising a compound as defined in any one of claims 1, 3 to 38 in combination with a pharmaceutically acceptable carrier, diluent or excipient.

78. The composition as claimed in claim 77 further comprising one or more active agents.

79. A process for the manufacture of a composition as defined in claim 77 or 78 comprising combining a compound as defined in any one of claims 1, 3 to 38 with the

pharmaceutically acceptable carrier or diluent, optionally with an additional active agent.

80. A compound as defined in any one of claims 1, 3 to 38, or a composition as defined in any one of claims 77 or 78, for use in medicine.

81. A compound as defined in any one of claims 1, 3 to 38, or a composition as defined in any one of claims 77 or 78, for inhibiting protein kinase.

82. A compound as defined in any one of claims 1, 3 to 38, or a composition as defined in any one of claims 77 or 78, for selectively inhibiting MAPKAP-K2.

83. A compound as defined in any one of claims 1, 3 to 38, or a composition as defined in any one of claims 77 or 78, for selectively inhibiting CDK.

84. A compound as defined in any one of claims 1, 3 to 38, or a composition as defined in any one of claims 77 or 78, for use in the prevention or treatment of a protein kinase-mediated disorder.

85. The compound or composition as claimed in claim 84, wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic

disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.

86. The compound or composition as claimed in claim 84, wherein the disorder is inflammatory disease and/or autoimmune disease.

87. The compound or composition as claimed in claim 84, wherein the disorder is autoimmune disease.

88. The compound or composition as claimed in claim 87, wherein the autoimmune disease is rheumatoid arthritis, systemic lupus erythematosus, glomerulonephritis, scleroderma, Sjogren's syndrome, juvenile rheumatoid arthritis, psoriatic arthritis, chronic thyroiditis, Graves's disease, autoimmune gastritis, diabetes, autoimmune haemolytic anaemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, ulcerative colitis, Crohn's disease, psoriasis or graft vs host disease.

89. The compound or composition as claimed in claim 87, wherein the autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.

90. A method of treating or preventing a protein kinase-mediated disorder in an individual, which method comprises administering to said individual a compound as claimed in any one of claims 1, 3 to 38 or a composition as defined in claim 77 or 78.

91. The method as claimed in claim 90 wherein the individual is in need of the treatment or prevention of the disorder.

92. The method as claimed in claim 90 or 91 wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.

93. The method as claimed in claim 90 or 91 wherein the disorder is autoimmune disease.

94. The method as claimed in claim 93 wherein the autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.

95. The method as claimed in any of claims 90 to 94 wherein one or more active agent is administered to the individual simultaneously, subsequently or sequentially to administering the compound.

96. Use of a compound as defined in any one of claims 1, 3 to 38 in the manufacture

of a medicament for the prevention or treatment of a protein kinase-mediated disorder.

97. Use as claimed in claim 96 wherein the disorder is a neurodegenerative/neurological disorder (including dementia), inflammatory disease, a disorder linked to apoptosis, particularly neuronal apoptosis, stroke, sepsis, autoimmune disease, destructive bone disorder, proliferative disorder, diabetes, cancer, tumour growth, infectious disease, allergy, ischemia reperfusion injury, heart attack, angiogenic disorder, organ hypoxia, vascular hyperplasia, cardiac hypertrophy and/or thrombin induced platelet aggregation.

98. Use as claimed in claim 96 wherein the disorder is autoimmune disease.

99. Use as claimed in claim 98 wherein the autoimmune disease is rheumatoid arthritis, psoriasis, ankylosing spondylitis, juvenile rheumatoid arthritis, psoriatic arthritis or Crohn's disease.

100. Use as claimed in claim 96 or 97 wherein one or more active agent is administered to the individual simultaneously, subsequently or sequentially to administering the compound.

101. An assay for determining the activity of the compounds as defined in any one of claims 1, 3 to 38, comprising providing a system for assaying the activity and assaying the activity of a compound as defined in any one of claims 1, 3 to 38.

102. The assay as claimed in claim 101 wherein the assay is for the protein kinase inhibiting activity of the compound.

103. A method of inhibiting the activity or function of a protein kinase, which method comprises exposing a protein kinase to a compound as defined in any one of claims 1, 3 to 38 or a composition as defined in claim 77 or 78.

104. The method as claimed in claim 103 which is performed in a research model, *in vitro*, *in silico* or *in vivo* such as in an animal model.

Pathogens, cytokines, growth factors, environmental stresses, GPCRs




FIGURE1: The p38 MAPK cascade

2/8




FIGURE 2

3/8




FIGURE 3

4/8




FIGURE 4

5/8




FIGURE 5

6/8




FIGURE 6

7/8




FIGURE 7

8/8




FIGURE 8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 2004/002522

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl.: C07D487/04, A61K31/519, A61P19/08, 35/00, 37/02, 43/00, 3/10, 13/12, 17/00, 27/00, 19/02, 7/00, 1/16, 21/04, 1/00, 17/06/02, 7/00, 1/16, 21/04, 1/00, 17/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl.: C07D487/04, A61K31/519, A61P19/08, 35/00, 37/02, 43/00, 3/10, 13/12, 17/00, 27/00, 19/02, 7/00, 1/16, 21/04, 1/00, 17/06/02, 7/00, 1/16, 21/04, 1/00, 17/06

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
Japanese Utility Model Gazette 1922-1996, Japanese Publication of Unexamined Utility Model Applications 1971-2004, Japanese Registered Utility Model Gazette 1994-2004, Japanese Gazette Containing the Utility Model 1996-2004

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN/CAS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHIOTA, T., et al., "Synthesis and Structure-Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- <i>a</i>]pyrimidine Derivatives", Chemical & Pharmaceutical Bulletin (1999), 47(7), pp928-938	1-89, 96-102
X	Novinson, T., et al., "Synthesis and Antifungal Properties of Certain	41, 42, 43, 45
A	7-Alkylaminopyrazolo[1,5- <i>a</i>]pyrimidines", Journal of Medicinal Chemistry (1977), 20(2), pp296-9	1-40, 44, 46-89, 96-102
A	EP 628559 A1 (Beiersdorf-Lilly GmbH) 1994.12.14 & US 5571813 A & CA 2125458 & JP 7-2860 & US 5602136 A & US 5602137 A	1-89, 96-102

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21.05.2004

Date of mailing of the international search report

08.6.2004

Name and mailing address of the ISA/JP

Japan Patent Office

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

Authorized officer

Satoshi MORIYASU

Telephone No. +81-3-3581-1101 Ext. 3452

4P

8519

INTERNATIONALSEARCHREPORT

International application No.

PCT/JP2004/002522

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
EX	WO 04/022561 (Schering Corporation) A1 2004.03.18 (Family:none)	1-89,96-102
EX	WO 04/026229 A1 (Schering Corporation) 2004.04.01 (Family:none)	1-89,96-102
EX	WO 04/022560 A1 (Schering Corporation) 2004.03.18 (Family:none)	1-89,96-102
EX	WO 04/022559 A1 (Schering Corporation) 2004.03.18 (Family:none)	1-89,96-102
EX	WO 04/022562 A1 (Schering Corporation) 2004.03.18 (Family:none)	1-89,96-102
PX	WO 04/000844 A1 (Bayer CropScience AG) 2003.12.31 (Family:none)	1-89,96-102

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 90-95, 103-104
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 90-95 and 103-104 pertain to a method for treatment of the human body by therapy.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

This application contains the following inventions or groups of invention which are not so linked as to form a single inventive concept under PCT Rule 13.1.

As the common chemical structure of Groups I-IV is not new (for example, WO 99/38868 A1 <RN:202579-57-5 etc.>, JP 3-204877 A <RN:137739-28-7 etc.> and so on), Groups I-IV lack the same or corresponding special technical features under PCT Rule 13.2.

Group I : Claims 1-38, 52-89, 96-102

Group II : Claim 39, 42-45, 46-47, 48, 49 (a compound of formula II-26)

Group III : Claim 40, 42-45, 48, 50 (a compound of formula III-01)

Group IV : Claim 41, 42-45, 48, 51 (a compound of formula IV)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.